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ABSTRACT OF DISSERTATION 
 
 
 
PRECLINICAL EVALUATION OF LOBELINE FOR THE TREATMENT OF 
ADHD: COMPARISON WITH PSYCHOSTIMULANT THERAPIES 
 
 This dissertation work investigated the effect of acute and repeated in vivo 
administration of lobeline on dopamine transporter (DAT) and vesicular 
monoamine transporter (VMAT2) function. The effects of lobeline were then 
compared to the effects of acute and repeated in vivo administration of 
methylphenidate and amphetamine to determine if lobeline produced similar 
effects compared to these Attention Deficit Hyperactivity Disorder (ADHD) 
medications. These medications are considered the first line of pharmacotherapy 
for ADHD, although there is a growing concern associated with their potential for 
abuse and other side effects. This merits the need for novel ADHD treatments 
that have a safer side effect profile. If lobeline alters DAT and VMAT2 function in 
the same way as methylphenidate or amphetamine, further investigation may be 
necessary to evaluate lobeline as a potential treatment for ADHD. Kinetic 
analysis of [3H]dopamine (DA) was utilized to determine the effect on DAT and 
VMAT2 function in rat striatum. Results from the DAT experiments, revealed that 
lobeline as well as amphetamine had no effect on DAT function. However, 
methylphenidate increased DAT function after acute and 7-day treatment. None 
of the drug treatment regimens altered Km. To determine if the methylphenidate-
induced increase in DAT function was due to DAT trafficking, biotinylation and 
Western blot analyses were performed. Acute administration of methylphenidate 
did not alter surface DAT, however repeated administration of methylphenidate 
for 7 days decreased intracellular DAT, suggesting that methylphenidate 
redistributes DAT in a time-dependent manner. Similar results were found in the 
VMAT2 experiments. Lobeline and amphetamine had no effect on VMAT2 
function after acute or repeated administration. Amphetamine decreased the Km 
after repeated administration for 7 days. Methylphenidate increased VMAT2 
function after acute and repeated administration for 7 days. The overall results of 
these experiments suggest that methylphenidate interacts with DAT and VMAT2 
in a different manner than amphetamine and lobeline. In addition, since lobeline 
and amphetamine had no effect on DAT and VMAT2 function, further 
investigation is warranted to elucidate the underlying mechanisms of the 
therapeutic actions of these agents. This additional information will aid in the 
development of novel treatments for ADHD. 
 
Keywords:  lobeline, methylphenidate, amphetamine, striatum, ADHD, dopamine 
transporter, vesicular monoamine transporter 
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Chapter One 
 
 Introduction and Background 
 
A. Attention-Deficit Hyperactivity Disorder  
Attention-Deficit Hyperactivity Disorder (ADHD) is defined in the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) as primarily 
a childhood psychiatric disorder; however, 30-60% of childhood cases continue 
into adulthood (American Psychiatric Association, 2000; Himelstein & Halperin;  
2000). Historically, this disease was labeled a “mental restlessness or a disease 
of attention”, specifically in 1798 by Sir Alexander Crichton, a Scottish author and 
physician (Palmer & Finger, 2001).  However, Sir George Fredrick Still, a British 
pediatrician, is most well-known for describing in 1902 the clinical manifestations 
of ADHD, based on his observations of over 40 children with serious problems of 
sustained attention and self-control. Sir Still described the behavior of these 
children as a “quite abnormal incapacity for sustained attention” (Still, 1902).  
Over the years, the classification of this condition has evolved from hyperkinetic 
reaction of childhood disorder  to attention deficit disorder in 1980 to ADHD, 
which includes the hyperactivity component of the behavior (American 
Psychiatric Association, 1987).   
1. Prevalence 
ADHD is a major clinical and public health problem due to its disruptive 
nature in school-age children, and rising prevalence and impact on the economy 
(Meijer et al., 2009). Research has shown that boys are 3 times more likely to 
have ADHD compared to girls (Barkley et al., 1990; Faraone et al., 2003). The 
world-wide prevalence of ADHD is 5-12% and 3-5% in children and adults, 
respectively, in the United States, depending on the diagnostic criteria utilized 
(Brown et al., 2001b; Faraone et al., 2003; Kessler et al., 2005; Kessler et al., 
2006; Polanczyk et al., 2007). The estimated mean annual cost for a 
child/adolescent with ADHD in the United States is $14,576 which includes 
health and mental healthcare costs ($2,636), education ($4,900), and crime and 
2 
delinquency ($7,040) with a range of $12,005 to $17,458 (Pelham et al., 2007).  
The overall cost of illness based on the 2000 census of 60 million school-aged 
children was estimated to be $42.5 billion annually, of which $7.9 billion is health 
and mental healthcare costs, $13.6 billion is educational cost, and $21.1 billion is 
crime and delinquency costs (Pelham et al., 2007).  Based on the prevalence in 
adults, the estimated cost of ADHD is between $36-77 billion, which is close to 
the costs associated with alcohol abuse ($85 billion); greater than the costs 
associated with drugs of abuse such as cocaine and marijuana ($58 billion);and 
greater than costs associated with depression ($43 billion) (Pelham et al., 2007; 
Reinberg, 2004). Furthermore, the National Health Statistics Report estimated 
that there were as many as 7 million ambulatory care visits for ADHD in 2006 
(Schappert, 2008). In addition, a study that included 10 countries concluded that 
adult ADHD was associated with 143.8 million lost days of productivity each year 
(de Graaf et al., 2008) and another study reported a work loss cost of adults with 
ADHD that is approximately $3.7 billion in the US (Birnbaum et al., 2005). Taken 
together, it is clear that ADHD has a huge economic impact on the health and 
economy for the US, as well as the world. 
2. Etiology 
The etiology of ADHD is unknown; however, there has been an enormous 
amount of research conducted on this topic. Generally, the overall conclusion is 
that the etiology of ADHD is complex and involves a combination of factors. 
These factors include genetics, prenatal exposure to tobacco smoking, or 
alcohol, or to both tobacco smoking and alcohol simultaneously (Betel, 1995; 
Dawson, 2000; Mayfield, 2008). 
As stated above, an important factor is genetic predisposition. Twin and 
adoption studies show that genes play a vital role in the familial transmission of 
ADHD (Biederman & Faraone, 2005).  For example, adoptive relatives are less 
likely than biological relatives to have the disorder or associated symptoms 
(Sprich et al., 2000). Numerous family studies have shown that there is a genetic 
link to ADHD, such that 25-33% of parents of ADHD children have ADHD 
themselves (Cormier, 2008). Specifically, variants of genes associated with 
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dopamine (DA) neurotransmission have been investigated most commonly with 
respect to the etiology of ADHD (Faraone & Khan, 2006).  These polymorphic 
genes include the DA D4 receptor gene (DRD4) (Benjamin et al., 1996; Gabriela 
et al., 2009; Rubinstein et al., 1997; Tahir et al., 2000), the DA D5 receptor gene 
(DRD5) (Hawi et al., 2005; Manor et al., 2004; Mill et al., 2004; Tahir et al., 
2000), and the DA transporter gene (Barr et al., 2001; Cook et al., 1995; Giros et 
al., 1996; Hawi et al., 2009; Henriquez et al., 2008; Hiongwa et al., 2004).   
Research has been conducted on ADHD using D4 knock-out (D4KO) 
mice. D4KO mice are genetically altered mice that have had the D4 receptor 
gene deleted. D4KO mice were found to have a 32% decreased basal locomotor 
activity compared to wild-type (Rubinstein et al., 1997). In addition, this study 
revealed that the D4KO mice were more sensitive to cocaine (15 and 30 mg/kg) 
and methamphetamine (1 and 2 mg/kg) administration, as demonstrated by a 
two-fold increase in stimulant response in D4KO mice compared to WT. These 
results suggest that the DRD4 gene is involved in hyperactivity, an ADHD 
hallmark symptom, as well as response to psychostimulants that are used as 
treatments for ADHD.    
 To follow up on the results of this preclinical study employing D4KO mice, 
relationships between the DRD4 exon III sequence variants and personality test 
scores were evaluated in 315 mostly male siblings and other family members of 
individuals with ADHD (Benjamin et al., 1996).  An association was found 
between the DRD4 variants and the novelty seeking personality trait in relatives 
of the ADHD individuals. Another study examined the association of the DRD4-7 
repeat (DRD4-7r) allele with novelty seeking in a sample of 303 15-year old 
adolescents (144 males and 159 females) using data from a high-risk community 
sample (Becker et al., 2005).  Males with the DRD4-7r allele polymorphism 
scored significantly higher with respect to the novelty seeking personality trait 
(p=0.002) of the Junior Temperament and Character Inventory and no 
association was found in females. However, a meta-analysis of 20 studies 
conducted by Kluger et. al., 2002, found no association between the DRD4 
polymorphism and novelty seeking. A meta-analysis combines the results of 
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several studies that address a set of related research hypotheses. In its simplest 
form, this is normally by identification of a common measure of effect size, for 
which a weighted average might be the output of a meta-analyses. Here the 
weighting might be related to sample sizes within the individual studies. More 
generally there are other differences between the studies that need to be allowed 
for, but the general aim of a meta-analysis is to more powerfully estimate the true 
"effect size" as opposed to a smaller "effect size" derived in a single study under 
a given single set of assumptions and conditions. It is only a statistical 
examination of scientific studies, not an actual scientific study, itself. 
  Nevertheless, the presence of high variability of the association between 
DRD4 polymorphism and novelty seeking suggests that there are unknown 
causes for observing weak to moderate positive effects in some studies. This 
issue could be addressed more fully by utilizing more advanced statistical 
techniques, high-through output genotyping and large numbers of polymorphoric 
markers such as single nucleotide polymorphisms. 
With respect to the DRD5 gene polymorphism, a transmission 
disequilibrium test (TDT) was used to evaluate the linkage of the DRD5 gene 
variant and ADHD (Hawi et al., 2005). ADHD was associated with over 
transmission of the variant paternal alleles of both DRD5 and DRD4 genes. 
Another study using TDT found only a trend for an association with the DRD5 
gene, but a significant increase in transmission of the DRD4-7r allele in ADHD 
individuals (Tahir et al., 2000).  Also, the role of DRD5 gene in ADHD individuals 
was studied by genotyping ADHD families and searching for the 148 base pair 
allele of DRD5 (Manor et al., 2004). A preferential transmission of this variant 
DRD5 gene was confirmed using TDT with the Family Based Association Test, 
suggesting that the DRD5 repeat polymorphism confers a small, but significant 
(p=0.037) risk for ADHD (Manor et al., 2004). Taken together, the results of these 
studies suggest that the DRD5 gene also plays a role as a genetic factor 
contributing to ADHD, which needs to be further evaluated. 
The DAT1 gene is another gene that has been found to be associated with 
ADHD. The  association between the presence of ADHD and the 480-bp DAT1 
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allele was determined in 49 subjects with ADHD based on DSM-IV criteria using 
the haplotype-based haplotype relative risk (HHRR) method to avoid effects 
associated with the small sample of subjects with regards to  population 
stratification (Cook et al., 1995).  This study found a significant association 
between the 480-bp DAT1 allele and ADHD. As a preclinical correlate, a 
disruption by homologous recombination of the mouse DAT gene knock-out 
(DAT-KO) resulted in 3-fold greater spontaneous hyperactivity, demonstrated as 
immediate hyperactivity when placed in a chamber with no treatment given, 
compared to heterozygotes and WT mice. Since hyperactivity is a hallmark 
symptom of ADHD, the DAT gene was suggested to be involved in the etiology of 
ADHD (Giros et al., 1996). Another study investigated the variable number 
tandem repeats (VNTR) polymorphism of DAT1, which is a location on the 
genome where a short nucleotide sequence is organized as a tandem repeat, 
where a pattern of 2 or more nucleotides is repeated and the repetitions are 
directly adjacent to one another (Barr et al., 2001). To determine if the VNTR was 
associated with ADHD; 333 subjects from 102 nuclear families were genotyped. 
A linkage of the 480-bp allele of the DAT1 gene with ADHD was found, 
suggesting that molecular analysis of the DAT gene may identify mutations that 
increase the risk for ADHD.   
The utilization of pharmacogenomics, which is a branch of pharmacology 
involving the influence of genetic variation on drug response by relating gene 
expression or polymorphisms with a drug’s efficacy or toxicity, may be a potential 
method in developing a gene therapy for ADHD. For example, 
pharmacogenomics is used in cancer research to determine which patient will 
have the best response to a certain treatment. Hopefully, in the same way 
biochemical analysis of these mutations in specific patients could lead to the 
development of more efficacious therapeutic treatment options for individuals 
with ADHD. 
In addition to DAT, the norepinephrine transporter (NET) gene is of 
interest due to the efficacy of atomoxetine, a selective norepinephrine uptake 
inhibitor, as a treatment for ADHD. In addition, NET is primarily responsible for 
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the reuptake of DA in the frontal cortex due to the low density of DAT in this brain 
region. In one study, 184 unrelated males (mean age 34.1 yrs) with adult ADHD 
were assessed according to the International Classification of Diseases (ICD-10), 
10th revision: Clinical Modifications, 6th (Greydanus et al., 2007), criteria for 
ADHD (Retz et al., 2008).  The results of this study found negative evidence of 
an association between the NET gene and ADHD. However, this result could be 
due to the fact that this was a study of adults in Germany with ADHD who may 
have less severe ADHD symptoms compared to adolescents; such that the age 
of the subjects and location of the study could play a role in the results. In 
contrast, Kim et al., (2006, 2008) observed in two separate studies a significant 
association between the polymorphism of the NET gene and ADHD, suggesting 
that anomalous transcription factor-based repression of NET may increase risk 
for the development of ADHD (Kim et al., 2006; Kim et al., 2008). Given the 
controversial results found in the investigation of the NET gene in regards to the 
etiology of ADHD, it is difficult to draw any conclusions as to its association with 
ADHD.  
Based on the evidence provided, genetics may play a vital role in the 
etiology of ADHD. There is still much to be determined in regards to which 
specific polymorphisms are more responsible for the development of ADHD, 
however, future advances that will be made in this area will help gain a better 
understanding of the role that genetics play in the etiology of ADHD. 
Other studies have shown that environmental conditions such as prenatal 
exposure to alcohol and tobacco smoking may be associated with the 
development of ADHD in childhood (Linnet et al., 2003; Mick et al., 2002; 
Milberger et al., 1996; Milberger et al., 1998). One study assessed 1,452 twin 
pairs and found that maternal smoking shows an association with ADHD 
symptoms in the offspring (Thapar et al., 2003). A meta-analysis on literature 
published before 2005 revealed a pooled odds ratio indicating more than a 2-fold 
increase in the risk for ADHD in individuals whose mothers smoked tobacco 
during pregnancy (Langley et al., 2005), suggesting that maternal smoking during 
pregnancy is a risk factor for ADHD.   With respect to alcohol exposure, one 
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study assessed 68 children who were born into three separate groups, women 
who reported not drinking during pregnancy, women who reported drinking 
during pregnancy, and women who reported drinking an equivalent amount, but 
who stopped after an educational intervention during the second trimester 
(Brown et al., 1991).  The results showed those children who were exposed to 
alcohol throughout pregnancy showed deficits in the ability to sustain attention. 
Another study analyzed a twin cohort consisting of 922 children with a history of 
maternal alcohol use (Knopik et al., 2006). The study used a children-of-twins 
design, which is a design that incorporates twins in order to explore the effects of 
genetics and environmental variance on a phenotype. In addition, diagnostic 
telephone interview data from high-risk families and control families targeted from 
a large Australian twin cohort were employed. The calculated odds ratio 
(OR=2.53) suggested that children exposed to prenatal alcohol were two-times 
more likely to exhibit ADHD compared to those not exposed to prenatal alcohol. 
The findings from the aforementioned studies imply that maternal alcohol and 
tobacco use may play a key role in the etiology of ADHD.  
 Evidence has shown that these risk factors of maternal tobacco and 
alcohol use may be important etiologies of ADHD. These risk factors may work in 
concert with genetic factors, in that the exposure to nicotine and alcohol may 
interact with genetic polymorphisms, making these children more at risk for 
ADHD. In contrast, there are children who were not exposed prenatally to 
nicotine or alcohol that have ADHD. With that in mind, further research is 
necessary to fully address the complexity of the etiology of ADHD. 
3. Symptomology and Diagnosis  
ADHD presents as a myriad of symptoms including the hallmarks, 
hyperactivity, impulsivity and inattention, with 30-60% of childhood cases 
extending into adulthood (American Psychiatric Association, 2000; Himelstein & 
Halperin, 2000).  The specific symptoms listed as diagnostic criteria for ADHD in 
the DSM-IV-TR include: 
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1) Six or more of the following symptoms of inattention have 
persisted for at least 6 months to a degree that is maladaptive and 
inconsistent with the developmental level:  
a) Often fails to pay close attention to details or makes 
careless mistakes in schoolwork, work, or other 
activities 
b) Often has difficulty sustaining attention in tasks or 
play activities.  
c) Often does not seem to listen when spoken to directly 
d) Often does not follow through on instructions and fails 
to finish schoolwork, chores, or duties in the 
workplace (not due oppositional behavior or failure to 
understand instructions) 
e) Often has difficulty organizing tasks and activities  
f) Often avoids, dislikes, or is reluctant to engage in 
tasks that require sustained mental effort (such as 
schoolwork or homework) 
g) Often loses things necessary for tasks or activities 
(i.e., toys, school assignments, pencils, books, or 
tools) 
h) Is often easily distracted by extraneous stimuli 
i) Is often forgetful in daily activities 
2)  Six or more of the following symptoms of 
hyperactivity/impulsivity have persisted for at least 6 months to a degree 
that is maladaptive and inconsistent with the developmental level:  
a) Often fidgets with hands or feet or squirms in seat 
b) Often leaves seat in classroom or in other situations 
in which remaining seated is required 
c) Often runs about or climbs excessively in situations in 
which it is inappropriate (in adolescents or adults, 
may be limited to subjective feelings of restlessness) 
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d) Often has difficulty playing or engaging in leisure 
activities quietly 
e) Is often “on the go” or often acts as if “driven by a 
motor” 
f) Often talks excessively 
g) Often blurts out answers before questions have been 
completed 
h) Often has difficulty waiting 
i) Often interrupts or intrudes on others (butts into 
conversations or games) 
(American Psychiatric Association, 2000; Greydanus et al., 2007) 
Some of the hyperactive-impulsive or inattentive symptoms that cause 
impairment were present before 7 years of age. In addition, some impairment 
from the symptoms is observed in 2 or more settings (i.e., at school, work, or at 
home). Due to the complex symptomology, ADHD has been divided into three 
subtypes: a) predominantly inattentive (known as Attention-Deficit Disorder 
(ADD), b) predominantly hyperactive/impulsive, and c) combined 
hyperactive/impulsive and inattentive subtypes, to help obtain a more accurate 
diagnosis and treatment of the disorder (American Psychiatric Association, 
2000). The inattentive subtype is characterized by inattention, distractibility, 
disorganization, forgetfulness, and lethargy. The hyperactive-impulsive subtype 
includes symptoms of interrupting, impatience, and fidgetiness. The combined 
subtype is a combination of both the inattentive and hyperactive-impulsive 
subtypes (Tamm et al., 2001). Dividing ADHD into these subtypes is helpful with 
respect to treatment, because ADHD symptoms are unique to each patient 
depending on their specific subtype and their individual response to the 
medication. Russell Barkley, a renowned ADHD researcher believes that 
methylphenidate is more effective in treating ADHD and that amphetamine is 
better suited for the treatment of ADD. This is based on the mechanism of action 
of amphetamine causing it to have a greater effect on norepinephrine than 
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dopamine, therefore, having more of an effect on the inattentive symptom 
(Barkley, 2001). 
Impulsivity and sensation seeking are personality traits that have been 
linked together for various reasons (Nower & Blaszczynski, 2006). Impulsivity is 
defined as “the failure to resist an impulse, drive, or temptation to perform an act 
that is harmful to the person or others” (American Psychiatric Association, 2000). 
Sensation seeking is defined as “the seeking of varied, novel, complex and 
intense sensations and experiences, and the willingness to take physical, social, 
legal, and financial risks for the sake of such experiences (Zuckerman, 1994).  
Adolescence appears to be a critical period of development for these traits. Two 
systems that are involved in the development of adolescent behavior are the 
subcortical socioemotional system and the cognitive control system (Nower & 
Blaszczynski, 2006). The subcortical socioemotional system includes the ventral 
striatum and the amygdala, which is responsible for emotion, novelty, and 
reward. The cognitive control system includes the prefrontal cortex, which is 
crucial for impulse control, emotion regulation, and decision-making. These 
systems mature at different time points throughout the course of development. 
For example, the socio-emotional system appears to become more sensitive in 
early adolescence, during the same time of the onset of puberty.  However, the 
cognitive control system develops more gradually during the end of early 
adulthood (Casey et al., 2005).  Therefore, adolescents may experience an 
increased responsiveness to rewards, affective cues, and novelty while still 
having immature capacities for impulse control and inhibition. A recent report 
conducted in humans found that mean levels of impulsivity were found to decline 
through adolescence and then plateau as youth reached their mid-20s; however, 
mean levels of sensation seeking were found to increase profoundly until mid-
adolescence, peaking around the age of 16 and then slowly decreasing through 
the mid-20s. Various experimental methods have been developed to examine 
impulsivity and sensation seeking in an animal model; however, most of these 
methods have only used a single task as the predictor variable. A novel study 
determined if measuring multiple behavioral tasks simultaneously would be 
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useful for characterizing aspects of sensation seeking and impulsivity as 
predictor variables for amphetamine self-administration (Marusich et al., 2011a).  
This study found that combining these predictor variables into a multivariate 
approached failed to produce any significant correlations among predictor and 
outcome measures. The results imply that multivariate tests are possibly 
insensitive as reliable predictors of drug self-administration, which could 
represent a limitation of animal models for assessing drug abuse vulnerability, at 
least for this particular study.   
 In conclusion, impulsivity and sensation seeking are human traits that are 
multifaceted and require a great deal of skill to evaluate. Furthermore, assessing 
these traits in an animal model is even more of a challenge based on the 
difference in life span between and human and a rat. In addition, impulsivity and 
sensation seeking are human traits that may not be fully modeled in laboratory 
animals. Studies have shown a relationship between impulsivity and sensation 
seeking, however more research is warranted to determine the extent of this 
relationship. 
Evaluation and diagnosis of ADHD are subjective because there are no 
objective diagnostic measurements to test for ADHD. However, there are 
numerous specific diagnostic criteria of ADHD available to assist clinicians in the 
diagnosis. The overall desired outcome of assessment criteria is to determine if a 
child or adult meets the qualifications for ADHD, which may rule out other 
conditions (Liu & Leslie, 2003). Other medical, psychiatric, or developmental 
disorders must be ruled out before the presence of developmentally 
inappropriate levels of inattention and/or hyperactivity/impulsivity can be 
diagnosed as ADHD (American Psychiatric Association, 2000). There are three 
commonly used diagnostic tools, including the DSM-IV-TR, Classification of Child 
an Adolescent Mental Diagnosis in Primary Care: Diagnosis and Statistical 
Manual for Primary Care (DSM-PC), and the ICD-10 (Greydanus et al., 2007). 
The American Psychiatric Association (APA) publishes the DSM-IV-TR and gives 
the most detailed list of symptoms by classification with diagnostic codes and 
criteria used to evaluate the disorder as stated previously. These methods for 
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diagnosis were developed based on different settings that patients are evaluated 
in, and generally are similar. Therefore, the most appropriate assessment 
method is chosen based on setting. The DSM-PC, intended for primary care 
environments, uses a developmental approach to diagnosis, and distinguishes 
between variations, problems, and disorders. The ICD-10 uses the term 
attention-deficit/hyperkinetic disorder, which is commonly used by insurance 
companies (Greydanus et al., 2007).  Questionnaires and rating scales, such as 
the Connors ADHD Index and the DSM-IV Symptoms scales have been 
suggested by the American Academy of Pediatrics (Forsback et al., 2004) as 
guidelines to ensure accurate diagnosis (Tripp et al., 2006). The Connors ADHD 
Index has various different versions based on who is taking the assessment 
(Conners, 1999).  For example, there is the Conners’ Parenting Rating Scale 
Revised-Long Version (CPRS-R:L). This version contains 80 items with 10 
different scales for the parents or caregivers to complete. The short version 
(CPRS-R:S) contains only 27 items and 4 scales. There is also the Conners-
Well’s Adolescent Self-Report Scale-Long Form (CASS:L). This self-report scale, 
which is ideal for adolescents between the ages of 12 and 17, contains 87 items 
and 8 scales.  There is also an assessment for adults called the Conner’s Adult 
ADHD Rating Scale-Self Report: Short Version (CAARS-S:S). It contains 26 
items that quantitatively measure ADHD symptoms while looking at the 
manifestations of ADHD in adults. Subjects read descriptive statements that they 
may, or may not, be presently experiencing (i.e., I have trouble sitting still). 
Subjects rate each statement on a four-point Likert scale ranging from “Not at all” 
to “Very much”. CAARS subscales include: A = Inattention/Memory Problems, B 
= Hyperactivity/Restlessness, C = Impulsivity/Emotional Reliability, D = Problems 
with Self-Concept and E = Total ADHD Index. In summary, there are several 
tools that clinicians can utilize to ensure accurate evaluation and diagnosis of 
ADHD. 
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4. Neuroanatomical and Neurochemical Basis of ADHD  
a. Neuroanatomy 
The neuroanatomical and neurochemical basis of ADHD is based on the 
general consensus that there is a dysregulation of the catecholaminergic 
neurotransmitter systems (Heal et al., 2008). Neuroimaging studies have 
suggested that brain regions, including the prefrontal cortex (PFC) and the basal 
ganglia (striatum, caudate nucleus and putamen)  are the regions with 
dysregulation of neurotransmission in ADHD (Casey et al., 2007).  The PFC and 
striatum are the most widely studied regions regarding ADHD, because these 
regions are involved in behavior, attention, motor control and cognition (Arnsten, 
2006; Kieling et al., 2008). Specifically, motor control is modulated by the 
nigrostriatal DA pathway projecting from the substania nigra to the basal ganglia 
(Stanwood & Zigmond, 2000).  The mesolimbic pathway, projecting from the 
ventral tegmental area (VTA) to the subcortical limbic regions (nucleus 
accumbens, olfactory tubercle and amygdala) is associated with motivated 
behavior (Ikemoto & Panksepp, 1999) and reinforcement (Schultz et al., 2000).  
The mesocortical DA pathway projects from the VTA to the PFC and is involved 
in cognitive function (Floresco & Magyar, 2006). 
Noradrenergic neurons originate both in the locus coeruleus and the 
lateral tegmental area. Norepinephrine containing cell bodies are only found in 
the pons and medulla. However, the pontine norepinephrine-containing cells 
which terminate in the nucleus locus coeruleus, give rise to extensive projections 
to the hypothalamus, thalamus, limbic regions, and cortex. Medullary 
norepinephrine cells project to the hypothalamus, locus coeruleus, and spinal 
cord (Rinaman, 2011). 
b. Neurochemistry 
i. DA synthesis and metabolism 
Research on the neurochemical basis of ADHD has focused primarily on 
dopaminergic neurotransmission and function (Figure 1). DA is transported by 
DAT and pharmacological agents that influence the DA system via DAT have 
been the most effective treatments for ADHD (Zhu & Reith, 2008). DA is a 
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catecholamine involved in behavior and cognition; voluntary movement, 
motivation and reward (Jaber et al., 1996).  The synthesis of DA takes place in 
DA neurons, starting with L-tyrosine which comes from the essential amino acid, 
phenylalanine, which is derived from food. L-Tyrosine is converted to L-
dihydroxyphenylalanie (L-DOPA) via an  enzyme located in the cytosol called 
tyrosine hydroxylase (TH), which is the rate limiting step in the synthesis of DA 
(Cooper et al., 2003). The co-factors for tyrosine hydroxylase include 
tetrahydrobiopterin, O2, and Fe2+ (Cooper et al., 2003). Enzyme activity is 
regulated by phosphorylation at four different serine sites at the N-terminus and 
through the end-product inhibition and through competition for the required 
cofactors for the enzyme (Cooper et al., 2003). L-DOPA is then decarboxylated 
by aromatic L-amino acid decarboxylase (also located in the cytosol), which 
produces DA. The co-factor for this enzyme is pyridoxal 5-phosphate and is 
regulated by induction of synthesis of new protein rather than changes in activity 
(Squire LR, 1999).  After DA is synthesized, it is stored in synaptic vesicles for 
future release from the terminal into the synapse. An action potential causes 
depolarization of the nerve terminal, which in turn causes the synaptic vesicles to 
fuse to the synaptic membrane and release DA into the synaptic cleft (Cooper et 
al., 2003; Squire LR, 1999).  Specifically, Na+ ions flow into the cell and K+ 
channels open allowing the flow of K+across the membrane causing the 
membrane to become depolarized. There is a rise in Ca2+ concentration that 
triggers the fusion of the vesicles with the plasma membrane and the release of 
their contents into the synaptic cleft. This is the physiological process  known as 
exocytosis (Squire LR, 1999).   
DA is inactivated by two enzymes, catechol-O-methyltransferase (COMT) 
and monoamine oxidase (MAO) that are located in the postsynaptic neuron and 
outer mitochrondrial membrane, respectfully. The pathway for the metabolism of 
DA by MAO involves the conversion of DA to 3, 4-dihydroxyphenylacetaldehyde. 
Then, this product is converted to dihydroxyphenylacetic acid (DOPAC) by 
aldehyde dehydrogenase. Subsequently, DOPAC is converted by COMT to form 
homovanillic acid (HVA). Another possible pathway is for DA to be converted to 
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3-methoxytyramine (3-MT) by COMT. 3-MT is then converted to 3-methoxy-4-
hydroxyphenylacetaldehyde, which is then converted to homovanillic acid (HVA) 
by aldehyde dehydrogenase. 
ii. DA receptors  
In the synapse, DA has access to both presynaptic and postsynaptic DA 
receptors to which it binds. DA acts at both the D1-like (D1 and D5) and D2-like 
(D2, D3, D4) receptor families (Arnsten, 2006).  The amino acid (AA) sequence 
for the entire family ranges from 387 AA (D4) – 477 AA (D5). The main structural 
differences between the D1-like and D2-like receptors are the intracellular loop 
between the 6th and 7th transmembrane domain (TMD) segments which are 
larger in the D2-like receptors. D2 receptors have a smaller C-terminal in the 
intracellular segments after the 7th TMD segment. There are two isoforms of the 
D2 receptor, D2-long and D2-short. The D2-long receptor has 444 AA in rats and 
443 AA in humans (Cooper et al., 2003). The D2-short has 415 AA in rats and 
414 AA in humans. D1 receptors have a high density in striatum and nucleus 
accumbens and their activation stimulates adenylate cyclase to produce cyclic 
adenosine monophosphate (cAMP). D5 receptors are mostly located in 
hippocampus and  hypothalamus, but are found also in striatum and nucleus 
accumbens to a lesser extent. The D5 receptor, which also stimulates adenylate 
cyclase, is only located in the hippocampus, thalamus, and hypothalamus. D5 
receptors have a 10-fold higher affinity for DA compared to D1 receptors (Cooper 
et al., 2003).  
The D2 receptor family includes the D2 subtype, which are both an 
autoreceptor located presynaptically and a postsynaptic receptor. The release of 
DA regulates the synthesis of DA by stimulating the DA receptors which can 
modulate the synthesis of DA via a negative feedback, such that when there is a 
decrease in DA, the DA receptors are stimulated to produce more DA (Cooper et 
al., 2003).  A greater number of D2 receptors are located on the postsynaptic 
membranes, compared to presynaptic D2 receptors. Postsynaptic D2 receptors 
are located in striatum, nucleus accumbens, olfactory tubercle, and neuron cell 
bodies in substantia nigra and VTA D1 and D2 receptors have opposite effects 
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on adenylate cyclase activity. Adenylate cyclase catalyzes the conversion of ATP 
to c-AMP and pyrophosphate via a G-protein, which signals a downstream 
cascade of events, including the activation of protein kinase A (PKA). 
Recently,methylphenidate was suggested to modulate D2 receptors, thus 
indicating the involvement of this receptor in the mechanism of action of 
methlyphenidate (Volz et al., 2008). D3 receptors are localized in the nucleus 
accumbens, olfactory tubercle, and hypothalamus. The D4 receptors are found in 
frontal cortex, midbrain, and amygdala.   
iii. DAT 
After DA binds to its receptors, it is then transported back into the terminal 
by DAT and is transported into vesicles by the vesicular monoamine transporter 
(VMAT2) for repackaging and future exocytotic release (Hiongwa, 2004). DAT 
plays a vital role in the function of DA. DAT is among the family of 12 
transmembrane  domain (TMD; Figure 2) neurotransmitter transporter sodium 
symporter class (Saier, 1999), which also includes the norepinephrine transporter 
(NET) and the serotonin transporter (SERT).  DAT is a Na+/Cl- dependent 
transmembrane transporter protein also called the neurotransmitter sodium 
symporter (NSS) that regulates the extracellular DA concentration (Amara & 
Sonders 1998; Krause et al., 2003). DAT contains 620 amino acid residues, and 
currently, there is no X-ray crystal structure of DAT. However, the recently 
published crystal structure of Aquifex aedicus leucine transporter (LeuTAa), allows 
researchers to have a suitable template for DAT because this prokaryotic 
organism processes a NSS that is homologous to the human NSS (Yamashita et 
al., 2005).  LeuTAa produced crystals which were determined by multi-wavelength 
anomalous dispersion (MAD), using crystals grown from selemethionine-labeled 
protein and diffraction data measured to Bragg spacings of 1.9A°. A more recent 
study employed a novel computational modeling approach, the Molecular 
Operating Environment program MOE 2005.06 and to two other modeling 
servers, using LeuT-Aa as a template, to expand upon the proposed molecular 
structure of DAT. As shown in Figure 2, the DAT model that was developed 
suggests, like the LeuTAa, that TMDs 3 and 8 combine with TMDs 1 and 6 to form 
17 
the substrate binding pocket. In addition, this model implies favorable interactions 
for substrate recognition between the 3rdTMD, and the valine amino acid, number 
152 side chain and either the aromatic ring or the lipophilic hydrocarbon portion 
of both DA and amphetamine (Indarte et al., 2008).   
DAT antibodies, which were all used for immunolocalization of DAT in rat 
brain at the light microscopic level, were characterized and developed by 
immunoblot analysis, immunoprecipitation, and immunocytochemistry to 
specifically detect DAT proteins. DAT is mainly expressed in the striatum and 
nucleus accumbens, but can also be found in the globus pallidus, cingulated 
cortex, olfactory tubercle, amygdala, and midbrain (Ciliax et al., 1995).    
DAT-like immunoreactivity has been detected in striatum, nucleus 
accumbens, olfactory tuberacle, nigrostriatal bundle, which is a group of nerve 
fibers and lateral habenula (Hersch et al., 1997). The specific localization of 
DAT on the synaptic terminal has been studied using dual localization of DAT 
and TH with electron microscopic immunocytochemistry in the rat ventral 
pallidum (Pickel et al., 2004).  Electron microscopy confirmed that the majority 
of DAT and TH were located in axonal profiles in the ventral pallidum. These 
findings were the first to provide structural evidence showing that DAT is 
localized to the axonal profiles with a significantly higher mean area density in 
the dorsolateral ventral pallidum than the ventromedial ventral pallidum. The 
pallidum is important because it is a major element of basal ganglia, which 
includes the striatum, which is also the region used in the studies of this 
dissertation research. 
There has been a wealth of research performed on DAT knock-out (KO) 
mice as well (Fauchey et al., 2000; Gainetdinov & Caron, 2003; Giros et al., 
1996; Hall et al., 2009; Jones et al., 1999; Jones et al., 1998a; Rocha et al., 
1998).  This research was performed in order to gain a better understanding of 
the function of DAT and to determine how the dopaminergic system acts in the 
absence of DAT.  One report found that despite the decreased amount of DA in 
tissue, DAT KO mice have more than normal levels of extracellular DA and 
spontaneous hyperlocomotor activity (Rocha et al., 1998).  One study reported 
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that DAT KO mice display a 300-fold increase in extracellular lifetime of DA and 
a 5-fold elevation in steady-state extracellular DA levels in striatum (Gainetdinov 
& Caron, 2003).  In addition, these mice do not display an increase in locomotor 
activity typically seen upon administration of high doses of cocaine (Giros et al., 
1996).   
D1 and D2 receptor levels have also been investigated in DAT KO mice. 
Jones and colleagues found that in striatum, the D1 and D2 receptors were 
decreased by approximately 50%; TH levels were increased even though 
protein levels were down nearly 90%; and total tissue DA levels were only 5% of 
normal, whereas extracellular DA was increased by at least 5-fold in striatum 
(Jones et al., 1998a).  Another study found that D1R mRNAs coding decreased 
for D1R and D2R by 34% and 36%, respectively in caudate putamen of DAT 
KO mice, which suggest that there are fewer D1R and D2R receptors in DAT 
KO mice (Fauchey et al., 2000). DAT KO mice have several characteristics 
found in individuals that have ADHD including hyperactivity, cognitive 
impairment, and a calming response to psychostimulants (Jones et al., 1999).   
A more recent study further explored the effect of DAT KO by investigating 
the rewarding effects of cocaine and the ability of repeated cocaine 
administration to induce conditioned locomotion (Hall et al., 2009).  Conditioned 
locomotion is the process by exposing animals to drug or stimuli over a period 
of time and then comparing those animals with control animals to determine if 
the drug or stimuli caused neurochemical changes, which are reflected by a 
change in locomotor activity. DAT KO mice were significantly more active 
compared to WT; however they did not have increased locomotion after acute 
cocaine administration. NET and SERT affect the ability of cocaine to produce 
conditioned locomotion. These results suggest that the ability of cocaine to 
produce conditioned locomotion is dependent on NET or SERT, but not DAT. 
In summary, the research on DAT KO mice has illuminated the 
mechanisms by which DAT acts and its importance to the overall dopaminergic 
system. This work may also have implications for the development of certain 
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pharmacological agents for disorders that involve DAT, such as drug abuse and 
ADHD. 
Numerous studies suggest that DAT is regulated by several mechanisms 
including, but not limited to internalization and recycling, also known as 
trafficking, which involves phosphorylation and protein-protein interactions 
(Kahlig & Galli, 2003; Loder & Melikian, 2003; Melikian, 2004; Torres et al., 
2003; Zahniser & Doolen, 2001).  Great efforts have been made towards 
elucidating the molecular and cellular mechanisms involved in the trafficking of 
DAT. Many different kinases, receptors and scaffolding proteins interact with 
DAT and regulate its activity or modulate its trafficking and degradation. Second 
messenger systems, such as protein kinase C (Boudanova et al., 2008), protein 
kinase A (PKA), and calcium-calmodulin kinase II alter DAT function, 
phosphorylation, and trafficking. Furthermore, DAT endocytosis is suggested to 
be the cause of the sustained DAT down-regulation in response to PKC 
activation (Eriksen, 2010). Another post-translational modification that may be 
involved in PKC activation is ubiquitination, a post-translational enzymatic 
modification that involves the ε-amino moiety of lysine residues in target cellular 
proteins (Miranda & Sorkin, 2007; Miranda et al., 2005; Sorkina et al., 2006). 
Although the underlying mechanisms of DAT trafficking are still not fully 
understood, new technical methodologies such as fluorescently tagged 
inhibitors and substrates have advanced our understanding of DAT trafficking. 
For example, fluorescence resonance energy transfer (FRET) experiments with 
cyan fluorescent protein-tagged DAT and yellow fluorescent protein tagged 
ubiquitin demonstrated that ubiquitination was most abundant in endosomes 
supporting that ubiquitination is a signal for endocytosis (Miranda et al., 2005). 
Other kinase pathways including downstream effectors of insulin signaling such 
as phosphatidylinositol-3-kinase and serine/threonine protein kinase, Akt have 
been shown to also affect DAT surface expression (Carvelli et al., 2002).  
In addition, [3H]DA uptake kinetics was assessed and the cellular 
localization profiles of the hDAT expressed in both Sf9 and COS-7 cells via 
immunofluorescent confocal microscopy following modulation of PKC and 
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protein PKA-dependent pathways were evaluated (Pristupa et al., 1998). Acute 
exposure of hDAT expressing Sf9 cells to the PKC activator PMA (1 µM), 
reduced the Vmax (approximately 1 pmol/min/105 cells) for [3H]DA uptake by 
approximately 40%, an effect which was blocked by the protein kinase inhibitor, 
staurosporine. Vmax is defined as the maximal velocity of uptake. Pretreatment 
of cells with staurosporine (500 nM) alone, however, increased [3H]DA uptake 
by approximately 30%, an effect mimicked by the potent PKA inhibitor 
Rp-cAMPS. Immunofluorescent confocal microscopy showed that PKC 
activation rapidly internalized the hDAT from plasmalemmal membrane, but 
PKC inhibition led to trafficking of hDAT to the cell surface. These results 
suggest that the differential regulation of DAT transport capacity by both PKC- 
and PKA-dependent pathways are not a result of modifications in DAT kinetics 
and that DAT function may be regulated by second messenger systems, 
possibly following activation of presynaptic DA receptors (Pristupa et al., 1998). 
A recent report has also suggested that the PKC-induced DAT regulation 
may depend on the membrane localization of the transporter in reference to raft 
and non-raft DATs (Foster et al., 2008). Lipid rafts contain 3 to 5 times more 
cholesterol than the surrounding bilayer. They are heterogeneous, dynamic 
membrane microdomains enriched in cholesterol and glycosphingolipids, which 
are wider than non-raft regions and resistant to solubilization by detergents. 
Lipid rafts are associated with internalization and endocytic cargo delivery.  
DATs are located between raft and non-raft microdomains in rat striatal tissue 
and have the potential to effect dopaminergic neuronal activity (Foster et al., 
2008). Decrease of surface DAT was only found in non-raft DAT populations. 
These results suggest that trafficking events regulate non-raft DATs and non-
trafficking regulatory mechanisms occurs in raft DATs. These authors identified 
the presence of DAT in cholesterol-rich membrane raft domains, which could 
possibly serve as a platform for regulatory DAT activity, phosphorylation, and 
subcellular interactions. Thus, DAT is distributed between membrane raft and 
non-raft populations, where it is subject to specific regulatory controls that could 
provide distinct modulation of DA clearance and efflux. More recently, Sorkina 
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et al., (2009) found that the intracellular N-terminal tail of DAT has an inhibitory 
influence on internalization, by promoting the presence of DAT on the cell 
surface. In addition, DAT-mediated uptake activity is increased by replacing the 
first 65 amino acids of the N-terminal tail of DAT with a DAT mutant. This was 
shown by visual examination of human epithelial cervical cancer cells (HeLA) 
and porcine aortic endothelial cells (PAE). A significant accumulation of the DAT 
mutant was found in intracellular compartments (Sorkina et al., 2009).  Another 
study used the fluorescent DAT substrate ASP+ and live cell imaging 
techniques, such as bioluminescence resonance energy transfer (Brett) to 
identify the role of two D2R-linked signaling pathways, extracellular signal-
regulated kinases 1 and 2 (ERK1/2) and phosphodinositide 3 kinase (P13K).  
These pathways mediate D2R activation and up-regulate DAT function based 
on the observations that ASP+ rapidly accumulated in the cytoplasm of EM 
(embryonic) cells (Bolan et al., 2007). This accumulation was intensified by the 
D2R agonist quinpirole. In addition, eticlopride a D2R antagonist blocked 
quinpirole-evoked increase in ASP+ accumulation. Furthermore, the MEK 
inhibitor PD98059 prevented quinopirole-evoked ERK1/2 phosphorylation, but 
the PI3K inhibitor LY294002 had no effect. These results suggest that D2SR 
regulation of DAT requires coupling to Gi/G0 proteins and ERK1/2 activation.   
DAT has also been reported to generate detectable currents during the 
process of substrate transport (DeFelice & Blakely, 1996; Lester et al., 1994; 
Sonders & Amara, 1996). One study used two-electrode clamp techniques with 
hDAT expressed in  Xenopus laevis oocytes to examine the electrophysiological 
and pharmacological characteristics of DAT (Sonders et al., 1997). Oocytes 
expressing hDAT were voltage-clamped at -60 mV and were superfused with 20 
µM DA, which produced a downward displacement in the current trace 
consistent with a net inward current. The inward current was suggested to be 
the result of the translocation of DA+ and Na+ ions. However, 10-µM cocaine 
produced an outward current, both on initial application and reapplication of 
cocaine after DA superfusion of the same oocyte. These findings suggest that 
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hDAT mediates at least two distinct steady-state ionic conductances that result 
from transport-associated currents (Sonders et al., 1997).   
A more recent study combined confocal imaging, whole-cell steady-state 
and transient current recordings with HEK-293 cells transfected with a yellow 
fluorescent protein-tagged hDAT to monitor DAT cell surface expression and 
activity (Kahlig et al., 2004).  At -160 mV, amphetamine decreased hDAT-
mediated transient currents, and these currents were dependent upon 
extracellular Na+. In addition, these currents corresponded to the amphetamine 
decrease in DAT expression at the cell surface, measured by cell-surface 
biotinylation. These findings suggest that DAT transient charge movements can 
be used to evaluate relative changes in DAT cell surface expression.  
DAT is considered the main target for stimulant action, and stimulants 
interact directly with DAT (Gainetdinov & Caron, 2003; Krause et al., 2003; 
Volkow et al., 2007). A plethora of research has been conducted on the 
mechanisms by which DAT is regulated and expressed. The studies discussed 
here have shown how DAT may be regulated by a number of different pathways 
and signaling messengers. Some of these pathways include PKA and PKC, 
which are involved in the internalization of DAT. Others have investigated DAT 
structure and how its conformation plays a role in the regulation of DAT. In 
addition, studies were performed to determine how trafficking plays a role in DAT 
expression and function. Furthermore, others have investigated how ion currents 
involved in the electrophysiological and pharmacological characteristics of DAT. 
Collectively, these studies have provided a better understanding of how DAT is 
regulated and expressed. Hopefully the knowledge gained from this research will 
lead to pharmacological agents that can be used in the treatment of diseases 
that involve DAT, such as ADHD. 
iv. NET 
The norepinephrine transporter (NET) is the primary target for the first and 
only non-stimulant medication, atomoxetine, Strattera® approved by the U.S. 
Food and Drug Administration (FDA) to treat ADHD (Wilens, 2006).  In addition, 
methylphenidate and amphetamine, the gold standard ADHD treatments, inhibit 
23 
NET function in addition to inhibiting DAT function (Bymaster et al., 2002; Han & 
Gu, 2006). The major function of NET is to translocate norepinephrine, a 
neurotransmitter involved in mood regulation, behavior, alertness and arousal, 
from the extracellular space to within the noradrenergic presynaptic terminals 
(Barker & Blakely, 1995; Pacholczyk et al., 1991; Zavosh et al., 1999; Zhou, 
2004).  NET is a member of the same family of transporters as DAT and is also a 
Na+/Cl- dependent transmembrane transporter protein (Hu et al., 2009; Zhou, 
2004).   
NET contains 617 amino acid residues (Torres et al., 2003).  Human NET 
(hNET) has 10 cysteine residues, and two of these which are located in the 
second intracellular loop are linked by a disulfide bond (Sucic & Bryan-Lluka, 
2005). TMD 2 and the first intracellular loop are important in determining cell 
surface expression of the transporter (Sucic & Bryan-Lluka, 2005). Residues 94-
111 of NET appear to not be involved in substrate interactions; however, these 
residues are associated with interactions with various inhibitors (Sucic & Bryan-
Lluka, 2005). The regulation of NET involves extracellular and intracellular 
signaling pathways including several associated proteins such as SNARE protein 
syntaxin 1A, protein phosphatase 2A (PP2A), catalytic sub unit (PP2A-C), and 
PP2A anchoring subunit (PP2A-Ar) (Miner et al., 2006; Sung & Blakely, 2007; 
Sung et al., 2005).   
Xu and colleagues found that NET knockout mice have reduced body 
temperature and body weight and are supersensitive to psychostimulants;  
however, they have reduced intracellular norepinephrine, increased 
norepinephrine synthesis and elevated extracellular norepinephrine (Xu et al., 
2000). These findings suggests that NET plays a role in regulating body 
temperature and body weight, and that the mechanism of action of the stimulant 
class of drugs involves NET, since in its absence supersensitivity to stimulants 
occurs. Focus on the development of selective NET inhibitors as a treatment for 
ADHD has increased, because of the potential abuse liability of stimulant 
medications, whereas NET inhibitors do not appear to have this side effect (Seu 
et al., 2009).   
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v. VMAT2 
Another important transporter for DA function is VMAT2, which is the only 
transporter that translocates cytoplasmic DA from the cytosol into synaptic 
vesicles for storage, providing availability for future exocytotic release (Yelin & 
Schuldiner, 2002).   VMAT2 and VMAT1 are members of the solute carrier (SLC) 
protein family encoded by separate genes VMAT1 (SLC18A1) located on 
chromosome 8p21 and VMAT2 (SLC18A2) located on chromosome 10q25 
(Adam et al., 2008; Eiden et al., 2004). VMAT2 is an integral membrane protein 
with 12 putative transmembrane domains containing a large, hydrophobic, N-
glycosylated loop between TMD1 and 2 facing the vesicle cytosol (Yao & Hersh, 
2007; Yelin & Schuldiner, 2002). During embryonic development, both VMAT1 
and VMAT2 are widely expressed in the CNS; however, by adulthood, VMAT2 
predominates (Hansson et al., 1998). The decrease in VMAT1 expression has 
been suggested to be due to the absence of VMAT1 gene expression. In 
adulthood, VMAT1 is primarily expressed in neuroendocrine cells such as 
chromaffin cells found in the adrenal medulla and enterochromaffin cells located 
in the intestinal tract (Erickson et al., 1996; Peter et al., 1995; Weihe et al., 1994). 
VMAT2 is expressed in at least 2 endocrine cell populations, and moreover, in 
neurons. Adult mammalian monoaminergic neurons of the central nervous 
system and sympathetic postganglionic neurons express VMAT2, not VMAT1 
(Erickson et al., 1996; Peter et al., 1995; Weihe et al., 1994). 
The pharmacology of VMAT1 and VMAT2 is distinct. Although they both 
transport monoamines such as serotonin, DA, epinephrine and norepinephrine, 
VMAT1 transports histamine, whereas VMAT2 transports histamine (Km~ 24 µM; 
(Erickson et al., 1996; Merickel & Edwards, 1995). Km is defined as the 
concentration of substrate at half of maximal velocity. In addition, VMAT1 has a 
higher affinity for serotonin compared to VMAT2 (Brunk et al., 2006). VMAT2 is 
responsible for the transport of neurotransmitters such as DA, serotonin, 
norepinephrine, epinephrine, and histamine from the cytosol into synaptic 
vesicles (Schuldiner et al., 1995). VMAT2 is an essential protein as indicated by 
the finding that homozygous VMAT2 knockout mice do not survive after birth 
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(Fon et al., 1997; Takahashi et al., 1997; Wang et al., 1997). Tetrabenazine, a 
benzoquinolizine compound (Zheng et al., 2006), and reserpine, an alkaloid, are 
considered classical VMAT2 inhibitors (Pletscher, 1977).  Studies have shown 
that VMAT2 binding is altered by psychostimulants (Brown et al., 2001a; 
Fleckenstein & Hanson, 2003). For instance, methamphetamine administration 
(15 mg/kg; 4 ip injections at 2 hr intervals) decreases (22%) striatal VMAT2 
binding of [3H]dihydrotetrabenazine, assessed 14 days after treatment (Guilarte 
et al., 2003). Also, methylphenidate (40 mg/kg, sc) redistributes VMAT2 within 
the nerve terminals an hour after treatment, distributing VMAT2 between the 
cytoplasmic and membrane-associated vesicle fractions. In contrast, 
methylphenidate did not cause redistribution since a majority of DAT was present 
in just the membrane-associated vesicle fraction, not the cytoplasm (Volz et al., 
2007).  In addition, lobeline, a novel alkaloid, inhibits [3H]DA uptake into rat 
striatal vesicle preparations with an IC50of 0.88 ± 0.001 µM and  displaces 
dihydrotetrabenazine binding with an IC50 of 0.90 ± 0.02 µM (Teng et al., 1998; 
Teng et al., 1997). VMAT2 plays an important role in protecting the neurons 
against damage from toxins, such as hydrogen peroxide, by maintaining a low 
cytoplasmic concentrations of neurotransmitter via translocating the 
neurotransmitters into synaptic storage vesicles (Liu & Edwards, 1997).  In 
addition, GBR 12935, a potent DAT inhibitor, also blocks uptake into brain 
synaptic vesicles (IC50 between 34-45 µM) compared to synaptosomes 
(IC50between1-6µM) (Reith et al, 1994) .   
5.  Pharmacotherapies for ADHD 
Once the diagnosis of ADHD has been established, the next step is to 
choose the most appropriate treatment for the patient. Stimulants are considered 
the first-line pharmacological treatment option for ADHD. These include various 
dosage forms and formulations of methylphenidate and amphetamine, (Meijer et 
al., 2009; Spencer et al., 1996). However, there are potential side effects 
associated with these stimulants that can limit their use. These agents, along 
with their side effects are discussed below in more detail.  
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Pemoline, approved in 1975, was another stimulant used to treat ADHD 
that increases DA transmission in the central nervous system (Zaczek et al., 
1989). However due to liver toxicity, pemoline was removed from the market in 
2005 (Greydanus et al., 2007; Olfson, 2004). The most recent medication 
approved for ADHD is a long-acting form of guanfacine (Intuniv®; Figure 3), a 
non-stimulant, approved in September, 2009.  Another non-stimulant approved to 
treat ADHD is atomoxetine (Strattera®; Figure 3). Atomoxetine is considered a 
second-line therapeutic agent since it is not as effective as stimulants (Michelson 
et al., 2003; Michelson et al., 2002; Michelson et al., 2001; Newcorn et al., 2008). 
These non-stimulant medications are a good alternative for parents with 
concerns about giving their children stimulants and for those patients that cannot 
tolerate or do not respond to stimulants. There are also drugs that are used off-
label to treat ADHD for the reasons stated above. These agents include tricyclic 
antidepressants, bupropion, clonidine, and modafinil. 
Stimulants produce pharmacological effects by inhibiting DAT and/or NET, 
which results in an increase in the amount of DA and norepinephrine in the 
synaptic cleft, which enhances neurotransmission in these systems (Greydanus 
et al., 2007). Additionally, stimulants are associated with untoward effects that 
include, but are not limited to insomnia, cardiac events, decreased appetite, 
abdominal pain, headache, weight loss, tics, depression, and growth delays 
(Bymaster et al., 2002; Cormier, 2008; Greydanus et al., 2007). Furthermore, the 
possibility of abuse and diversion have become major concerns with the use of 
stimulant medications (Bymaster et al., 2002; Cormier, 2008; Greydanus et al., 
2007; Holman, 1994; Olfson, 2004), even though the AAP guidelines recommend 
a trial of at least three types or formulations of stimulant medication before 
considering different agents (Cormier, 2008).  This recommendation is to ensure 
that each patient is treated as an individual, because there is such a high degree 
of variability of response to these medications. Thus, the issue with stimulants is 
apparent because they are considered the first line therapy for ADHD, even 
though the possibility of abuse is present. 
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a. Methylphenidate 
i. Historical Background 
Originally, methylphenidate was approved to treat chronic fatigue, 
lethargy, depressive states, disturbed senile behavior, psychosis associated with 
depression, and narcolepsy. In 1968, methylphenidate was approved to treat 
ADHD, and is a gold standard treatment for ADHD (Folsom et al., 1956; Leonard 
et al., 2004). The landmark study, conducted in the early 1990s, by the National 
Institute on Mental Health Multimodal Treatment study of children with ADHD 
(MTA), which found that methylphenidate treatment was superior to behavioral 
therapy for children with ADHD, which led to its widespread use (Heal et al., 
2008; National Institute, 2001). Thus, the pharmacotherapeutic use of stimulants 
became the first line pharmacological therapy for ADHD.   
ii.  Formulations 
Methylphenidate, a piperazine substituted phenylisopropylamine (Figure 
3), was first synthesized in 1944 by Dr. Leandro Panizzon and marketed by Ciba-
Geigy pharmaceutical company as Ritalin (Leonard et al., 2004). There are 
various trade names for methylphenidate depending on the formulation and 
dosage form. For instance, dl-threo-methylphenidate has the following trade 
names; Ritalin®, RitalinSR ®, MetadateCD ®, Concerta® and Daytrana®. The initial 
formulations were short-acting (3-4 hrs), which was a limitation for school-aged 
children, who would need medication administered multiple times per day 
(Greydanus et al., 2007).  Ritalin SR® and Concerta® were developed to 
overcome this pharmacokinetics problem, since they have similar duration of 
actions, with Ritalin SR® being 8-9 hours and Concerta® being 10-12 hours 
(Biederman & Faraone, 2005). Daytrana®, which was approved in 2006, is a 
transdermal methylphenidate preparation and has a  9-12 hour duration of action 
(Greydanus et al, 2007).  D-threo-Methylphenidate (dexmethylphenidate) has a 
higher affinity for DAT than l-threo-methylphenidate (Heal & Pierce, 2006; Patrick 
et al., 1987). Thus, dexmethylphenidate was developed as an immediate release 
formulation and as an extended release formulation (Focalin® and Focalin XR®).  
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iii. Pharmacokinetics and mechanism of action 
The half-life of methylphenidate is 2-4 hours depending on the formulation. 
Its bioavailability is between 11-53% (Chan et al., 1983).  Its onset of action is 
approximately 2 hours after administration (May & Kratochvil, 2010).  
Furthermore, a clinical study in which healthy subjects were given 
[11C]methylphenidate intravenously (iv), found that the peak concentration of 
methylphenidate in the brain was achieved in 4-10 minutes and peak 
concentration of oral methylphenidate did not occur until 60 minutes after 
administration (Volkow et al., 1995). Methylphenidate is metabolized primarily 
through deesterification in humans to ritalinic acid, which is inactive. 
The mechanism of action of methylphenidate involves binding to DAT and 
inhibiting its function, which leads to a greater concentration of DA in the 
synaptic cleft to bind to both postsynaptic and presynaptic DA receptors, thus 
augmenting dopaminergic neurotransmission. Surgical lesions of the medial 
forebrain bundle or intracerebroventricular administration of 6-hydroxydopamine 
(6-OHDA) were utilized to determine effects on [3H]threo-(+/-)-methylphenidate 
and [3H]DA uptake. After both of these procedures a reduction in the specific 
binding of [3H]threo-(+/-)-methylphenidate to membranes of rat striatum was 
observed, which was highly correlated with the decrease in [3H]DA uptake. 
However, intracerebroventricular administration of 5, 7-hydroxytryptamine, 
AF64A, or chronic parenteral administration of reserpine did not alter the 
number of [3H]threo-(+/-)-methylphenidate binding sites. These results suggest 
that localization of the specific [3H]threo-(+/-)-methylphenidate sites in striatum 
is on dopaminergic nerve terminals (Janowsky et al., 1985).  Another report 
found that the highest specific [3H]methylphenidate binding was in caudate 
putamen, olfactory tubercle, nucleus accumbens, bed nucleus of the stria 
terminalis, and median eminence; in contrast to [3H]amphetamine, 
[3H]methylphenidate binding was not high in brainstem; however, the Bmax was 
not included in this report (Unis et al., 1985). Although methylphenidate has 
high affinity for DAT (Ki = 160-340 nM), it also has high affinity for NET (Ki = 40-
238 nM) and a lower affinity for serotonin transporter (SERT;Ki= 1000-22,000 
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nM) (Andersen, 1989; Easton et al., 2007; Kuczenski & Segal, 1997; Richelson 
& Pfenning, 1984).   
Inhibition of DAT function leads to concerns regarding the use and 
diversion of methylphenidate for recreational purposes. In fact, methylphenidate 
and cocaine have similar affinity for DAT, with cocaine having a Ki of 555-640 
nM for DAT (Gatley et al., 1996; Schweri et al.,1985; Ukairo et al., 2005). 
Methylphenidate is prescribed for ADHD and has a high potential for being 
diverted for recreational use (Klein-Schwartz, 2002; Kollins et al., 2001; McCabe 
et al., 2005; McCabe et al., 2006; Parran & Jasinski, 1991; Setlik et al., 2009; 
Sussman et al., 2006; Teter et al., 2003; Weyandt et al., 2009; Wilens et al., 
2008).  However, methylphenidate may have a lower abuse potential than 
cocaine due to its pharmacokinetics, such that methylphenidate has a longer 
half-life than cocaine, 90 minutes and 20 minutes, respectively (Volkow et al., 
1999). Cocaine has a faster onset of action than methylphenidate, which likely 
attributes to the euphoric feeling of “high”. An animal study using rats, 
(Izenwasser et al., 1990) examined the pharmacological effects of cocaine and 
methylphenidate and other monoamine uptake inhibitors on DA uptake. This 
study showed that methylphenidate and cocaine had similar Km values (100 
nM) in striatum, nucleus accumbens, olfactory tubercle, and medial prefrontal 
cortex; however, cocaine inhibited [3H]DA uptake to a lesser extent than 
methylphenidate. This suggests that there is a possible additional effect of 
cocaine that contributes to the potent reinforcing characteristics of this drug. 
Another study found that cocaine and methylphenidate have similar potency in 
the septum-caudate synaptosomes for inhibiting serotonin uptake based on the 
IC50 values of 70 µM and 118 µM, respectively. These results imply that the 
effect of cocaine on serotonin uptake may play a role in its increased abuse 
liability, compared to methlyphenidate (Taylor & Ho, 1978).                                                     
Positron emission tomography (PET) studies utilizing 
[11C]methylphenidate in human subjects showed that occupation of 50% of DAT 
sites by [11C]methylphenidate in striatum is required to elicit a therapeutic effect, 
and that the estimated oral dose of methylphenidate required to occupy 50% of 
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DAT sites corresponded to 0.25 mg/kg (Volkow et al., 1998). In other work, the 
temporal and spatial distribution of [11C]methylphenidate was determined, and 
the result compared to those obtained previously with [11C]cocaine (Volkow et 
al., 1999). DAT occupancies were measured with PET using [11C]cocaine, as 
the DAT ligand, in 8 healthy subjects (average age of 32, 4 men and 4 women) 
for the methylphenidate study and 17 active cocaine abusers for the cocaine 
study (average age of 35, 12 men and 5 women). The 8 healthy subjects were 
injected with 4-8 mCi of [11C]cocaine and then scanned four times over a 3 day 
period. The first scan was the placebo scan to establish a baseline and the 
other three scans were performed after intravenous methylphenidate doses 
(0.025, 0.1, 0.25, and 0.5 mg/kg). The subjects for the cocaine studies were 
scanned four times over a 2-day period, with the first scan being a placebo to 
achieve a baseline and the second scan was done 2 hours after the first, and 
the rest were performed after a range of intravenous doses of cocaine (0.05, 
0.1,0.3, and 0.6 mg/kg). Cocaine was co-administered with [11C]cocaine, while 
methylphenidate was given 5-8 minutes prior to [11C]cocaine. The results from 
this study showed that methylphenidate has a slightly higher potency at DAT 
than cocaine in the human brain, based on the ED50 of 0.07 mg/kg and 0.13 
mg/kg, respectively. Also, a double dose of cocaine was required to induce DA 
increases equivalent to those induced by methylphenidate utilizing PET and 
[11C]raclopride, which is a D2R antagonist. The potencies of methylphenidate 
and cocaine were compared to other DAT blockers, including but not limited to 
norcocaine, mazindol, lidocaine, procaine, and WIN 35,065-3. These DAT 
blockers have 50-100 fold higher affinities than cocaine. These results show 
that the potencies of methylphenidate and cocaine are similar. Based on these 
observations, the difference in the abuse liability of these agents is not solely 
based on the pharmacological potencies at DAT. Pharmacokinetics may also 
play an important role in the abuse potential of these two drugs (Volkow et al., 
1999). In another study by some of the same authors, PET was used to 
measure temporal and spacial distribution of [11C]methylphenidate and 
[11C]cocaine (Volkow et al., 1995). Eight healthy male subjects between the 
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ages of 20 and 51 years of age were scanned with [11C]methylphenidate. The 
scans were done two hours apart. Three subjects underwent two repeated 
scans to test for re-test reproducibility. Four subjects underwent a baseline scan 
and a second scan 10 minutes after administration of methylphenidate (0.5 
mg/kg, iv) to assess specific to nonspecific binding. One subject was scanned 
with both [11C]methylphenidate and [11C]cocaine  to compare the distribution 
and kinetics of these two compounds in the same individual. The authors did not 
mention how they were able to tell the difference between the compounds, 
however based on their different pharmacokinetics; it may have been possible 
to distinguish the two compounds. In the same study, two baboons were 
scanned to evaluate if methylphenidate and cocaine compete for the same 
binding sites in brain. One animal underwent a baseline scan with [11C]cocaine  
and a second scan with [11C]cocaine 5 minutes after administration of cold 
methylphenidate (0.5 mg/kg, iv). The other animal underwent a baseline scan 
with [11C]methylphenidate and a second scan with [11C]methylphenidate 5 
minutes after administration of cold cocaine (0.2 mg/kg, iv). In the human 
studies, the uptake of [11C]methylphenidate into brain was 7.5 ± 1.5% (mean ± 
SD) of the injected dose, and  was comparable to the uptake of cocaine, which 
was 7.5 ± 3.0% (mean ± SD) of the injected dose. Maximal concentrations of 
methylphenidate were observed in striatum, however low levels were detected 
in the cortex and cerebellum. Furthermore, pretreatment with cold 
methylphenidate 5 minutes prior to the administration of [11C]cocaine and 
pretreatment with cold cocaine 5 minutes prior to administration of 
[11C]methylphenidate significantly decreased binding of the corresponding 
tracer, but only in striatum, not in cerebellum. These results indicate that 
methylphenidate and cocaine compete for the same binding sites in the 
striatum. 
The distribution of methylphenidate was very similar to that of cocaine. 
Although the brain regional distribution of [11C]methylphenidate was identical to 
that of [11C]cocaine, and these drugs competed for the same binding sites, they 
differed markedly in their pharmacokinetics. Clearance of [11C]methylphenidate 
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from striatum (90 minutes) was significantly slower than clearance of 
[11C]cocaine (20 minutes). For both drugs, fast uptake, 4-10 minutes for 
[11C]methylphenidate and 2-4 minutes for [11C]cocaine in striatum paralleled the 
experience of the "high” reported by the subjects. For methylphenidate, the 
“high” decreased rapidly despite that a significant amount of drug was still 
bound in striatum. In contrast, for cocaine, the decline in the feeling of “high” 
paralleled its fast rate of clearance from striatum. Therefore, the “high” appears 
to be associated with the fast uptake of methylphenidate and cocaine into brain, 
and the slow clearance of methylphenidate from brain may serve as a limiting 
factor in promoting its frequent self-administration (Gatley et al., 1996; Volkow 
et al., 1999). Thus, the pharmacokinetics alter the pharmacology, specifically 
the abuse liability of methylphenidate. 
A recent study found that methylphenidate (0.3 mg/kg/infusion) is a 
relatively robust reinforcer for all strains, SHR, WKY, and SD based on the 
results that these strains acquired methylphenidate self-administration 
(Marusich et al., 2011b).  Another study also conducted in the SHR strain found 
the same result in regards to methylphenidate self-administration, such that this 
strain acquired methylphenidate (0.25 mg/0.1ml infusion) self-administration as 
well (Pena et al., 2001).  In addition, this study also showed that 
methylphenidate induced conditioned place preference (CPP) in SHR, however 
there was no difference found between the SHR and WKY in regards to CPP, 
suggesting that SHR may not be more sensitive to the rewarding effects of 
methylphenidate. These studies provide evidence that methylphenidate has the 
potential to be abused.  
Evidence has been provided that methylphenidate also interacts with 
VMAT2, the only transporter that translocates cytoplasmic DA from the cytosol 
into synaptic vesicles for storage, providing availability for future exocytotic 
release (Yelin & Schuldiner, 2002). Pre-clinical studies have demonstrated that 
unlike amphetamine, the effects of methylphenidate on brain catecholamines 
were completely inhibited by reserpine, suggesting that methylphenidate 
interacts with a reserpine-sensitive pool of DA (Scheel-Kruger, 1971). 
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Methylphenidate rapidly and reversibly increases VMAT2 binding and vesicular 
uptake of DA (Sandoval et al., 2003).  Rotating disk electrode (RDE) methods 
were utilized to measure the initial velocities of inwardly directed vesicular DA 
transport in vesicles purified from rat striata. VMAT2 immunoreactivity was used 
to measure the amount of VMAT2 protein. Methylphenidate (40 mg/kg, s.c.), 
which is considered a high dose for this animal model, was found to decrease 
VMAT2 immunoreactivity in membrane-associated vesicle fraction and increase 
VMAT2 immunoreactivity in the cytoplasmic vesicle fraction in nerve terminals 
by a 2-fold difference compared to control. In addition, membrane-associated 
vesicles were able to sequester 5-9 fold more DA than cytoplasmic vesicular 
associated vesicles (Volz et al., 2007).  In another study using RDE, both 
eticlopride, the D2 receptor antagonist, and scopolamine, the muscarinic 
receptor antagonist, blocked methylphenidate-induced K+ stimulated DA 
release (Volz et al., 2008). These results suggest that effects of 
methylphenidate are mediated by both D2 and muscarinic receptors. 
In addition to the effects of methylphenidate on the neurotransmitter 
transporters, PET studies using human subjects have investigated the effects of 
methylphenidate on DA release and how it relates to appetitive stimuli in the 
response. DA neurons fire in response to salient events. Salient events are 
defined as relevant events that require a response from the subject. Salient 
events have been hypothesized to contribute to the therapeutic effects of 
methylphenidate. Subjects were given methylphenidate (20 mg/kg, po) or 
placebo and then shown a salient stimuli (visual and olfactory presentation of 
food) or neutral stimuli, which was the description of family genealogy. No 
increase in DA was found in the placebo group shown the salient stimuli, 
demonstrating that the salient stimulus alone does not increase DA. Moreover, 
methylphenidate increased DA in striatum in response to the salient stimuli, but 
not to the neutral stimuli,  suggesting that the methylphenidate-induced increase 
of DA in the striatum was dependent upon stimulus context (Volkow et al., 
2005).  This could impact therapy because the increase in the amount of DA in 
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the striatum is, in part, based on the stimulus a patient reacts to, which may be 
lead to an increase in the abuse liability of methylphenidate.  
In conclusion, a wealth of research has been performed on 
methylphenidate and the mechanism by which it produces its pharmacological 
effect.  Research, thus far, has found that methylphenidate inhibits DAT function, 
thereby causing an increase in extracellular DA. However, methylphenidate 
interacts with other systems within the brain, which may also contribute to its 
pharmacological effect. Additional work is needed to further study the effects 
methylphenidate to obtain a more comprehensive understanding of its underlying 
mechanisms.  
b. Amphetamine 
i. Historical background 
Lazar Edeleano, a Romanian chemist studying in Germany, was the first to 
synthesize amphetamine (Figure 3) in 1887 (Edeleanu, 1887).  In 1927, Gordon 
Alles first reported the stimulant effects of sympathomimetics. In 1937, Charles 
Bradley, reported the therapeutic effects of dl-amphetamine in children with 
neurological and behavioral problems (Alles, 1933; Bradley, 1937). The 
pharmaceutical company, Smith, Kline, and French, marketed amphetamine as 
Benzedrine® in 1932, and this drug was used for decongestion as an inhaled 
dosage form (Rasmussen, 2006).  Benzedrine® was sold without a prescription, 
and over 50 million Benzedrine® tablets were sold during the initial 3 years of 
availability as an oral dosage form (Sulzer et al., 2005). The Spanish Civil War 
marked the beginning of the military using amphetamine to promote alertness in 
the troops (Sulzer et al., 2005). Also, the alerting properties of amphetamine 
were exploited by American troops during World War II, especially those in the 
air force during extended bombing missions. Today, amphetamine is still used by 
the air force in some cases in which prolonged attention is required (Caldwell et 
al., 2003).   
The escalation in the use of amphetamine abuse during the early periods 
of its over the counter availability, led to the decision in 1939 to make it only 
available by prescription (Sulzer et al., 2005). During the subsequent period of 
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time, the recognized therapeutic uses of amphetamine increased, such that by 
1946, it had more than 30 indications, including the treatment of schizophrenia, 
opiate addiction, sea sickness, and radiation sickness (Brett, 1946; Miller & 
Hughes, 1994).  Even though amphetamine was considered a prescription-only 
drug, its diversion for recreational use continued. In 1972, in an attempt to 
discourage its diversion, the United States Justice Department enforced legal 
quotas of amphetamine production (Sulzer et al., 2005). D-amphetamine 
appears to have a similar dose-related profile of effects in humans to 
methamphetamine, which suggest their equivalence for abuse (Kirkpatrick et al., 
2011). 
ii. Formulations 
There are various dosage forms of amphetamine available today. The 
most prescribed is Adderall®, which is a complex formulation of mixed-
amphetamine salts consisting of ¼ dextroamphetamine saccharate, ¼ 
dextroamphetamine sulfate, ¼ racemic dextro/levo amphetamine aspartate 
monohydrate, and ¼ racemic dextro/levo amphetamine sulfate, resulting in a 
3:1 ratio of d-amphetamine to l-amphetamine. Adderall®is available as 
immediate-release and extended-release formations (Adderall XR®).  
Dextroamphetamine (Dexedrine®) is an immediate release formulation and is 
marketed also in a capsule formulation for controlled release called Dexedrine 
SR®. The most recent development in the amphetamine series for the treatment 
of ADHD is lisdexamfetamine (Vyvanse®) and was FDA-approved in 2007 for 
the treatment of ADHD in children, and subsequently approved in 2008, for 
ADHD treatment in adults (Cowles, 2009).  Lisdexamfetamine, a prodrug, is a 
novel agent designed to lower the potential for abuse, since it must be 
catabolized to the active compound dextroamphetamine which provides the 
pharmacological effect.  
iii. Pharmacokinetics and mechanism of action 
The pharmacokinetics of amphetamine is similar to that of 
methylphenidate. The onset of action is 30-60 minutes and the duration of 
action for immediate release is 4-6 hours and 10-12 hours for extended release 
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mixed-amphetamine salts (MAS-XR). An even longer duration of 16 hours is 
seen with the MAS-triple-bead formulation (Greydanus et al., 2007).  
The mechanism of action of amphetamine is complex. Amphetamine 
produces a redistribution of DA from synaptic vesicles to the cytoplasm by 
reducing the vesicular pH gradient. VMAT2 mediated transport involves a 
vacuolar-type H+ pumping, which creates a pH gradient across the vesicle 
membrane. When amphetamine is transported into the vesicle, it reduces the 
synaptic vesicle pH gradient required for monoamine storage, thus reducing 
concentration of monoamines inside the vesicle (Sulzer & Rayport, 1990). In 
addition, amphetamine inhibits DA uptake at DAT and reverses the transport of 
DA causing its release into perisynaptic area and into the extracellular space, 
whereas cocaine and methylphenidate bind to DAT and only inhibit DA uptake 
at DAT, i.e., do not release DA (Bannon et al., 2000; Seiden et al., 1993; 
Solanto, 2002; Sonders et al., 1997). The mechanism of action of amphetamine 
is dependent on the amphetamine concentration, whereby at lower 
concentrations amphetamine is exchanged for DA via DAT, but at higher 
concentrations amphetamine can diffuse across the plasmalemmal membrane 
independently of DAT (Mack & Bonisch, 1979).   Amphetamine is widely 
accepted to elicit its pharmacological effect by: 1) binding to neurotransmitter 
transporters and reversing the transport of  neurotransmitters such as DA, 
norepinephrine, and serotonin from inside the presynaptic terminal to the 
extracellular space which facilitates their release and 2) inhibiting monoamine 
oxidase (MAO) (Seiden et al., 1993).  
With respect to the effect on the plasmalemmal transporters, 
amphetamine has affinity (Ki) for NET (30 - 100 nM), followed by DAT (30 - 600 
nM), and lastly SERT (1000 - 40,000 nM; (Easton et al., 2007; Han & Gu, 2006; 
Heal et al., 1998; Kula & Baldessarini, 1991; Richelson & Pfenning, 1984; 
Rothman et al., 2001).  Extensive research has been conducted on the 
interaction of amphetamine with these transporters; however, most of the focus 
has been on the interaction with DAT. Amphetamine binds to the extracellular 
surface of DAT, competing with  its substrate (e.g., DA), thus decreasing DA 
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uptake into the neuron (Seiden et al., 1993).  Once inside the neuron, 
amphetamine is released from DAT, leaving DAT unoccupied. DA binds to the 
internally facing DAT protein and is reverse transported to the outside or 
extracellular space, where it is released, and the result is an increase in the 
extracellular concentration of DA (Levi & Raiteri, 1993; Sulzer et al., 1995).   
A study by Cass and colleagues used in vivo electrochemistry to 
determine the effects of locally applied raclopride, a D2 receptor antagonist, and 
SCH-23390, a D1 receptor antagonist, on the clearance of locally applied DA in 
the striatum, nucleus accumbens, and medial prefrontal cortex of rats. Raclopride 
or SCH-23390 was applied locally prior to the pressure injection of DA. 
Raclopride increased the amplitude and time course of DA signals, suggesting 
significant inhibition of DAT. However, SCH-23390 had no effect of DA signals. 
These results were interpreted to indicate that D2, not D1 receptors, modulate 
the activity of DAT (Cass & Gerhardt, 1994).  Another study confirmed these 
results by employing continuous amperometry and cyclic voltammetry and 
determined that amphetamine (10µM)-induced stimulation of DA overflow from 
striatal slices was inhibited (47%) by sulpiride, a D2 receptor antagonist (Schmitz 
et al., 2001), suggesting that the response to amphetamine may be indirect and 
involve D2 autoreceptor activation following DA release.   
Amphetamine is a substrate for DAT.  Amphetamine accumulation into 
striatal synaptosomes is saturable, temperature-dependent, and ouabain-
sensitve, indicating that it is a substrate for transport (Zaczek et al., 1991).  
Similarly,  a study investigating the effects of uptake blockers and substrates on 
transporter-associated ion currents found that amphetamine induced currents, 
whereas methylphenidate blocked transporter-associated current, indicating that 
amphetamine is a substrate for DAT (Sonders et al., 1997).  More recently, 
studies using neuronal cultures and heterogeneous cells stably expressing hDAT 
showed that amphetamine produces DA efflux via two mechanisms that involve a 
rapid channel-like configuration with a millisecond firing rate of DA neurons and 
the other consisting of a slower, exchange-like mechanism of DA release (Kahlig 
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et al., 2005). Thus, results from these studies provide evidence that 
amphetamine is a substrate for DAT. 
Amphetamine also modulates DAT cellular expression. The role of PKC 
in DAT modulation has been widely investigated because DAT is regulated by 
activation of protein kinase, which decreases DAT cell surface expression after 
amphetamine administration (Pristupa et al., 1998; Vaughan et al., 1997; Zhang 
et al., 1997). This stems from findings that phosphorylation of the N-terminus of 
DAT, which may be PKC dependent, causes an amphetamine-induced DA efflux 
(Khoshbouei et al., 2004). If phosphorylation is needed for internalization and 
PKC causes phosphorylation, then PKC may play a vital role in the regulation of 
DAT (Copeland et al., 1996; Huff et al., 1997; Vaughan et al., 1997; Zhang et al., 
1997). 
Specifically, amphetamine has been shown to increase striatal PKC and 
PKC activation stimulates DAT-mediated release of DA and triggers rapid 
internalization of DAT from the plasmalemmal membrane (Giambalvo, 1992; 
Kantor & Gnegy, 1998). For example, amphetamine acutely decreased cell 
surface expression of human DAT (hDAT) in cell lines, which was concomitant 
with a loss of DAT function (Saunders et al., 2000). In addition, HEK-293 cells 
transfected with a yellow fluorescent protein-tagged hDAT were employed to 
determine if loss of transporter activity was due to a modification in DAT function 
independent of cell surface redistribution or due to a reduction in the number of 
active transporters at the plasma membrane resulting from DAT trafficking 
(Kahlig et al., 2004).  Confocal imaging combined with electrophysiology of the 
HEK cells revealed that after 1 hr exposure to 10 µM amphetamine, a reduction 
in hDAT function resulted and was directly related to the redistribution of hDAT 
from the plasma membrane. Thus, the decrease in DA uptake was associated 
with an increase in intracellular hDAT.  
In other work, Gnegy and coworkers investigated the effects of 
amphetamine on DAT expression at very early time points using biotinylation in 
rat striatal synaptosomes. Within 3 seconds of application of 3 µM amphetamine, 
there was an increase in synaptosomal DAT surface expression was observed 
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lasting less than 2.5 min, which was prevented by cocaine pretreatment and 
associated with increased delivery of DAT to the plasmalemmal membrane 
(Johnson et al., 2005a).   
The innovative work of Zahniser and colleagues showed that the hDAT 
oligomerizes (Sorkina et al., 2003). hDAT was fused with yellow or cyan 
fluorescent protein and transfected and expressed in PAE, human embryonic 
kidney (HEK) 293 cells, and an immortalized dopaminergic cell line 1RB3AN27 to 
examine the oligomeric state and trafficking of DAT in different compartments of 
different types of living cells (Sorkina et al., 2003). Fluorescence resonance 
energy transfer (FRET) was used to determine the location of these specific 
compartments. FRET involves a donor chromophore in its electronic excited 
state that transfers energy to an acceptor chromophore through nonradiative 
dipole-dipole coupling in near field region. The excited chromophore emits a 
virtual photon that is instantly absorbed by a receiving chromophore. The FRET 
signals were strongest in the endosomes, which provides evidence of the 
involvement of vesicles, where amphetamine caused the intracellular 
accumulation of hDAT on endosomal vesicles. Based on the results that a DAT 
mutant was retained in the endoplasmic reticulum after biosynthesis, suggests 
that DAT oligomers are formed in the endoplasmic reticulum and are maintained 
both at the cell surface and during trafficking between the plasma membrane and 
endosomes.  
Another target for amphetamine action is VMAT2. An early study used 
isolated chromaffin granules and [3H]reserpine-binding measurements to 
determine amphetamine interaction with VMAT2 (Rudnick & Wall, 1992). 
Amphetamine analogs such as 3,4-methylenedioxymethamphetamine (235 µM) 
and fenfluramine (30 µM) inhibited 50% of maximal binding; but 
parachloroamphetamine (800 µM) inhibited less than 10% of [3H]reserpine 
binding. These results were interpreted to suggest that parachloroamphetamine 
effects on isolated chromaffin granules were only due to an alteration in pH, 
whereas methamphetamine and fenfluramine exerted effects both by altering the 
pH gradient and vesicular transport, which was also measured (Rudnick & Wall, 
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1992). This study demonstrates that there is a way to determine if a compound 
solely changes the pH versus directly interacts with the transporter.  
Although, amphetamine interacts with VMAT2 (Brown et al., 2002; 
Gonzalez et al., 1994; Johnson, 1988; Mosharov et al., 2003); at this point in 
time, the focus in the literature has switched from amphetamine to 
methamphetamine, coinciding with the more wide spread abuse of the latter.  
One study found that 10-15 min of application of 10 µM amphetamine induced a 
15-fold increase in cystosolic DA in synaptosomes, strongly suggesting 
redistribution of vesicular storage from the vesicle to the cytosol  (Mosharov et 
al., 2003). Amphetamine displaced [3H]tetrabenazine binding, a VMAT2 ligand 
with a nM affinity (Teng et al., 1998), which suggests amphetamine may increase 
cytoplasmic DA concentrations by inhibiting vesicular DA uptake (Ary & 
Komiskey, 1980; Gonzalez et al., 1994; Philippu & Beyer, 1973).   
Yet, another target of amphetamine action is MAO. Thus, amphetamine 
also alters DA intracellular and extracellular concentrations by inhibiting MAO.  
MAO is one of the enzymes which metabolize catecholamines in brain. Thus, by 
inhibiting MAO, amphetamine increases the amount of cystolic DA available for 
reverse transport by DAT (Sulzer et al., 2005).  
An alternative hypothesis regarding amphetamine-evoked DA release 
involves the physicochemical properties of amphetamine, as alluded to above. 
Amphetamine is a weak base, with apKa of 9.9. This has been suggested also to 
play a role in the release of dopamine from the terminal into the extracellular 
space (Sulzer & Rayport, 1990).  The weak base theory suggests that 
amphetamine enters the cell through both transport and diffusion, diffuses across 
the vesicular membrane, accumulates in vesicles, disrupts the proton gradient by 
binding to free protons, and thereby, increases the pH inside the vesicles, which 
is normally around 5.5 (Johnson, 1988).  This disruption in pH decreases the 
driving force that provides energy for the accumulation of DA in the vesicle, 
causing the vesicle to release the stored DA. This DA release from the vesicle 
results in an increase of cytoplasmic DA available for reverse transport by DAT, 
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ultimately producing an increase in DA in the extracellular space (Sulzer et al., 
1993; Sulzer & Rayport, 1990).   
In summary, there has been a plethora of work conducted on amphetamine 
and its underlying multi-faceted mechanisms of action, which likely work in 
concert to ultimately increase the extracellular concentrations of DA and other 
neurotransmitters to produce its pharmacological effects including its therapeutic 
effects on ADHD. Despite the tremendous efforts to understand how 
amphetamine works in brain, further studies are needed to gain additional insight 
into the action of this very complicated pharmacotherapy.  This dissertation work 
will compare the effects of amphetamine and methylphenidate, two gold standard 
treatments for ADHD, on DAT and VMAT2 function in rat striatum. 
6. Alternative Therapies 
Alternative therapies for ADHD include tricyclic antidepressants (TCA), such 
as desipramine and nortriptyline (Biederman & Spencer, 1999; Spencer et al., 
1996; Wilens et al., 1996; Wood et al., 2007). These agents are somewhat 
effective in the treatment of ADHD, because they have affinity for NET, DAT and 
SERT (Wong et al., 1995).  Desipramine has been reported to have a Ki of 3.8 
nM for NET, 179 nM for SERT, but over 10,000 nM for DAT (Bymaster et al., 
2002).  Nortriptyline has been reported to have a Ki of 4.4 nM for NET, 18.5 nM 
for SERT, and 1140 nM for DAT (Owens et al., 1997). Unfortunately, these 
antidepressants have considerable side effects. For example, nortriptyline is 
associated with dry mouth (19% of subjects), constipation (11% of subjects), and 
headache (9% of subjects). Desipramine produces loss of appetite (25% of 
subjects), insomnia (19% of subjects), and dry mouth (10% of subjects), all of 
which have deterred the wide spread use of TCAs for ADHD (Prince et al., 2000; 
Spencer et al., 2002).   
Another antidepressant, which is not a TCA, but is used in the treatment of 
ADHD is bupropion (Wellbutrin®). Bupropion is also used as smoking cessation 
agent (Zyban®).This is of interest because lobeline has been investigated as a 
smoking cessation aid. Both bupropion and lobeline interact with nicotinic 
systems (Damaj et al., 1997; Dwoskin & Crooks, 2002; Yamada et al., 1985). 
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Bupropion is an aminoketone antidepressant (Figure 3), that interacts with 
noradrenergic, dopaminergic, and nicotinic systems. Bupropion is thought to 
inhibit DA uptake in the mesolimbic DA system thereby, aiding in smoking 
cessation (Jorenby et al., 2006). However, bupropion is considered an adjunctive 
treatment for ADHD, because it is less effective than stimulants in eliminating 
symptoms of ADHD when used alone (Greydanus et al., 2007; Olfson, 2004; 
Wilens, 2006; Wilens et al., 2005; Wilens et al., 2001).   
In addition, the antihypertensive medications, clonidine (Figure 3) and 
guanfacine (Figure 3), have been shown to be effective in the treatment of 
ADHD. A number of studies have shown that clonidine improved the hyperactivity 
and impulsivity symptoms, but not the inattention symptoms associated with 
ADHD (Connor et al., 1999; Heal et al., 2008; Nair & Mahadevan, 2009; Rains et 
al., 2006; Scahill et al., 2001).  With respect to guanfacine, one study employing 
25 children between the ages of 7-16 years with ADHD found that this 
therapeutic agent improved hyperactivity by 27%, improved teacher ratings on 
the hyperactivity/impulsivity scale by 36% and the teacher ratings on the ADHD 
scale by 32%, as well as the total tic severity scale by 39% (Boon-yasidhi et al 
2005).  Compared to clonidine, guanfacine may be more beneficial clinically 
because it has a longer duration of action (Greydanus et al., 2007). The major 
side effects of clonidine are sedation and hypotension (Greydanus et al., 2007; 
Olfson, 2004). In addition, comparisons of clonidine and guanfacine revealed that 
that guanfacine caused less somnolence than clonidine (21% vs. 35%, 
respectively; (Wilson et al., 1986). 
With respect to the mechanism of action, clonidine acts centrally as an 
agonist at both α1 and α2 adrenergic receptors (Wilens, 2006).  Clonidine is 
thought to improve neuropsychological function associated with the PFC by 
inhibiting norepinephrine release through stimulation of α2 autoreceptors that are 
located presynaptically on noradrenergic neurons. This action is suggested to 
explain the effect of clonidine on impulsivity and cognition in ADHD (Arnsten & 
Dudley, 2005; Arnsten & Li, 2005).   
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Guanfacine is thought to act similar to clonidine, however, this drug is 
actually more selective for a subtype of α2 adrenergic receptors. There are 2 
main subtypes of adrenergic receptors, which are α and β. Both of these 
subtypes have several subtypes. Theα-receptors have the subtypes α1 and α2. 
The α2-receptors have three highly homologous subtypes, which are α2A, α2B and 
α2C-receptors. Theα2A-receptors inhibit norepinephrine uptake in the PFC, which 
produces improvements in working memory, attention, and enhancement of 
impulse control. There is a high density of norepinephrine in PFC and locus 
coeruleus. Since guanfacine is a selective agonist of theα2A subtype of 
norepinephrine receptor, with a reported wide range of Kd (0.1-100 nM), it effects 
the neural transmission of norepinephrine (Greydanus et al., 2007; Khalid et al., 
2002; Wilens, 2006). Guanfacine inhibits norepinephrine release in this area, 
thereby increasing the blood flow to PFC. This effect is thought to improve the 
attention deficits associated with ADHD (Kolar et al., 2008).  A preclinical study 
employing nonhuman primates revealed that guanfacine (0.2 mg/kg, im) 
increased blood flow in the PFC as determined by single photon emission 
computed tomography (Loo et al., 2003; Avery et al., 2000). Specifically, a 
significant 5.8% increase in the mid-dorsolateral PCF and an 8.5% increase in 
the caudal dorsolateral PFC were found. Cognitive function was evaluated using 
the delayed response task and three of the four subjects demonstrated 18% 
improvement in the task. Therefore, guanfacine may be an acceptable treatment 
for ADHD, without the adverse side effects associated with stimulants. 
Another therapeutic agent that has been investigated for the treatment of 
ADHD is modafinil, an analeptic medication approved for the treatment of 
narcolepsy (Boellner et al., 2006; Greenhill et al., 2006; Hou et al., 2005; 
Swanson et al., 2006; Wilens, 2006).  Modafinil is structurally different from 
methylphenidate and amphetamine (Figure 3). In a discrimination study using 
rhesus monkeys, modafinil dose-dependently substituted for cocaine in 6 out of 7 
monkeys. These results suggest that modafinil shares discriminative stimulus 
effects with cocaine which alludes to the abuse potential of modafinil (Newman et 
al., 2010). One of the most recent clinical studies was a six week double-blind, 
44 
randomized trial that included 46 children between the ages of 6-15, who were 
given  200-300 mg/day of modafinil (depending on weight-200 if < 30kg and 300 
if > 30kg) (Kahbazi et al., 2009).  Modafinil significantly reduced parent ADHD 
rating scores, which was the primary outcome measure compared to baseline 
being -22 ± 8.9 (mean ± SD) and -8.2 ± 6.2 for modafinil and placebo, 
respectively.  Modafinil significantly reduced the secondary outcome measure 
(teacher ADHD rating scores) compared to baseline being -23 ± 8.2 (mean ± SD) 
and -7.7 ± 5.0 for modafinil and placebo, respectively. No subjects discontinued 
treatment with modafinil during the study due to side effects. Side effects 
associated with modafinil include dry mouth (8.7%), insomnia (8.7%), and 
decreased appetite (15%) being most common. Limitations of this trial included a 
small n and no reasons were given as to why one subject dropped out of the 
modafinil group and 2 subjects dropped out of the placebo group.   
With respect to mechanism of action, modafinil alters the balance of 
GABA and glutamate in brain, resulting in activation of hypothalamus, which is 
thought to improve the symptoms of narcolepsy (Ferraro et al., 1996; Kahbazi et 
al., 2009; Keating & Raffin, 2005; Lin et al., 1996; Wilens, 2006). The complex 
mechanism of action of modafinil has not been fully elucidated. Modafinil has at 
least four possible targets in the treatment of narcolepsy that are components of 
the wakefulness-promoting orexin-containing neurons of the lateral 
hypothalamic/perifornical area, the histamine-containing neurons of the 
tuberomammillary nucleus of the posterior hypothalamus, the noradrenergic 
neurons of the pontine locus coeruleus (LC), the mesencephalic dopaminergic 
neurons, and a group of sleep-promoting GABA and galanin-containing neurons 
of the ventrolateral preoptic nucleus of the hypothalamus (Hou et al., 2005).  
Cocaine and amphetamine-regulated transcript (CART) is also a potential 
modulator for alertness, which is found in the hypothalamus as well (Keating et 
al., 2010).  In addition, it is localized in neurons of the nucleus accumbens, 
synaptic terminals of the ventral tegmental area and the substantia nigra, partially 
engaging the mesolimbic DA circuits. This involvement may have influence upon 
reward/motivation and locomotion. One of the targets of modafinil is the lateral 
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hypothalamic/perifornical area, where CART is expressed. This interaction 
between modafinil and CART suggests that modafinil may improve ADHD 
symptoms, especially those related to alertness and hyperactivity, which is the 
pathway that involves CART.   
With regards to ADHD, modafinil elevates DA and norepinephrine levels in 
PFC and in rostromedial hypothalamus (de Saint Hilaire et al., 2001). Modafinil 
may activate noradrenergic neurons in the LC associated with the arousal 
without affecting the extra LC noradrenergic neurons involved in cardiovascular 
regulation (Hou et al., 2005).  The papillary control of modafinil is of interesting 
because it is comparable with LC phasic responses to task relevant events 
(Beatty, 1982; Richer & Beatty, 1987), suggesting the potential for 
LC/norepinephrine  system involvement in optimizing cognitive task performance 
(Aston-Jones & Cohen, 2005).  Furthermore, a study demonstrated that a low 
dose of yohimbine, an α-2 antagonist, potentiated the modafinil-induced 
wakefulness and activity (Lin et al., 1992).  However, at high doses yohimbine 
attenuated the modafinil-mediated effects on activity (Duteil et al., 1979).  These 
findings suggest that there is evidence that the adrenergic system may play a 
role in the mechanism of action of modafinil.    
In addition, modafinil effects have been evaluated in ADHD. Contrasting 
results from various studies have been reported when investigating if modafinil 
improves the symptoms of ADHD. However, the variables of these studies such 
as dose, length of administration, age of subjects, and test measurements need 
to be taken into consideration. For example, a study including 20 adult ADHD 
subjects were given a single dose of 200 mg modafinil, which was associated 
with significant improvements in performance on digit span, visual recognition 
memory, spatial planning, and Stop-Signal Reaction Time (SSRT; (Turner et al., 
2004).  Conversely, a two-week study including 22 adult ADHD patients in which 
the modafinil-treated group was given a titrated dose over 4-7 days that 
averaged dose of 207 mg/day, found no treatment effects of modafinil on the 
Stroop or Digit Span tests (Taylor & Russo, 2000).  Nevertheless, the majority of 
the modafinil studies have shown that modafinil is effective in treating the 
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symptoms of ADHD in children, adolescents and adults. In addition, modafinil is 
well tolerated at the dosages used (Biederman et al., 2006; Biederman et al., 
2005; Greenhill et al., 2006;, Rugino & Copley, 2001; Rugino & Samsock, 2003).      
The only FDA-approved (in 2002) non-stimulant medication for ADHD is 
the selective NET inhibitor, atomoxetine (Cormier, 2008; Heal et al., 2008; 
Olfson, 2004; Wilens, 2006). Atomoxetine has been shown to be effective in 
children, adolescents and adults with ADHD. Atomoxetine may not be as 
effective as the gold standard stimulants, as indicated by a study showing 
improvement of only 45% in ADHD ratings compared to a 56% improvement with 
methylphenidate (Michelson et al., 2003; Michelson et al., 2002; Michelson et al., 
2001; Newcorn et al., 2008).  Due to the untoward side effects of atomoxetine, 
the FDA requires a black box warning which states the potential for suicidal 
ideation (0.4%). In addition, the atomoxetine black box label was updated in 2004 
to include information about the cases of serious liver injury. From January 2005 
to March 2008, six post market cases of serious liver injury with atomoxetine 
were reported to the FDA (Diak & Senior, 2009).  Furthermore, based on the 
FDA receiving six additional reports of serious liver injury in patients taking 
atomoxetine, the label was revised again in 2007. The Warnings and Precautions 
section of the label advises prescribers about the risk of severe liver injury with 
this drug (Diak & Senior, 2009; Lim et al., 2006). Thus, the use of atomoxetine 
has its own unique concerns to be aware of when employed as a treatment for 
ADHD that must be balanced with therapeutic benefit (Cormier, 2008; Greydanus 
et al., 2007). The most common side effects of atomoxetine are sedation (6% of 
subjects), abdominal pain (11% of subjects), decreased appetite (14% of 
subjects), and headache (18% of subjects; (Newcorn et al., 2008). Although, 
atomoxetine is not considered to be a first line agent, it is still a treatment option 
for ADHD, particularly in patients who do not tolerate or respond to stimulants. 
Between 2002 and 2007, 3.3 million patients received a prescription for 
atomoxetine in the US (Diak & Senior, 2009). 
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 With regards to mechanism of action, atomoxetine has a high affinity for 
NET (Ki value of 2-5 nM) and lower affinity for other neurotransmitter transporters 
(Gehlert et al., 1995; Tatsumi et al., 1997; Wong et al., 1982). One study 
reported a Ki value of 1.9 nM for atomoxetine for NET (Wong et al., 1982). 
Another study extended that finding by determining that a tomoxetine inhibited 
binding of radioligands ([3H]paroxetine, [3H]nisoxetine, [3H]WIN 35,428) to clonal 
cell lines transfected with human NET, SERT or DAT with Ki values of 5.0, 77 
and 1450 nM, respectively, thus demonstrating over a 10-fold selectivity for NET 
over SERT and DAT (Bymaster et al., 2002). In the same study, microdialysis in 
male Sprague Dawley rats showed that local perfusion of 0.34 µM atomoxetine 
via dialysis probe into PFC significantly increased extracellular norepinephrine 
and DA to a maximum effect of 175 ± 33 and 190 ± 15% of basal concentration, 
respectively. In addition, atomoxetine (0.3, 1, 3 mg/kg, ip) produced a 3-fold 
increase in extracellular levels of norepinephrine in PFC, but did not alter 
extracellular serotonin levels. Atomoxetine also produced a 3-fold increase in 
extracellular DA in PFC, but no changes in striatum or nucleus accumbens 
(Bymaster et al., 2002), suggesting that it will not have drug abuse liability. In 
contrast, methylphenidate (3 mg/kg, ip) increased extracellular DA in striatum 
and nucleus accumbens to the same degree, whereas atomoxetine did not alter 
the amount of DA in these regions of the brain. However, methylphenidate 
increased extracellular norepinephrine and DA equally in PFC compared with 
atomoxetine. Furthermore, the latter study found that the expression of neuronal 
activity marker Fos was increased 3.7-fold in PFC by atomoxetine administration, 
but was not increased in striatum or nucleus accumbens, consistent with the 
regional distribution of increased extracellular DA. This study did not evaluate 
methylphenidate’s effect on Fos expression. However, a previous study found 
that an oral administration of methylphenidate (2.5 mg/kg) given to cats 
increased Fos expression in striatum (Lin et al., 1996). The atomoxetine-induced 
increase of catecholamines in PFC, a region involved in attention and memory, 
may mediate the therapeutic effects of atomoxetine in ADHD and may be 
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associated with the improvements in executive function and other cognitive 
functions (Wilens, 2006). 
7. Investigational Treatments 
The current treatment options for ADHD have been discussed, however 
due to the adverse side effects of some of these medications, along with the lack 
of effectiveness of others, has spurred the development of novel therapeutic 
options for ADHD. According to the National Institute of Mental Health, there are 
clinical trials underway to investigate new candidate pharmacotherapies.   
One particular clinical trial is entitled Betahistine: Novel Therapeutic in 
Attention Deficit Hyperactivity Disorder.  Betahistine is an antivertigo drug, which 
was first registered in Europe in 1970 for the treatment of Méniére’s disease. 
Betahistine has a high affinity for H3 receptors and a low affinity for H1 receptors. 
However, the mechanism of action of Betahistine is related to its ability to 
increase the levels of neurotransmitters in the brainstem (Barak, 2008).  This 
study started in January of 2009 with an estimated completion date of December 
of 2009 (NIH, 2010).   
Another ongoing clinical trial is an open-label multicenter sequential group, 
phase 1 study in 6-11 year old patients with ADHD (NIH, 2010).  The agent being 
investigated is JNJ-310001074. However, there was no available literature on the 
pharmacology of this compound and how it relates to ADHD. An additional trial 
on this compound is ongoing in Wisconsin, where the investigators are 
evaluating the efficacy and safety/tolerability of 3 different doses of JNJ-
310001074 compared to placebo. 
There is one clinical trial investigating a medication that has already 
received approval from the FDA for another condition. This medication, called 
varenicline (Chantix®), was approved for the treatment of smoking cessation in 
May of 2006 (NIH, 2010).  Varenicline interacts with specific nicotinic receptors. 
Nicotinic receptors are a complex system of different subunits that are a part of 
the super-family of ligand-gated ion channels (Xiong et al., 2007). These 
complexes are incorporated within the cell membrane and are composed of 
pentameric groups of α (α2-10) and β (β2-4) subunits. The subtypes contain only 
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one subunit type and are therefore called homomeric. Most of the subtypes are 
heteromeric, i.e., containing both an α (α2-10) and β (β2-4) subunit (Symons et 
al., 2010).  The most common subtypes in the brain include the homo-oligomeric 
α7 and the heteromeric α4β2. The composition of the subtype can determine its 
sensitivity of a receptor for nicotine. Varenicline binds more potently to the α4β2 
subtype of the nicotinic acetylcholine receptor compared to α7subunit>3500 fold; 
(Mihalak et al., 2006), without producing a full nicotinic effect on dopamine 
release. Therefore, it is considered a partial agonist of the α4β2 subtype. In 
addition, varenicline inhibits the ability of nicotine to stimulate the central nervous 
mesolimbic DA system. The purpose of this clinical trial is to determine if 
varenicline can improve the symptoms of ADHD and also decrease the amount 
of smoking in this population. A secondary outcome is to assess the tolerability 
and response to varenicline more fully in this population. 
The most promising candidate for the treatment of ADHD is a new 
chemical entity, called AZT3480 (TC-1734; (NIH 2010).  This compound, which 
is a partial agonist for the nicotinic acetylcholine receptor, is selective for the 
α4β2 subtype of the nicotinic acetylcholine receptor. As of May 2009, it has 
been evaluated in six Phase 2 clinical trials in various neurocognitive disorders, 
including ADHD. It has been evaluated in about 1,350 subjects from Phase 1 
and Phase 2 trials and has exhibited consistently a favorable tolerability profile 
(Dunbar et al., 2007). Preliminary results show that AZT3480 met the primary 
outcome measure in a Phase 2 clinical trial in adult ADHD. The most common 
side effects that have been reported include dizziness and headache (Gatto et 
al., 2004). As of July of 2009, there were plans to conduct a vigorous drug 
development program for AZT3480.  
One novel clinical candidate for the treatment of ADHD and the focus of 
our research is the alkaloid lobeline. The rationale for the potential utility of 
lobeline as a treatment option for ADHD is that it interacts with the same 
transporter proteins, DAT and VMAT2, as methylphenidate and amphetamine, 
which are the gold standard treatments for ADHD. In addition, it also has a high 
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affinity (Ki of 4-30 nM) for central nicotinic receptors as well (Broussolle et al., 
1989; Damaj et al., 1997; Lippiello & Fernandes, 1986; Yamada et al., 1985).   
8. Lobeline as a Candidate for ADHD Pharmacotherapy 
a. Historical background and clinical uses: 
Lobeline (Lob; Figure 3), an alkaloidal component of Lobelia inflata, is a 
novel compound that has been investigated in the treatment of drug abuse, 
including but not limited to, methamphetamine, nicotine, cocaine, opioid, and 
alcohol abuse (Dwoskin & Crooks, 2002; Farook et al., 2009; Miller et al., 2007; 
Polston et al., 2006).  The first report of Lobelia inflata being used for medicinal 
purposes occurred in 1813, when Reverend D. Cutler referred to the alkaloid as 
a effective remedy for asthma (Millspaugh, 1974).  In 1938, Proctor was the first 
to document the pharmacological effects of an alkaloid extract of the plant and 
reported on its use as an expectorant, asthma treatment, anti-spasmodic, emetic, 
diuretic, respiratory stimulant, and for narcotic overdose. The seeds of the plant 
contain the highest amount of lobeline, the principal alkaloid. Lobeline was 
named after Matthias de Lobel who was a French botanist and physician 
(Dwoskin & Crooks, 2002).  Wieland identified the chemical structure of lobeline 
and subsequently synthesized it in 1925 (Wieland H, 1925).   
Lobeline has also been considered as a therapeutic agent for smoking 
cessation dating back to 60 years ago (Dwoskin & Crooks, 2002). Lobeline was 
first reported by Dorsey, in 1936 as a smoking cessation agent (Dwoskin & 
Crooks, 2002). Although a review on the clinical studies using lobeline stated 
that lobeline had no effect on smoking (Stead & Hughes, 2001), others believe 
that if a new dosage form of lobeline was developed with improved 
bioavailability, lobeline would be an efficacious smoking cessation agent 
(Schneider & Olsson, 1996).  Poor compliance due to the multiple dosing and 
side affects such as nausea, dizziness, vomiting, and hypertension could have 
contributed to the lack of efficacy.  The evidence supporting the utility of lobeline 
as a smoking cessation agent may be inconclusive, but nevertheless, the 
interest in lobeline to reduce smoking is ongoing (Buchhalter et al., 2008). Due 
to this interest, a recent study was published in 2010 that had an objective of 
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evaluating the safety and efficacy of sublingual lobeline on smoking cessation 
(Glover et al., 2010). This was a multicenter Phase 3 trial involving 3 separate 
sites and a total of 750 smokers (250 from each site). The results of this study 
showed that the efficacy for lobeline was not significant (p= 0.62) compared to 
placebo. Based on these results, the authors concluded that lobeline does not 
appear to be an efficacious smoking cessation aid. It would be interesting to 
learn if another dosage form of lobeline would be more effective in smoking 
cessation by reducing the adverse effects, since the sublingual tablet does not 
seem to have any significant effect.      
b. Pharmacokinetics and Mechanism of action 
Research examining the pharmacokinetics of lobeline is very scarce. In a 
previous study in rats (Reavill et al., 1990), lobeline (4mg/kg, sc) had a reported 
lipophilicity of 1.68 at a ph of 7.4. The plasma concentration at this dose was 
74.3 ng/ml and the brain concentration was 237 ng/ml. These results imply that 
lobeline has the ability to penetrate the blood-brain barrier by both carrier and 
lipid mediation. In addition, the authors suggest that based on the behavioral 
data demonstrating that lobeline did not produce a nicotine-like effect in doses 
as large as 6.4 mg/kg, that other receptors other than nAChRs may mediate the 
effects of lobeline (Reavill et al., 1990a).  However, previous research has 
revealed similarities in the pharmacology of nicotine and lobeline, which resulted 
in lobeline being classified as a nicotinic agonist. Lobeline may have the similar 
effects of nicotine on cognition, based on studies utilizing radial-arm maze and 
spatial discrimination water maze, which showed that lobeline improved 
performance and learning in rats (Decker et al., 1993; Levin & Christopher,  
2003). However, there is no common pharmacophore or apparent structural 
likeness of lobeline to nicotine (Dwoskin & Crooks, 2002).  Some of the reasons 
why lobeline was considered a nicotinic receptor agonist were because lobeline 
caused tachycardia, hypertension, hyperalgesia, improvement of learning and 
memory, and in anesthetized rats it causes bradycardia and hypotension; which 
are all pharmacological effects of nicotine (Decker et al., 1993; Hamann & 
Martin, 1994; Olin et al., 1995; Sloan et al., 1988).  In addition, studies have 
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shown that nicotine improves cognition. One study involved 62 male non-
smokers, who were randomized into two groups, a low attention group and a 
high attention group (Poltavski & Petros, 2006). Based on the results from the 
Wisconsin Card Sorting Test, classic Stroop Test and the Conner’s Continuous 
Performance Test (CPT), transdermal nicotine improved attention in the low 
attention group and decrease working memory in the high attention group. This 
suggests that nicotine optimizes rather than just improving cognitive function. 
Another study investigated transdermal nicotine in healthy non-smoking adults 
with no attentional deficits (Levin & Simon, 1998).  Based on the results from the 
Profile of Mood States Test, nicotine significantly improved self-perceived vigor. 
Using the CPT, it was found that nicotine significantly reduced the number of 
errors of omission. Taken together, these results suggest that nicotine not only 
reduces attentional impairment, it also can improve attentiveness in normal adult 
non-smokers. A more recent study (Potter & Newhouse, 2008) used the Stop 
Signal Reaction Time to measure the effect of nicotine on cognition. The results 
showed that nicotine had a significant positive effect on this task without 
changes in the Go reaction time or accuracy. These data suggest that 
cholinergic agents like nicotine, may be potential pharmacotherapies for the 
cognitive deficits associated with ADHD. 
However, lobeline also has effects that are different from nicotine. For 
instance, nicotine is reported to be self-administered by rats (Corrigall & Coen,  
1989; Goldberg et al., 1981; Rasmussen & Swedberg, 1998; Sorge & Clarke,  
2009); however lobeline is self-administered in mice and is not self-administered 
by rats (Harrod et al., 2003; Rasmussen & Swedberg, 1998).  Chronic nicotine 
treatment results in an increase in locomotor activity (Clarke, 1990; Clarke & 
Kumar, 1983; Fung & Lau, 1988) and produces conditioned place preference 
(Fudala et al., 1985; Risinger & Oakes, 1995; Shoaib et al., 1994), but lobeline 
does not produce these effects (Dwoskin & Crooks, 2002).  Even though one 
study reported that lobeline generalized to nicotine in a drug discrimination assay 
(Geller et al., 1971),  additional studies have not been able to reproduce this 
finding (Reavill et al., 1990b; Romano & Goldstein, 1980; Schechter & 
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Rosecrans, 1972). Lobeline also produces transient, small cardiovascular effects, 
such as increase in heart rate, and with chronic use, it acts as a depressant of 
the sympathetic and parasympathetic ganglia as well as the adrenal medulla 
(Sloan et al., 1988), with side effects including decreased breathing rate and 
hypothermia.   
Due to the complexity of the pharmacological actions of lobeline, further 
investigation is necessary to evaluate other potential effects of lobeline in 
addition to its nicotinic receptor agonist effects. Lobeline has high affinity for the 
nAChR (Ki = 4-30 nM; (Broussolle et al., 1989; Damaj et al., 1997; Lippiello & 
Fernandes, 1986; Reavill et al.,1990b; Yamada et al., 1985). Furthermore, in a 
study using in vitro [3H]nicotine binding assays in rat brain, lobeline displaced 
binding of [3H]nicotine with a Ki value of 4.4 ± 2.2 nM (Damaj et al., 1997). This 
finding confirms that lobeline has a high affinity for nicotinic receptors, but does 
not indicate if lobeline is an agonist or antagonist at these sites. However, using 
a frog oocyte expression system with a two-electrode voltage-clamp, 0.1 and 1 
mM lobeline produced only a small current when applied for 10 sec to oocytes 
expressing the α4β2 subtype, suggesting that lobeline is  not acting as an 
agonist at this subtype of nAChR (Damaj et al., 1997).   Moreover, 10 µM 
lobeline antagonized 50% of the current-induced by 3 µM nicotine, although 
antagonism is not observed in vivo in mice (Damaj et al., 1997).  Also, 
pretreatment with mecamylamine and dihydro-β-erythroidine at a dose of 10 
µg/mouse, sc, 5 min before lobeline (40µg/mouse) did not decrease lobeline-
induced motor impairment, but these compounds did inhibit effects of nicotine, 
including lethality, seizures, and cardiovascular effects. Taken together, the 
results of this study suggest that lobeline interacts with a different mechanism 
than nicotine. Furthermore, the interaction of ligands with their receptors depends 
on a number of factors including receptor localization, subtype specificity, and 
potency of antagonist (Damaj et al., 1997).   
A series of studies investigated the action of lobeline as a nicotinic 
antagonist. The subsequent studies that investigated the action of lobeline, 
concluded that lobeline is a nicotinic antagonist (Clarke & Reuben, 1996;. Teng 
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et, al 1998; Teng et al., 1997; Terry et al., 1998). Specifically, lobeline evokes 
86Rb+ efflux from striatal synaptosomes with low efficacy (Terry et al., 1998). This 
86Rb+ efflux assay is a chemical method of investigating ion flux, whereby the 
86Rb+ acts like K+. If there is an increase in 86Rb+ efflux, then the compound in 
question acts as an agonist. In this case, lobeline produced low 86Rb+ efflux, 
suggesting that it acts as an antagonist instead of an agonist.  
In addition, lobeline-induced [3H]DA release is independent of extracellular 
calcium concentration and is not sensitive to mecamylamine, which indicates that 
the lobeline-evoked DA release is not mediated by nAChRs, and that lobeline 
does not act as an agonist nAChRs (Clarke & Reuben, 1996; Teng et al., 1998; 
Teng et al., 1997).  Importantly, a study using in vivo brain microdialysis was 
used to investigate the influence of lobeline on DA and DOPAC overflow in the 
core of nucleus accumbens in freely-moving rats pretreated with nicotine (0.4 
mg/kg, sc) once daily for 5 days. Lobeline (4.0 and 10 mg/kg) inhibited nicotine-
evoked [3H]DA overflow when administered 10 minbefore nicotine, but not after 
60 min (Benwell & Balfour, 1998). In addition, the low dose of lobeline had no 
effect at either time point in this study. The effect of lobeline on nicotine-evoked 
[3H]DA overflow was investigated using striatal slices (Miller, 2000). Striatal slices 
were superfused with lobeline for 30 min and 1 of 4 concentrations of nicotine 
was added to the buffer containing lobeline and superfusion continued for an 
additional 60 minutes. The results showed that lobeline blocked nicotine-evoked 
[3H]DA overflow from rat striatal slices (Benwell & Balfour, 1998; Miller et al., 
2000), which suggests that lobeline is an nicotinic antagonist.   
In addition, lobeline interacts with the same transporter proteins, DAT and 
VMAT2, at which psychostimulant drugs of abuse  and treatments for ADHD 
interact (Miller et al., 2003).  Lobeline inhibits [3H]DA uptake into vesicles with 
an IC50 of 0.88 µM and inhibits the binding of [3H]dihydrotetrabenazine, a 
VMAT2 ligand, to vesicular membranes with an IC50 of 0.90 µM (Teng et al., 
1998; Teng et al., 1997). Lobeline inhibits [3H]DA uptake into synaptosomes 
with an IC50 value of 80 µM (Teng et al., 1997). Results from this same study 
also demonstrated that lobeline increased DOPAC efflux, and did not increase 
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endogenous DA release (Teng et al., 1997). The increase in DOPAC suggests 
that lobeline does not inhibit MAO like amphetamine does. In addition, lobeline 
is more potent inhibiting DA uptake in vesicles (IC50= 0.88 µM) than releasing 
DA, whereas amphetamine is equipotent in inhibiting and promoting DA release 
(EC50~2.22 µM;(Teng et al., 1998). Both of these effects of lobeline may explain 
at least in part why lobeline is not self-administered.  
Taken together, the evidence from the above studies indicates that the 
overall mechanism of action of lobeline is a combination of interactions with 
different targets, the outcome of which is a diminished extracellular concentration 
of DA. Specifically, lobeline inhibits nAChR, DAT and VMAT2 function. The 
outcome of the interaction with VMAT2 would be expected to decrease the 
vesicular DA pool and increases the cystosolic DA, although this has not been 
determined directly. The proposed increase in cryptozoic DA would be expected 
to be metabolized by MAO, leading to an increase in extracellular DOPAC, which 
has been observed (Teng et al., 1997).   
9. Animal Models for ADHD 
The development of an appropriate animal model to evaluate potential 
new agents for ADHD is based on the behavioral, neurochemical, and 
neuroanatomical profile of ADHD individuals. A valid ADHD animal model should: 
1) mimic the clinical symptoms and presentation of individuals with ADHD (face 
validity), 2) show the underlying neurochemical changes in ADHD,  thus 
confirming the theoretical underlying etiology for ADHD (construct validity) and 3) 
predict an appropriate response to the effective, currently available, ADHD 
treatments (van der Kooij & Glennon, 2007).  Another factor to consider is the 
age of the rats in the animal models, since ADHD is primarily found in children 
and adolescents (American Psychiatric Association, 2000), but also persists into 
adulthood (Kessler et al., 2006). There are many ADHD animal models; however 
no one model satisfies all the criteria of an animal model for ADHD. Current 
models have been developed by either creating a lesion in the brain or by 
manipulation of the genome.   
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a. Neonatal 6-OHDA  
The first studies to model ADHD used 6-hydroxydopamine (6-OHDA) 
administered to neonatal rats to produce hyperactivity, which was expressed 
temporarily from postnatal day  (PND) 12-22 (Shaywitz et al., 1976).  6-OHDA 
(20 µg/µl; intracereoventricularly) is toxic to dopaminergic and noradrenergic 
neurons, decreasing DA and norepinephrine content and neurotransmission in 
brain. DA decreased in the frontal cortex by 76%, in striatum by 96%, and in 
nucleus accumbens by 84%.  Norepinephrine levels decreased by 13% in frontal 
cortex and by 39% in nucleus accumbens (Archer et al., 1988). This model 
resulted in learning and memory deficits, which are consistent with ADHD 
symptoms (Archer et al., 1988). Autoradiographic studies have demon strated 
the involvement of the DA D4 receptor in the effects of neonatal 6-OHDA in this 
model of ADHD (Avale et al., 2004; Zhang et al., 2002; Zhang et al., 2001). 
These latter findings are consistent with clinical observations that there is a 
higher incidence of ADHD when a polymorphism, in which a direct repeat in the 
48-base-pair sequence in the DA D4 receptor gene exists (Benjamin et al., 1996; 
Van Tol et al., 1992). Additional research has shown that the indolamine in 
addition to the noradrenergic neurotransmitter systems appear to be involved  in 
the pathology of ADHD due to the observations that NET inhibitors, such as 
desipramine and nisoxetine and 5-HT inhibitors citalopram and fluvoxamine 
reduced hyperactivity in 6-OHDA (100 µg) lesioned juvenile male rats, but the DA 
inhibitors had no effect on hyperactivity in  6-OHDA (100 µg) lesioned juvenile 
male rats (Davids et al., 2002).  These results suggest that the neonatal 6-OHDA 
rat is not a good model for ADHD. The neonatal 6-OHDA lesion model using rats 
also has excellent predictive validity because in one study methylphenidate (0.25 
mg/kg, sc) reduced hyperactivity in 6-OHDA lesioned rats (Shaywitz et al., 1978).  
However, it takes more than predictive validity for an animal model to be 
considered a good model for ADHD. In another study, methylphenidate (1 and 4 
mg/kg, sc) and amphetamine (0.25 and 1 mg/kg, sc) both decreased 
hyperactivity in neonatal 6-OHDA lesioned rats (Luthman et al., 1989).  
Moreover, a study evaluating the effect of atomoxetine (1 mg/kg) on neonatal 6-
57 
OHDA lesioned rats found that this non-stimulant also was effective in reducing 
motor hyperactivity in this animal model (Moran-Gates et al., 2005). Taken 
together, these studies provide evidence that the neonatal 6-OHDA lesioned rat 
model is not the best animal model for ADHD. Furthermore, this model has 
limitations because there is a lack of evidence showing that ADHD medications 
improve learning and memory deficits, not just hyperactivity. 
b. Neonatal alternative models 
Alternative ADHD animal models include the neonatal hypoxia rat model 
and the neonatal bromodeoxyuridine (BrdU) rat model. The neonatal hypoxia rat 
model was developed by immersion of rats in 100% nitrogen for 25 min at 
various stages of development ranging from 30 min after birth (Davids et al., 
2002), PND 2 (Dell'Anna et al., 1991), PND 4 (Shimomura & Ohta, 1988), or at 
PND 10 (Decker et al., 2003).  This animal model also produces permanent 
deficits in learning and memory (Gramatte & Schmidt, 1986).  Although 
amphetamine decreased hyperactivity, stimulants have not been thoroughly 
investigated for effects on improving learning and memory (Speiser et al., 1983). 
However, based on the limited research of this model, its predictive validity as a 
ADHD model is not clear (van der Kooij & Glennon, 2007).   
The neonatal BrdU rat model incorporates BrdU administration (50 mg/kg 
body weight, ip, every 12 hours for 2.5 days) to dams during gestational days 
between 9 and 15 (van der Kooij & Glennon, 2007). This treatment produces 
behavioral problems, impaired sexual behavior, deficits in learning and memory, 
and hyperlocomotion in the male offspring of these dams (van der Kooij & 
Glennon, 2007).  Nevertheless, no construct validity has been examined in this 
model and research has shown that methylphenidate (1 or 4 mg/kg, s.c.) has no 
effect in the BrdU rat model (Muneoka et al., 2006), which also questions the 
predictive validity of this model. In addition, this model also has a hyposexuality 
aspect that is not associated with ADHD. In conclusion, the overall validity of the 
neonatal BrdU rat model for ADHD remains questionable based on the above 
evidence. 
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c. Genetic models 
 There are also established genetic rat models of ADHD. These models 
include the spontaneously hypertensive rat (Schmitt et al., 2008), the Wistar-
Kyoto derived hyperactive rat (WKHA), and the Naples high (and low) excitability 
rat (Krause et al) models. The SHR model, the most commonly studied animal 
model of ADHD, was developed in the 1960’s by inbreeding individuals in the 
WKY strain that showed high systolic blood pressure, which resulted in 
hypertension in subsequent generations (Okamoto & Aoki, 1963).  The SHR 
model satisfies many of the criteria for a valid model of ADHD because these rats 
display hyperactivity, impulsivity, poor performance stability, poor sustained 
attention, and spatial working memory deficits (De Bruin et al., 2003; Hernandez 
et al., 2003; Ueno et al., 2002) when compared to WKY (Tsai & Lin, 1988; van 
den Bergh et al., 2006).   
However, hypertension is not associated with ADHD patients, leading to 
potentially confounding interpretations as to the results obtained with this model, 
i.e., the role that hypertension plays in contributing to the effects. In addition, the 
predictive validity of this model in identifying novel treatments is questionable 
because amphetamine and methylphenidate have been shown to increase 
hyperactivity in this rat model, which is the opposite result that is observed 
clinically (Amini et al., 2004; McCarty et al., 1980; Wultz et al., 1990).  The age of 
these rats in this model may also be a concern to some investigators, because 
the rats between 10-12 months old, which is considered an adult rat (Spear, 
2000), yet ADHD is diagnosed in adults and is an ongoing issue in the adult 
population as well.  Conversely, a more current study found that methylphenidate 
(1.5 mg/kg, po) lowered the amount of errors in the attentional set-shifting task in 
the SHR rat model using 9 week old rats  (Kantak et al., 2008). This same  study 
sought to advance the SHR animal model of ADHD toward medication 
development by utilizing 3 behavioral tests to assess the validity of this model 
with respect to the deficiency in learning and memory associated with ADHD, 
using 9 week old rats versus adult rats (Kantak et al., 2008).  Specifically, the 
function of the orbitofrontal cortex, the dorsal striatum, and the prelimbic cortex 
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were evaluated using the odor-delayed win-shift task (Di Pietro et al., 2004), the 
win-stay task (Kantak et al., 2001), and the attentional set-shift task (Birrell & 
Brown, 2000). The odor-delayed win-shift task training phase involves the rats 
discriminating among four odors in four arms and keeping online the memory of 
the odors for which the reinforcer was already received. The rats were given 
eight training trials per day for 4 days to learn to dig in an unscented sand cup for 
a hidden fruit loop reinforcer. The turn bias used a T-configuration for the maze 
and the rats were started from the less familiar stem arm and had to choose the 
correct strategy to advance to the extradimensional set-shifting trials conducted 
the following day. The food well of each choice arm was baited with a single 
pellet and a visual cue was randomly placed on the left wall of the one of the 
choice arms before each trial. If a rat made an incorrect choice, the 
discrimination trials continued until it was able to reach five consecutive correct 
reinforced choices.        
         In addition, Kantak and colleagues included a genetic control in this latter 
study, the WKHT strain, which is a Wistar-Kyoto-derived strain of rat inbred for 
hypertension, but not exhibiting the hyperactivity. This important aspect provided 
the first direct test of the impact of hypertension in these ADHD-relevant learning 
paradigms. Furthermore, in the experiments the authors used 9-week old rats, an 
age which is considered more comparable with adolescence. The results from 
the odor-delayed win-shift task revealed that the over the entire task there was 
no strain differences in the cumulative number of working memory errors or 
reference memory errors made over the 20 test phase sessions. However, the 
methylphenidate-treated SHR strain completed the test phase 78% faster than 
the vehicle-treated WKY strain. This suggests that methylphenidate elevates 
some of the working memory deficits. The SHR strain latencies to traverse the 
arm and recover a food pellet in the win-stay task were 42% faster than the WKY 
strain and the WKHT strain was 20% faster than the WKY strain. This indicates 
that the learning deficits of the SHR strain are not associated with a lower 
motivation level compared to the other two control strains. The model was 
validated by the findings that methylphenidate(1.5 mg/kg, po, 30 min 
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pretreatment) significantly improved latencies in the win-stay task, where the 
methylphenidate-treated SHR finished the task 66% faster than the vehicle-
treated WKY strain. These results demonstrate that methylphenidate treatment 
was effective in enhancing the performance of the SHR, thus allowing them to 
complete the task faster than the vehicle-treated WKY. With the attentional set-
shifting task, the vehicle-treated SHR strain had 23% more errors compared with 
the vehicle-treated WKY. Methylphenidate-treated WKY strain had 30% less 
errors compared to the methylphenidate-treated SHR strain. These findings 
demonstrate that methylphenidate eliminates strain differences in attention. The 
WKHT strain performed similarly to the WKY, suggesting that the hypertension is 
not associated with the hyperactivity found in the SHR rat model. The overall 
results of this study support the use of the SHR as a valid model for ADHD, 
particularly with respect to the neurocognitive deficits associated with this 
disease, and that the WKY is an appropriate control strain to compare with the 
SHR when neurocognitive endpoints are evaluated. 
 The SHR strain and the WKY strain were crossbred in order to develop a 
strain without the hypertension associated with the SHR model. This led to the 
development of the WKHT rat having hypertension but no hyperactivity and the 
WKHA rat model, which had no hypertension but had hyperactivity (Hendley & 
Ohlsson, 1991).  In regards to face validity, in the absence of hypertension, this 
model has abnormal attentional processing, impulsivity, and learning deficits. The 
WKHA model also had a low predictive validity. This conclusion was 
demonstrated by the results of a study that administered methylphenidate (5 
mg/kg) to WKHA rats and found that their locomotor activity increased by 200% 
(Drolet et al., 2002). Based on these results, the increase in locomotor activity 
decreases the predictive validity because methylphenidate should not increase 
locomotor activity, but decrease it. Furthermore, more research is needed to 
investigate the construct validity of this model because the role of the DA 
receptors and DAT is still unclear. In conclusion, these observations limit the 
usefulness of the WKHA model as an ADHD animal model.  
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The Napel High Excitability (NHE) rat model has been investigated as an 
ADHD model because of the different exploratory activity in the Làt maze, a 
commonly used method of testing locomotor activity and habituation in a novel 
situation. This model was based on reactivity to novelty, not baseline activity 
level (Sadile et al., 1993). NHE rat model has an advantage over the SHR model, 
because the NHE strain does not have hypertension (Cerbone et al., 1993), and 
does not have the limitation of evaluating the effect of hypertension. The face 
validity of this model needs to be improved because even though it demonstrates 
hyperactivity and attention deficits, no impulsivity has been observed. In addition, 
the predictive validity of this model still needs to be investigated. In reference to 
construct validity, one study evaluated mesencephalic TH expression in coronal 
sections as determined by immunohistochemistry in the NHE rat model (Viggiano 
et al., 2003). Results showed a larger neuron size in the VTA. These results 
suggest that the mesolimbic and nigrostriatal DA pathway are normal, but the 
mesocortical DA pathway is hyperfunctional and hyperinnervated.  However, a 
larger VTA neuron size in ADHD has not been reported, thus limiting its construct 
validity. In addition, the size of the neuron can not be the only factor involved in 
the functional of the pathway. The NHE could be potential ADHD animal model 
because it demonstrates the aspects of ADHD including hyperactivity and deficits 
in tasks requiring visuospatial attention (Aspide et al., 1998; Papa et al., 2000). 
Nevertheless, further study is necessary to determine how ADHD medications 
affect this rat model and if this model demonstrates the other symptoms of 
ADHD, such as impulsivity. The age of the animal is not a limitation because this 
model used adult rats and as stated earlier, adults suffer with ADHD as well. In 
conclusion, this model should not be considered a suitable model for ADHD until 
additional research is performed such as investigating the construct validity in 
more detail in order to validate the model more appropriately.  
There are also models of ADHD which employ mice, rather than rats. 
Some of these models include the hyperactive-wheel turning mice, the coloboma 
mutant mice, and the DAT-KO mice. The hyperactive wheel-running mouse only 
demonstrates hyperactivity in regards to face validity (Rhodes et al., 2001). As 
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far as construct validity, altered dopaminergic function regarding the D1 and DAT 
may be involved in producing the hyperactivity (Rhodes et al., 2001). The 
predictive validity is weak because only amphetamine has been shown to 
attenuate the hyperactivity (Rhodes et al., 2001). The coloboma mutant mice 
model was developed by neuron irradiation in mice (Searle, 1966).  This model 
has been used as a ADHD model because it possesses a weak face validity in 
that it displays spontaneous hyperactivity (Hess et al., 1992) and delayed 
development (Heyser et al., 1995).  However, impulsivity has not been observed. 
It is suggested that the neurochemical basis of this model is produced by 
elevated noradrenaline levels in striatum and nucleus accumbens of the 
coloboma mouse (Jones et al., 2001). The predictive validity is questionable 
because amphetamine blocks the hyperactivity, however methylphenidate 
increases hyperactivity (Hess et al., 1996).  Based on the lack of validity of these 
two models, they are not recommended as suitable ADHD models. Due to the 
lack of research of these models, a greater focus has been placed on DAT-KO 
mice.   
Since DAT is the major regulator of DA clearance and DAT-gene 
alterations have been associated with ADHD, DAT-KO mice were developed 
(Cook et al., 1995; Gill et al., 1997). In support of the validity of this model, DAT-
KO mice have been found to display hyperactivity and spatial learning deficits 
(Gainetdinov & Caron, 2001; Gainetdinov et al., 1999). Methylphenidate and 
amphetamine attenuate the hyperactivity observed in the DAT-KO mice, also in 
support of the validity of the model. However, a disadvantage of this model is that 
the target of psychostimulants, DAT is missing, which makes it more difficult to 
assess the predictive validity. There is the possibility that not all the DAT has 
been knocked out which depends on the process used to develop the DAT-KO 
mice (NIH, 2010).  The pups born from the embryos that had the altered 
embryonic stem cells injected into them do not have the DAT completely knocked 
out because there is also normal tissue present as well. In order to produce a 
homozygous line of knockout, crossbreeding is required where each copy from 
respective chromosomes is knocked out in the present tissue (NIH, 2010).  
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Nevertheless, a study utilizing fast scan cyclic voltammetry of extracellular striatal 
DA levels, show impaired DA clearance in DAT-KO mice x 300 times compared 
to controls. These results demonstrate that the DAT gene was knocked-out. A 
more logical explanation is that these psychostimulants are interacting with other 
neurotransporters, such as NET and 5-HT, to elicit their effects. This leaves open 
the question of the involvement of other targets for the action of effective 
pharmacotherapies for ADHD. 
In order to eliminate some of the disadvantages associated with the DAT-
KO mice mode, such as premature death, growth retardation, and the absence of 
DAT, the DAT-knock-down (DAT-KD) mouse model was created. This line was 
developed by breeding heterozygous mutants in a 129 Su/J genetic background 
(Zhuang et al., 2001). Both the DAT-KO/KD models respond to amphetamine 
and methylphenidate, thus supporting the predicative validity of the models for 
ADHD. However, more research is needed to find the construct validity marker 
such as D4 receptor involvement. In reference to the face validity, both models 
possess hyperactivity, impulsivity, and attention deficits. Another advantage of 
the DAT-KD model is that it expresses a small percentage of DAT, thus allowing 
it to have a more acceptable predictive validity because pharmacotherapies 
targeting DAT can be evaluated. The age of the mice used in these models is not 
clear, however the model suggest that the mice are adolescents since some do 
not live to adulthood. 
 In conclusion, there are several potential ADHD animal models from which 
to choose. Nonetheless, ADHD animal model needs to demonstrate the 
symptoms associated with ADHD (face validity), confirm an underlying theory of 
ADHD (construct validity), and possess the appropriate response to ADHD 
treatments (predictive validity). There is no perfect animal model for ADHD, but 
the most promising models include the neonatal 6-OHDA lesion model and the 
DAT/KO-KD mice model based on their ability to meet the aforementioned 
criteria.  
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10.  Specific Aims and Hypotheses 
The work discussed in this dissertation was based on the hypothesis that 
DAT and VMAT2 are the primary targets for the pharmacological effects of 
ADHD psychostimulants, methylphenidate, and amphetamine. DAT is generally 
thought to be a major target for these agents; however, it may not be the only 
target. In addition, these pharmacotherapies have untoward effects such as 
abuse liability, which limits their use and demonstrates the need for additional 
ADHD treatment options. Lobeline may be a potential treatment option for 
ADHD because it interacts with the same transporters as methylphenidate and 
amphetamine, but does not have abuse liability.  
The specific hypotheses for this project were:  
1) Lobeline will decrease DAT function after acute and repeated in 
vivo administration, as shown by a decrease in Vmax, based on results 
from previous in vitro studies performed in our lab 
2) Lobeline will have a greater effect on VMAT2 function after acute 
and repeated in vivo administration as shown by the parameters of Vmax 
and Km, based on results from previous in vitro studies 
3) DAT trafficking is the underlying mechanism behind the 
modulation of DAT function as shown by an increase of DAT to the 
neuronal cell surface of the striatum. 
 a. Specific Aims 
 Specific Aim 1) Determine the effect of lobeline after acute and repeated 
in vivo administration on DAT function using [3H]DA uptake assay.  
 Specific Aim 2) Determine the effect of lobeline after acute and repeated 
in vivo administration on VMAT2 function using [3H]DA uptake assay.   
 Specific Aim 3) Determine if the underlying mechanism of modulation of 
DAT function is due to DAT trafficking, using biotinylation and western blot 
analysis.  
 The effects of lobeline were compared to the effects of methylphenidate 
and amphetamine for all experiments. 
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Figure 1. Schematic of a DA nerve terminal. 
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Figure 2.  3D-Image of a DA transporter. Used with permission by Dr. Zhan. 
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Figure 3. Structures 
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Figure 3. Structures (Continued) 
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Chapter Two 
 
Effect of Acute and Repeated In Vivo Administration of Lobeline, 
Methylphenidate, and Amphetamine on Dopamine Transporter Function 
A. Introduction 
 ADHD is a childhood disorder that can, in some cases, persist into 
adulthood (Madras et al., 2005) and is associated with behavioral dysfunctions 
including three major components, hyperactivity, impulsivity, and inattention.  
Estimations are that ~15% of school age children (Scahill et al., 1999) and 5-10% 
of adults have ADHD, which translates into at least 8 million adults having ADHD. 
(Swanson et al., 1998a). This suggests that ADHD is not just a childhood 
disorder, but a disorder of all ages. The striatum, which contains high 
concentrations of DA, is suggested to be involved in executive function and 
motor response associated with ADHD (Dinn et al., 2001; Volkow et al., 2001; 
Wilens, 2008).  
The etiology of ADHD is unknown; however DAT, which is located on the 
DA nerve cell membrane, is believed to play a major role in the pathophysiology 
of ADHD (Easton et al., 2007). DAT is the primary regulator of extracellular DA 
concentration (Gainetdinov & Caron, 2003). DAT is thought to be involved in the 
mechanism of action of stimulants, which are the gold standard options to treat 
ADHD (i.e., methylphenidate and amphetamine). This is supported by work that 
shows that stimulants that block DAT are effective treatments for ADHD (Volkow 
et al., 2002); thus, DAT is a pharmacological target for ADHD therapeutic agents.   
Methylphenidate inhibits the reuptake of DA into the synaptic terminal, 
thus increasing the amount of DA in the synaptic cleft (See Introduction; 
(Greydanus et al., 2007).  Amphetamine increases the amount of DA via a 
different mechanism, whereby it releases DA from the terminals by causing a 
reversal of DAT (Jones et al., 1998b). Due to the potential for abuse associated 
with these stimulants, there are concerns about the use of these agents. 
Additional concerns include cardiovascular effects, abnormal growth, and 
suppressed appetite (Gibson et al., 2006). 
70 
Lobeline may be a suitable candidate for the treatment of ADHD. When 
lobeline was evaluated in behavioral studies, lobeline was not self-administered 
by rats, nor did it substitute for d-methamphetamine, which suggest that it has no 
abuse liability (Harrod et al., 2003).  Lobeline is the major alkaloidal component 
of the Indian tobacco plant, Lobelia inflata, and is similar to nicotine in some 
ways.  For example, both have a high affinity for the nicotinic receptor despite the 
structural differences of nicotine and lobeline (Dwoskin & Crooks, 2002). Based 
on in vivo studies, lobeline does not stimulate locomotor activity (Miller et al., 
2003) and acts as a nicotinic antagonist, in vitro, (Miller et al., 2001) and in vivo 
(Miller et al., 2003).  Lobeline binds to and inhibits (IC50 value ≈ 40-100 µM) DAT, 
inhibiting DA uptake in vitro (Miller et al., 2004; 1998, Teng et al., 1997). 
The concerns of the use of stimulant medications clearly indicates that 
more effective treatment options with less side effects are needed for ADHD. 
Based on in vitro experiments where lobeline inhibited DAT function, lobeline 
may be an option (1998, Teng et al., 1997). However, the effect of in vivo 
administration of lobeline needs to be determined. In order to determine if the 
mechanism of action of lobeline on DAT function is similar to either 
methylphenidate or amphetamine, the effects of methylphenidate and 
amphetamine on DAT function were also investigated after in vivo administration. 
Therefore, the goal of the present study was to elucidate the effect of acute and 
repeated in vivo administration of lobeline and to determine if this effect was 
observed in a dose-dependent manner. In addition, the effect of lobeline on DAT 
function was compared to the effect of methylphenidate and amphetamine 
administered in vivo. Such experiments are helpful in providing more insight into 
the mechanism of action of all these agents. 
B.  Methods 
Materials.  
[3H]DA (3,4-ethyl-2[N-[3H]dihydroxyphenylethylamine Specific Activity 28 
Ci/mmol) was purchased from PerkinElmer Life Sciences Inc. (Boston, MA). L-
Ascorbic acid, bovine serum albumin (BSA), catechol, α-D-glucose, N-(2-
hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) (HEPES), nomifensine 
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maleate, pargyline hydrochloride, sucrose, methylphenidate hydrochloride, 
amphetamine hydrochloride, and 3-hydroxytyramine hydrochloride DA were 
obtained from Sigma Chemical Co. (St. Louis, MO). Lobeline was purchased 
from ICN Biomedicals (Costa Mesa, CA). All other chemicals used in the in vitro 
assay buffers were purchased from Fisher Scientific (Pittsburgh, PA).   
Subjects. 
Adult male Sprague-Dawley rats (200-220g body weight upon arrival) 
were obtained from Harlan Inc. (Indianapolis, IN). Adult male rats were used 
because as stated earlier, ADHD is found in adult humans as well as adolescents 
(Swanson et al., 1998b). Animals were housed two per cage with free access to 
food and water in the Division of Lab Animal Resources, University of Kentucky. 
Experimental protocols were in concordance with the NIH 1996 Guide for the 
Care and Use of Laboratory Animals and were approved by the Institutional 
Animal Care and Use Committee at the University of Kentucky.   
Drug Administration. 
Lobeline, methylphenidate, and amphetamine were administered by 
subcutaneous (sc) injection in a volume of 1 ml/kg body weight and expressed as 
the salt weights. In order to remain consistent with previous studies, the 
subcutaneous route was selected. Groups of rats were injected acutely with 
either saline (control), lobeline (1, 3, and 10 mg/kg), methylphenidate (2.5, 5, 20, 
and 40 mg/kg), or amphetamine (0.1, 0.25, 1, and 5 mg/kg). The striatum was 
obtained 20 min after the last injection for the lobeline group, 60 min for the 
methylphenidate group and 30 min for the amphetamine group. Separate groups 
of rats were injected repeatedly for either 7 or 14 days once daily with saline, 
lobeline (3.0 mg/kg), methylphenidate (2.5, 5, and 20 mg/kg), or amphetamine 
(0.25 and 5 mg/kg). The doses for the repeated experiments were chosen based 
on the effect observed during the acute experiments. If no effect was observed in 
the acute experiments, doses were chosen based on results of previously 
reported behavioral studies (Harrod, 2003; Miller, 2001).   
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Lobeline dose range and time point after injection was chosen based on 
previous behavioral studies in which the effect of lobeline (1, 3, and 10 mg/kg) on 
methamphetamine self-administration was determined. Results showed that 
lobeline (3 mg/kg) inhibited methamphetamine self-administration 20 min after 
administration (Harrod et al., 2001).  Methylphenidate dose range and time point 
were chosen based on experiments assessing [3H]DA uptake, 60 min after 
administration and behavioral studies which concluded that doses of 2.5 and 5.0 
of methylphenidate were more clinically relevant (Kuczenski & Segal, 2001; 
Wooters et al., 2006). Amphetamine dose range and time point were based on 
behavioral studies showing that low doses of amphetamine (0.25-0.75 mg/kg) 
improved stimulus detection performance in rats  30 min after injection (Grilly, 
2000).   
Striatal Synaptosomal Preparation and [3H]DA Uptake Assay (DAT 
Function).  
[3H]DA uptake assays were conducted using previously published 
methods (Zhu et al., 2004).  Briefly, striata were dissected and homogenized with 
10-12 passes of a Teflon pestle homogenizer in 20 mL of ice cold 0.32 M 
sucrose buffer containing 5 mM sodium bicarbonate (pH 7.4). Homogenates 
were centrifuged at 2000 g for 10 min (4°C). Supernatants were centrifuged at 
20,000 g for 15 min (4°C). Pellets were resuspended in 2.4 ml of ice-cold assay 
buffer (125 mM NaCl, 5 mM KCl, 1.5 mM MgSO4, 1.25 mM CaCl2, 1.5 mM 
KH2PO4, 10 mM glucose, 25 mM HEPES, 0.1 mM ethylenediaminetetraacetic 
acid (EDTA), 0.1 mM pargyline and 0.1 mM L-ascorbic acid, saturated with 95% 
O2/5% CO2, pH 7.4). Protein concentrations were determined using the Bradford 
assay (Bradford, 1976).  Striatal synaptosomes (20 µg protein in 50 µl) were 
incubated in an oxygenated environment for 5 min at 34°C. [3H]DA (1 nM - 5µM) 
was added to the samples. Total assay volume was 500 µl. Nonspecific uptake 
was determined in the presence of 10 µM nomifensine. Incubation continued for 
10 min at 34°C and was terminated by the addition of 3 ml ice-cold assay buffer 
containing 1 mM pyrocatechol. Samples were filtered through Whatman GF/B 
glass fiber filters (presoaked with  1 mM pyrocatechol  for at least 3 h) and 
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washed three times with ice-cold assay buffer containing 1 mM pyrocatechol, 
using a Brandel cell harvester (Model MP-43RS; Biochemical Research and 
Development Laboratories Inc., Gaithersburg, MD). Radioactivity was determined 
using a liquid scintillation spectrometer (Model B1600TR, Perkin-Elmer Life 
Sciences, Downers Grove, IL).     
C. Data Analysis.  
A one-way ANOVA with each dose of drug serving as an independent 
group revealed that [3H]DA uptake was not different among the saline groups 
across the dose range for each drug (Table 1, 2, and 3). Therefore, the data for 
the saline-control groups were pooled for statistical analysis and graphical 
presentation, which also explains the wide range of n. 
Kinetic parameters Vmax(pmol/min/mg) and Km(µM)) for [3H]DA uptake 
were determined using GraphPad Prism software (GraphPad Prism,  version 
5.02; GraphPad Software, San Diego, CA). Vmax is the maximum velocity at 
which the substrate is 100% bound and Km is the concentration of the substrate 
at half of the Vmax. Data are expressed as mean values ± S.E.M. To analyze the 
kinetic parameters, separate unpaired Student t-tests were performed on the 
Vmax and Km for [3H]DA uptake of the drug-treated group  for each drug at each 
dose and saline-control groups. Log transformed Km values were used for 
statistical analyses using the SPSS (Statistical Packages for the Social Sciences; 
standard version 17, SPSS Inc., Chicago, IL). To determine the methylphenidate 
(20 mg/kg) response on DAT cell surface expression, separate student t-tests 
were conducted on DAT immunoreactivity from each of the cell fractions (total, 
non-biotinylated and biotinylated) between methylphenidate-treated and saline 
control groups. Differences were considered significant at p< 0.05.  
D. Results 
Effects of Acute and Repeated In Vivo Methylphenidate Administration on 
DA Transporter Function 
Kinetic analysis of [3H]DA uptake was performed on synaptosomes after 
acute in vivo administration of methylphenidate. Specific [3H]DA uptake for the 
saline-control groups for methylphenidate 2.5, 5.0, 20.0, and 40.0 mg/kg doses 
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were 16.7 ± 1.5, 12.8 ± 2.1, 17.4 ± 3.9, and 10.8 ± 2.5 pmol/mg/min, respectively. 
Methylphenidate (5.0, and 20 mg/kg) increased (~60%) Vmax (23.5 ± 1.6 and 23.3 
± 2.7 pmol/mg/min) for [3H]DA uptake compared to pooled saline-control (14.5 ± 
1.3 pmol/mg/min, Table 1), respectively. The current results show an increase 
(~60%) of DAT function, with acute methylphenidate (5.0 and 20 mg/kg) having a 
significantly higher Vmax compared to control (Fig. 4A). Acute in vivo 
administration of methylphenidate had no effect on Km values (Table 6). 
  Repeated methylphenidate administration for 7 days at 2.5 and 20 mg/kg 
doses had a Vmax of 25.1 ± 0.9 and 27.3 ± 2.0 pmol/mg/min, respectively, which 
increased (36% and 48%, respectively) DAT function compared to pooled saline-
control with a Vmax of 18.5 ± 1.3 pmol/mg/min (Fig. 5A). No significant effect was 
observed for the 5.0 mg/kg dose after 7 days or after 14 days (Fig. 5A). 
Repeated methylphenidate in vivo administration had no effect on Km values 
(Table 6). 
Effects of Acute and Repeated In Vivo Amphetamine Administration on DA 
Transporter Function 
 Acute in vivo administration of amphetamine had no effect on DAT 
function (Fig. 7). Seven-day repeated in vivo administration of amphetamine had 
no effect on DAT function (Fig. 8). Fourteen-day-repeated in vivo administration 
of amphetamine had no effect on DAT function (Fig. 9). Specific [3H]DA uptake 
for the saline-control groups for acute amphetamine 0.1, 0.25, 1.0, and 5.0 mg/kg 
doses were 18.6 ± 1.0, 27.0 ± 4.9, 15.3 ± 1.1, and 14.6 ± 0.7 pmol/mg/min, 
respectively, with no effect onKm  (Table 7). Specific [3H]DA uptake for repeated 
amphetamine 0.1, 0.25, 1.0, and 5.0 mg/kg doses were 15.9 ± 2.2, 17.7 ± 1.4, 
14.3 ± 1.1, and 15.9 ± 0.9 pmol/mg/min, respectively, compared to the pooled 
saline-control group with a Vmax of 19.1 ± 1.7 pmol/mg/min (Table 2).  
Effects of Acute and Repeated In Vivo Lobeline Administration on DA 
Transporter Function 
 Kinetic analysis of synaptosomal [3H]DA uptake after acute and repeated 
(7 or 14 days) in vivo administration of lobeline showed no effect on Vmax or  Km 
values (Fig. 10-12;Table 8). Specific [3H]DA uptake for the saline-control groups 
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for lobeline 1.0, 3.0, and 10.0 mg/kg doses were 16.4 ± 2.3, 20.8 ± 2.3, and 13.1 
± 1.8 pmol/mg/min, respectively. Specific [3H]DA uptake for acute lobeline 1.0, 
3.0, and 10.0 mg/kg doses were 13.3 ± 0.9, 20.3 ± 1.5, and 13.3 ± 1.7 
pmol/mg/min, respectively, compared to16.3 ± 1.3 pmol/mg/min for the pooled 
saline-control group (Table 3). The 3 mg/kg dose had the highest effect of all the 
doses with a Vmax of20.3 ± 1.5 pmol/mg/min; however, this effect was not 
significant. 
E. Discussion 
 In the present study, the effects of in vivo administration of lobeline were 
determined and compared to the effects of methylphenidate and amphetamine 
using kinetic analysis of [3H]DA uptake into striatal synaptosomes. This work 
investigating in vivo drug administration, extends previous work in our laboratory 
demonstrating that in vitro lobeline inhibits DAT function (Teng et al., 1997). 
However, the results from these studies show that lobeline (1, 3, and 10 mg/kg) 
has no effect on DAT function 20 min after in vivo administration. There are a 
number of possible explanations for this observation.  
First, the concentration of lobeline after in vitro administration may be 
higher than the final concentration after in vivo administration. In vitro 
experiments involve the direct application of the drug in question to the striatal 
slice of tissue or synaptosomes; however with in vivo administration that is not 
the case because the drug is injected into the whole animal. Furthermore, when 
a drug is given in vivo, the drug is exposed to various processes that could 
decrease the amount of drug available to elicit its pharmacological effect such as 
absorption, distribution, metabolism, and elimination. Previous research has 
provided evidence that the ability of any compound to alter monoamine uptake in 
vitro does not necessarily predict its ability to modulate monoamine transporters 
after in vivo administration (Fleckenstein et al., 1999).   
Another plausible explanation for the lack of effect with lobeline could be 
that the time point may not have been appropriate. The time point of 20 minutes 
post injection, was based on behavioral effects, such as the lobeline-induced 
decrease in methamphetamine self administration in rats, observed after in vivo 
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administration. A way to address this issue would be to conduct a time-course 
curve to determine if the effect of lobeline is seen at any other time point besides 
20 min post injection, such as every 5-10 minutes.   
A third possible explanation for not observing an effect with lobeline, may 
be that the brain region examined was not the region where the effect was taking 
place. Even though the striatum is very dense in DA, the PFC is an important 
region also involved in ADHD, where DA is present to a lesser degree (Arnsten, 
2006; Casey et al., 2007; Kieling et al., 2008).   
Acute in vivo administration of methylphenidate showed an increase in 
DAT function at 5 and 20 mg/kg, but showed no effect with the 40 mg/kg dose. 
While surprising, this result is consistent with previous results showing that a 
single 40 mg/kg s.c. injection of methylphenidate caused little or no change in 
synaptosomal DA uptake (Fleckenstein et al., 1999; Sandoval et al., 2002). This 
present study also extends the work of Fleckenstein by including a dose-
response curve as well as 7 and 14 day repeated daily injections. The 7-day 
response curve showed an increase of 36% by the 2.5 mg/kg methylphenidate 
dose and the 20 mg/kg dose showed an increase of 48%. It has been shown that 
methylphenidate indirectly acts as a DA agonist (Wilens, 2008).  This may 
explain the increase of DAT function because if methylphenidate acts as a DA 
agonist, it could activate both presynaptic and postsynaptic D2 DA receptors. 
This action could indirectly cause an increase in DAT function that removes the 
DA in the synaptic cleft, which would decrease the activation of the D2 DA 
receptors. Furthermore, methylphenidate has a more direct and less complicated 
mechanism of action when compared to amphetamine and lobeline, which could 
also explain the increase of DAT function compared to lobeline and 
amphetamine, whereas both have a more complex mechanism of action.   
After 7 days of repeated in vivo methylphenidate administration, the 2.5 
and 20 mg/kg doses showed a significant increase in Vmax, while the 5.0 mg/kg 
dose had no effect. However, after 14-days of repeated in vivo administration of 
methylphenidate (2.5, 5.0 or 20 mg/kg) the effect was no longer present. 
Methylphenidate administration did not alter the Km, which suggests that 
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methylphenidate competes with DA at DAT in a noncompetitive manner.  It could 
also be possible that methylphenidate increased the number of receptors in order 
to enhance DAT function.  
 Acute and repeated in vivo administration of amphetamine did not alter 
DAT function in these studies. Previous investigations have shown that 
amphetamine causes a biphasic effect on DAT trafficking and acts rapidly to 
control DAT in the plasmalemmal membrane (Johnson et al., 2005a). 
Intracellular amphetamine produces DAT trafficking (Kahlig et al., 2003). Since 
amphetamine causes DAT trafficking, one would expect to see a difference in 
DAT function after in vivo administration of amphetamine. However, consistent 
with our results, Johnson et al.,  found that amphetamine did not alter [3H]DA 
uptake following a 1-min incubation (Johnson et al., 2005b).  This suggests that 
the chosen time point plays a critical role when determining if an effect is present. 
It is possible that the DAT response was not observed with the time point that 
was chosen. In addition, DAT may not be the primary target responsible for 
pharmacological actions of amphetamine based on its complex mechanism of 
action, which includes acting as a DAT substrate. The results also showed the 
amphetamine did not alter Km, which may imply that amphetamine also competes 
with DA at DAT in a noncompetitive manner.   
The current results suggest that lobeline acts more similar to 
amphetamine compared to methylphenidate, with respect to the effects observed 
on DAT function. Since there was no effect of amphetamine at DAT, we 
reevaluated the doses used in these experiments by searching the literature. 
Amphetamine administered at 0.25 mg/kg appears to be an adequate dose to 
observe a behavioral effect since it increased choice accuracy in rats (Grilly et 
al., 1998).  Another study of  amphetamine administration (0.25, 0.75, and 1.25 
mg/kg, s.c.) prior to behavioral testing, observed an increase in accuracy at 0.25 
mg/kg however, a decrease in accuracy at 1.25 mg/kg (Grilly et al., 1989).  
Based on a recent review by Grilly and Loveland, 0.1-0.4 mg/kg of amphetamine 
was considered a low dose, 0.4-1.0 mg/kg a moderate dose, 1.0-3.0 mg/kg a 
high dose, and ≤3.0 mg/kg was considered a very high dose (Grilly & Loveland, 
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2001).  Furthermore, Kuczenski and colleagues have done extensive research 
with amphetamine and found using microdialysis, the maximal concentration of 
amphetamine was achieved 30 minutes after administration (Kuczenski et al., 
1997). Thus, the dose range of 0.1-5.0 mg/kg of amphetamine, which was used 
in the current studies, offers a complete dose-response.   
The results of this study suggest  that amphetamine, lobeline and 
methylphenidate influence DAT differently at the time points and doses used in 
this study, since the drugs have been shown to target DAT (Greydanus et al., 
2007; Thanos et al., 2007). However, there are limitations to this current study 
that need to be addressed. The first limitation is the choice of the time point. The 
time points were based on behavioral observations, and may not be the optimal 
time points to observe the pharmacological effects ex vivo. A complete time-
course of the pharmacological effect is necessary to determine the best time 
point for each drug after in vivo administration. However, the data in these 
studies could be a result of the difference in their mechanisms of action. The 
interaction of methylphenidate at DAT may depend on the release of DA in the 
synaptic cleft, whereas amphetamine induces release of vesicular DA from the 
synaptic terminal (Schiffer et al., 2006).  This could possibly explain our 
observations of an increase in Vmax by methylphenidate and no effect by 
amphetamine. Another limitation is the fact that we are evaluating the effect on 
DAT using synaptosomes. This limits the findings to only effects found in the 
synaptosomes, while other effects may be present in other areas, such as in 
vesicles as well.   
 The common lack of effect with in vivo administration of lobeline and 
amphetamine on DAT function is consistent with the fact that both are weak 
bases and very lipophilic compounds (Teng et al., 1997). The IC50 value 
determined in previous studies suggest that the synaptic vesicular DA transporter 
is significantly more sensitive to lobeline versus the plasma membrane DA 
transporter, which provides additional evidence as to why in vivo VMAT2 
experiments need to be conducted (Teng et al., 1997). 
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Overall, the results of the present study, present evidence that 
methylphenidate effects DAT function after in vivo administration in a different 
manner than that of lobeline and amphetamine, suggesting that more research is 
necessary to further understand the mechanisms of actions of these agents.   
In conclusion, there is evidence to warrant more investigation of lobeline 
to determine its effects on VMAT2, due to the lack of effect on DAT function after 
in vivo administration of amphetamine and lobeline. This may propose that 
another target may be involved in the mechanisms of actions of these drugs, 
such as VMAT2. Lobeline binds to and inhibits (IC50 value ≈ 1 µM) the function of 
the VMAT2, which is the only transporter protein that transports DA from the 
cytoplasm into the vesicle (Eyerman & Yamamoto, 2005; Teng et al., 1998; 
Wilhelm et al., 2004; Zheng et al., 2006). Therefore, additional experiments need 
to be conducted to determine the effects of in vivo administration of lobeline, 
methylphenidate, and amphetamine on VMAT2 function. Ultimately, studies of 
this nature may aid in the discovery of new treatment options for ADHD that 
improve behavioral symptoms while reducing detrimental drug side-effects by 
providing more information as to how certain compounds interact with the targets 
in question. 
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TABLE 1. Acute saline-treated control groups did not differ between MPD 
doses for DAT experiments.  Acute independent saline-treated controls did not 
vary between MPD doses during DAT experiments based on results of a one-
way ANOVA (F3,21 = 1.110, p>0.05), with the Vmax as the dependent variable. 
This demonstrates that the saline-treated control groups did not differ over time 
or between treatment groups. aData are presented as mean ± S.E.M for n = 4-8 
rats/group. 
 
ACUTE 
MPD (mg/kg) 
 
 
Vmax 
pmol/min/mg 
 
MPD 2.5 (n= 7) 17 ± 1.5 
MPD 5 (n= 8) 13 ± 2.1 
MPD 20 (n= 6) 17 ± 3.9 
MPD 40 (n= 4) 11 ± 2.5 
POOLED MEAN 15 ± 1.3a 
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TABLE 2. Acute saline-treated control groups did not differ between AMPH 
doses for DAT experiments.  Acute independent saline-treated controls did not 
vary between AMPH doses during DAT experiments based on results of a one-
way ANOVA (F3,12 = 3.010, p>0.05), with the Vmax as the dependent variable. 
This demonstrates that the saline-treated control groups did not differ over time 
or between treatment groups. aData are presented as mean ± S.E.M for n = 4-5 
rats/group. 
 
 
 
ACUTE 
AMPH (mg/kg) 
 
 
Vmax 
pmol/min/mg 
 
AMPH 0.1 (n= 5) 19 ± 1.0 
AMPH 0.25 (n= 5) 27 ± 5.0 
AMPH 1.0 (n= 5) 15 ± 1.1 
AMPH 5.0 (n= 4) 15 ± 0.7 
POOLED MEAN 19 ± 1.7a 
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TABLE 3. Acute saline-treated control groups did not differ between LOB 
doses for DAT experiments.  Acute independent saline-treated controls did not 
vary between LOB doses during DAT experiments based on results of a one-way 
ANOVA (F2,16 = 2.221, p>0.05), with the Vmax as the dependent variable. This 
demonstrates that the saline-treated control groups did not differ over time or 
between treatment groups. aData are presented as mean ± S.E.M for n = 3-8 
rats/group. 
 
 
ACUTE 
LOB (mg/kg) 
 
 
Vmax 
pmol/min/mg 
 
LOB 1 (n= 8) 16 ± 2.3 
LOB 3 (n= 3) 21 ± 2.3 
LOB 10 (n= 8) 13 ± 1.8 
POOLED MEAN 16 ± 1.9a 
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TABLE 4. Repeated 7-day saline-treated control groups did not differ 
between drug treatments for DAT experiments.  Repeated 7-day independent 
saline-treated controls did not vary between drug treatments during DAT 
experiments based on results of a one-way ANOVA (F3,17 = 0.5413, p>0.05), with 
the Vmax as the dependent variable. This demonstrates that the saline-treated 
control groups did not differ over time or between treatment groups. aData are 
presented as mean ± S.E.M for n =4-6 rats/group. 
 
 
 
 7-Day  
Drug Treatment 
 
 
Vmax 
pmol/min/mg 
 
MPD (n=4-6) 18 ± 1.9 
AMPH (n=6) 20 ± 2.3 
LOB (n=5) 18 ± 1.8 
POOLED MEAN 18 ± 1.8a 
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TABLE 5. Repeated 14-day saline-treated control groups did not differ 
between drug treatments for DAT experiments. Repeated 14-day 
independent saline-treated controls did not vary between drug treatments during 
DAT experiments based on results of a one-way ANOVA (F2,10 = 3.021, p>0.05), 
with the Vmax as the dependent variable. This demonstrates that the saline-
treated control groups did not differ between treatment groups. aData are 
presented as mean ± S.E.M for n = 5-6 rats/group. 
 
14-Day  
MPD (mg/kg) 
 
 
Vmax 
pmol/min/mg 
 
MPD (n=6) 22 ± 3.3 
AMPH (n=6) 19± 3.0 
LOB (n=5) 12 ± 0.7 
POOLED MEAN 23 ± 3.3a 
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Figure 4. A. Acute MPD increased DAT function in striatal synaptosomes. 
Rats were injected acutely once daily with MPD (0 (n = 24), 2.5 (n = 7), 5.0 (n = 
7), 20 (n = 8), and 40 (n = 6) mg/kg, s.c.; open bars). Synaptosomes were 
prepared 60 min post-injection. Control (0; black bar) represents saline-treated 
control group. Acute MPD (5 and 20 mg/kg) increased striatal [3H]DA uptake 60 
min after administration (*p<0.05 for the 5 mg/kg group and **p<0.01 for the 20 
mg/kg group compared to control).Vmax is represented in pmol/min/mg. Data are 
presented as mean ±S.E.M for n = 6-25 rats/group. Data were pooled for control 
groups, Figure 4. B. Comparison of saturation analysis of control and acute 
MPD (5 and 20 mg/kg). Specific uptake for MPD (0, 5 and 20 mg/kg) increased 
by ~60% compared to control. 
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Figure 5. A. Repeated 7-day MPD increased DAT function. Rats were injected 
repeatedly once daily for 7 days MPD (0 (n = 10), 2.5 (n = 4), 5.0 (n = 5), and 20 
(n = 5) mg/kg, s.c.; open bars). Synaptosomes were prepared 60 min post-
injection. Control (0; black bar) represents saline-treated control group. Repeated 
MPD (2.5 and 20 mg/kg for 7 days) increased [3H]DA uptake (*p<0.05 for 5 and 
20.0 mg/kg group compared to control).Vmax is represented in pmol/min/mg. 
Data are presented as mean ±S.E.M for n = 4-10 rats/group. Data were pooled 
for control group, Figure 5. B.  Comparison of saturation analysis of control 
and acute MPD (2.5 and 20 mg/kg). Specific uptake for MPD (0, 2.5 and 20 
mg/kg) increased by 36% and 48%, respectively, compared to control.   
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Figure 6. Repeated 14-day MPD did not alter DAT function. Rats were 
injected repeatedly once daily for 14 days MPD (0 (n = 9), 2.5 (n = 3), 5.0 (n =3), 
and 20 (n = 5) mg/kg, s.c.; open bars). Synaptosomes were prepared 60 min 
post-injection. Control (0; black bar) represents saline-treated control group. 
Repeated MPD (2.5, 5.0, or 20 mg/kg for 14 days) did not alter [3H]DA uptake. 
Vmax is represented in pmol/min/mg. Data are presented as mean ±S.E.M for n 
= 3-9 rats/group. Data were pooled for control group, Table 5. 
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Figure 7. Acute AMPH did not alter DAT function. Rats were injected acutely 
once daily with AMPH (0 (n = 19), 0.1 (n = 4), 0.25 (n = 5), 1.0 (n = 5), 5.0 (n = 5) 
mg/kg, s.c.; open bars). Synaptosomes were prepared 30 min post-injection. 
Control (0; black bar) represents saline-treated control group. Acute AMPH had 
no effect on striatal [3H]DA uptake 30 min after administration. Vmax is 
represented in pmol/min/mg. Data are presented as mean ±S.E.M for n = 5-19 
rats/group. Data were pooled for control group, Table 2. 
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Figure 8. Repeated 7-day AMPH did not alter DAT function. Rats were 
injected repeatedly once daily for 7 days AMPH (0 (n = 6), 0.25 (n = 5) and 5.0 (n 
= 5) mg/kg, s.c.; open bars). Control (0; black bar) represents saline-treated 
control group. Repeated AMPH (7 days) did not alter striatal [3H]DA uptake. 
Vmax is represented in pmol/min/mg. Data are presented as mean ±S.E.M for n 
= 5-6 rats/group. Data were pooled for control group, Table 4). 
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Figure 9. Repeated 14-day AMPH did not alter DAT function. Rats were 
injected repeatedly once daily for 14 days AMPH (0 (n = 6), 0.25 (n = 6) and 5.0 
(n =4) mg/kg, s.c.; open bars). Control (0; black bar) represents saline-treated 
control group.  Repeated AMPH (14 days) did not alter striatal [3H]DA uptake. 
Vmax is represented in pmol/min/mg. Data are presented as mean ± S.E.M for n 
= 4-6 rats/group. Data were pooled for control group, Table 5. 
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Figure 10. Acute LOB did not alter DAT function. Rats were injected acutely 
once daily with LOB (0 (n = 19), 1.0 (n = 7), 3.0 (n = 3), and 10.0 (n = 6) mg/kg, 
s.c.; open bars). Synaptosomes were prepared 20 min post-injection. Control (0; 
black bar) represents saline-treated control group. Acute LOB did not alter 
[3H]DA uptake 20 min after injection. Vmax is represented in pmol/min/mg. Data 
are presented as mean ± S.E.M for n=3-19 rats/group. Data were pooled for 
control group, Table 3.  
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Figure 11. Repeated 7-day LOB did not alter DAT function. Rats were 
injected repeatedly once daily for 7 days with LOB (0 (n = 5), 3.0 (n = 5) mg/kg, 
s.c.; open bars) Synaptosomes were prepared 20 min post-injection. Control (0; 
black bar) represents saline-treated control group. Repeated LOB for 7 days did 
not alter [3H]DA uptake 20 min after injection. Vmax is represented in 
pmol/min/mg.  Data are presented as mean ± S.E.M for n = 5 rats/group. Data 
were pooled for control group, Table 4. 
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Figure 12. Repeated 14-day LOB did not alter DAT function. Rats were 
injected repeatedly once daily for 14 days with LOB (0 (n = 5), 3.0 (n = 5) mg/kg, 
s.c.; open bars). Synaptosomes were prepared 20 min post-injection. Control (0; 
black bar) represents saline-treated control group.  Repeated LOB for 14 days 
did not alter [3H]DA uptake. Vmax is represented in pmol/min/mg. Data are 
presented as mean ± S.E.M for n = 5 rats/group. Data were pooled for control 
group, Table 5. 
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Table 6. Km values for [3H]DA uptake at DAT were not altered by 
acute, 7-day, or 14-day MPD treatment regimens. 
 
 
 
 
 
 
 
aData are presented as mean ± S.E.M for n= 4-25 rats/treatment group. ANOVA 
(F4,47 = 2.67, p>0.05) revealed that Km values were not different among 
independent control groups across the given treatments, and thus, these data for 
the saline-treated groups for each treatment group were pooled for statistical 
analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACUTE 7-DAY  14-DAY  
MPD 
(mg/kg) 
Km 
(Mick et 
al) 
MPD 
(mg/kg) 
Km 
(Mick et 
al) 
MPD 
(mg/kg) 
Km  
(Mick et 
al) 
0 16±3.7 0 21±1.8 0 14±1.0a 
2.5 14±2.1 2.5 24±1.1 2.5 11±2.4 
5 25±3.5 5 12±2.4 5 14±5.4 
20 22±2.9 20 27±1.2 20 11±2.1 
40 22±4.8       
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Table 7. Km values for [3H]DA uptake at DAT were not altered by 
the acute, 7-day, or 14-day AMPH treatment regimens. 
 
 
ACUTE 
AMPH  
7-DAY 
AMPH  
14-DAY 
AMPH  
(mg/kg) 
Km 
(Mick et 
al) (mg/kg) 
Km 
(Mick et 
al) (mg/kg) 
Km  
(Mick et 
al) 
0 18±2.9 0 16±1.4 0 13±1.9a 
0.1 16±3.7 0.25 10±1.7 0.25 12±2.3 
0.25 10± 0.9 5 14±1.9 5 10±2.3 
1 9.0±1.2       
5 16±2.2       
 
 
aData are presented as mean ± S.E.M for n= 4-19 rats/treatment group. ANOVA 
(F4,32 = 1.67,p>0.05 revealed that Km values were not different among 
independent control groups across the given treatments, and thus, these data for 
the saline-treated groups for each treatment group were pooled for statistical 
analysis. 
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Table 8. Km values for [3H]DA uptake at DAT were not altered by 
the acute, 7-day, or 14-day LOB treatment regimens. 
 
 
ACUTE 
Lobeline  
7-DAY 
Lobeline 
14-DAY 
Lobeline  
(mg/kg) 
Km 
(Mick et 
al)  (mg/kg)
Km 
(Mick et 
al) (mg/kg) 
Km (Mick 
et al) 
0 19±2.5 0 19±1.9 0 20±3.4a 
1 16±4.6 3 20±1.5 3 22±4.7 
3 24±2.8       
10 12±3.7         
 
 
aData are presented as mean ± S.E.M for n= 3-19 rats/treatment group. ANOVA 
(F3,32 = 1.80, p>0.05) revealed that Km values were not different among 
independent control groups across the given treatments, and thus, these data for 
the saline-treated groups for each treatment group were pooled for statistical 
analysis. 
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III. Chapter Three 
Effect of Acute and Repeated In Vivo Administration of Methylphenidate on 
Dopamine Transporter Trafficking 
 
A. Introduction 
DAT plays a vital role in regulating the dopaminergic signaling in the 
synaptic cleft and in maintaining a releasable storage of DA (Eriksen et al., 2010; 
O'Malley et al., 2010). Numerous studies have shown that various factors such 
as kinase activators, phosphatase inhibitors, and transported substrates are 
involved in regulating DAT trafficking between the plasma membrane and 
endosomal compartments (Eriksen et al., 2010; Kahlig & Galli, 2003; Loder & 
Melikian, 2003; Merickel & Edwards, 1995; O'Malley et al., 2010; Torres et al., 
2003).  DAT is the primary target for certain psychostimulants which are 
commonly abused (Thomsen et al., 2009). Second messenger systems and 
psychostimulants can alter function, phosphorylation, and trafficking of DAT.  For 
example, protein kinase C beta, which is a kinase important for DAT trafficking, 
was found to co-localize with DAT in mesencephalic neurons (O'Malley et al., 
2010).  Methylphenidate which is a psychostimulant as well, was the only drug to 
alter DAT function after acute and repeated in vivo administration in the present 
studies. Based on these results, we investigated if the effect of methylphenidate 
involved DAT trafficking.   
B.  Methods 
Materials   
Methylphenidate hydrochloride was obtained from Sigma Chemical Co. 
(St. Louis, MO). All other chemicals used in the in vitro assay buffers were 
purchased from Fisher Scientific (Pittsburgh, PA).   
Subjects 
Adult male Sprague-Dawley rats (200-220g body weight upon arrival) 
were obtained from Harlan Inc. (Indianapolis, IN). Adult male rats were used 
because as stated earlier, ADHD is found in adult humans as well as adolescents 
(Swanson et al., 1998b). Animals were housed two per cage with free access to 
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food and water in the Division of Lab Animal Resources, University of Kentucky. 
Experimental protocols were in concordance with the NIH 1996 Guide for the 
Care and Use of Laboratory Animals and were approved by the Institutional 
Animal Care and Use Committee at the University of Kentucky.   
Drug Administration 
Methylphenidate (20 mg/kg) was administered by subcutaneous (sc) 
injection in a volume of 1 ml/kg body weight and expressed as the salt weights. 
Groups of rats were injected acutely with either saline (control) or 
methylphenidate (20 mg/kg). The striatum was obtained 60 min for the 
methylphenidate group.  Separate groups of rats were injected repeatedly 7 days 
once daily with saline or methylphenidate (20 mg/kg).  
Biotinylation and Western Blot Assay (DAT Cellular Localization) 
 Cell surface biotinylation experiments were performed as described 
previously (Zhu et al., 2005). Synaptosomes from striatum (500 µg 
protein/sample) were incubated for 1 h at 4°C with sulfo-NHS-biotin, a 
biotinylation reagent, and continual shaking in 500 µl of 1.5 mg/ml sulfo-NHS-
biotin in PBS/Ca/Mg buffer (138 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 9.6 mM 
Na2HPO4, 1 mM MgCl2, 0.1 mM CaCl2, pH 7.3). After incubation, samples were 
centrifuged at 8,000 g for 4 min at 4°C. To remove the free biotinylation reagent, 
the resulting pellet was resuspended 3 times with 1 ml of ice-cold 100 mM 
glycine in PBS/Ca/Mg buffer, and centrifuged at 8,000 g for 4 min at 4°C. 
Resuspension and centrifugation steps were repeated using the same 
parameters. Final pellets were resuspended in 1 ml of ice-cold 100 mM glycine in 
PBS/Ca/Mg buffer and incubated with continual shaking for 30 min at 4°C. 
Subsequently, samples were centrifuged at 8,000 g for 4 min at 4°C, and the 
resulting pellets were resuspended in 1 ml ice-cold PBS/Ca/Mg buffer and 
centrifuged again. Resuspension and centrifugation steps were repeated twice 
more using the latter parameters.  Final pellet was lysed by sonication for 2-4 s in 
300 µl Triton X-100 buffer (10 mM Tris, 150 mM NaCl, 1 mM EDTA, 1.0% Triton 
X-100, 1 µg/ml aprotinin (protease inhibitor), 1 µg/ml leupeptin (protease 
inhibitor), 1 µM pepstatin (protease inhibitor), 250 µM phenylmethysulfonyl 
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fluoride (serine protease inhibitor), pH 7.4) followed by incubation and continual 
shaking for 20 min at 4°C.  Lysates (300 µl) were centrifuged at 21,000 g for 20 
min at 4°C.  Pellets were discarded, and 100 µl of the supernatants were stored 
at -20°C for determination of total immunoreactive DAT. Remaining supernatant 
was incubated with continuous shaking in the presence of monomeric avidin 
beads (Pierce Biotechnology, Inc, Rockford, IL) in Triton-X100 buffer (100 
µl/tube) for 1 h at room temperature. Subsequently, samples were centrifuged at 
17,000 g for 4 min at 4°C, and supernatants (containing non-biotinylated, 
intracellular protein) were stored at -20°C. Resulting pellets containing the avidin-
absorbed biotinylated proteins (cell-surface) were resuspended in 1 ml of 1.0% 
Triton X-100 buffer and centrifuged at 17,000 g for 4 min at 4°C, and the pellet 
was resuspended and centrifuged twice. Final pellets consisted of the 
biotinylated proteins adsorbed to monomeric avidin beads. The biotinylated 
proteins were eluted by incubating with 50 µl Laemmli buffer (62.5 mM Tris-HCl, 
20% glycerol, 2% sodium dodecyl sulfate (SDS), 0.05% β-mercaptoethanol and 
0.05% bromophenol blue (Bio-Rad Hercules, CA), pH 6.8) for 20 min at room 
temperature. The samples were stored at -20°C.  
To obtain the immunoreactive DAT protein in the three separate fractions:  
total, intracellular and cell surface, samples were thawed and subjected to gel 
electrophoresis and Western blotting.  Briefly, proteins were separated by 10% 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) for 90 min at 150 V, and 
subsequently, transferred to Immobilon-P transfer membranes (Cat # 
IPVH00010, 0.45 µm pore size; Millipore Co., Bedford, MA) in transfer buffer (50 
mM Tris, 250 mM glycine, 3.5 mM SDS) using a Mini Trans-Blot Electrophoretic 
Transfer Cell (Bio-Rad Laboratories Ltd., Hercules, CA) for 110 min at 72 V.  The 
transfer membranes were incubated with blocking buffer (5% dry milk powder in 
PBS containing 0.5% Tween 20) for 1 h at room temperature, followed by 
incubation with goat polyclonal DAT antibody (sc-1433; 1:1000 dilution in 
blocking buffer) overnight at 4 ºC. All specific antibodies were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA). Transfer membranes were washed 
5 times with washing buffer (PBS containing 0.5% Tween 20) at room 
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temperature, and then incubated with rabbit anti-goat DAT antibody (sc-7210; 
1:4000 dilution in blocking buffer) for 1 h at 22°C. Bands were detected using 
enhanced chemiluminescence and developed on Hyperfilm (ECL-plus; 
Amersham Biosciences UK Ltd., Little Chalfont Buckinghamshire, UK). After 
detection and quantification of DAT protein, each membrane was stripped in 10% 
of Re-blot plus mild antibody stripping solution (Chemicon, Temecula, CA) for 20 
min at room temperature and reprobed for detection of PP2A (FL-309) and β-
actin. PP2A and β-actin were used as control proteins for monitoring biotinylation 
and protein loading between methylphenidate- and saline-treated samples. 
C. Data Analysis 
Multiple autoradiographs were obtained using different exposure times, 
and immunoreactive bands within the linear range of detection were quantified by 
densitometric scanning using Kodak Image Station software (Carestream Health, 
New Haven, CT). Band density measurements, expressed as relative optical 
density, were used to calculate levels of DAT in total, non-biotinylated and 
biotinylated fractions. The net density measurements were calculated by 
substracting the background from the raw density value. Specifically, total DAT 
levels in the biotinylated and non-biotinylated fractions were calculated based on 
the density of DAT-immunoreactive bands in an aliquot of synaptosomal extract 
multiplied by total volume of extract and divided by the total volume of 
synaptosomal extract subjected to SDS-PAGE. To determine the 
methylphenidate (20 mg/kg) response on DAT cell surface expression, separate 
student t-tests were conducted on DAT immunoreactivity from each of the cell 
fractions (total, non-biotinylated and biotinylated) between methylphenidate-
treated and saline control groups. Differences were considered significant at p< 
0.05.  
D.  Results 
Effects of Acute and Repeated In Vivo Methylphenidate Administration on 
DA Transporter Trafficking  
The biotinylation and western blot assay revealed that methylphenidate 
(20 mg/kg)given acutely, decreased intracellular DAT expression with no change 
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in total or surface DAT expression (Fig. 13B), although not significantly. 
However, in vivo administration of methylphenidate (20 mg/kg) after 7 days 
significantly decreased intracellular DAT expression, leaving only 20% of 
intracellular DAT (19.8 ± 3.3%) compared  to control without changing the total or 
surface DAT expression (Fig. 14B). PP2A, an intracellular protein, was the 
control for monitoring biotinylation during experiments. One would expect to find 
more PP2A in the intracellular section, which is the non-biotinylated section, than 
in the biotinylated section since the biotinylated section is the section on the 
surface of the membrane. If more PP2A was found in the biotinylated section, 
this would suggest that cell leakage has occurred, thus implying that the 
biotinylation inefficient. However, these present results show that there is more 
PP2A in the non-biotinylated section, therefore indicating that there was very little 
cell leakage during the biotinylation experiment. β-actin was the control for 
protein loading for the samples used in the biotinylation experiments. The level of 
β-actin should remain consistent through all the samples to ensure that the same 
amount of protein was added to each sample. Our results showed that the levels 
of β-actin were constant throughout the samples, thus confirming that the level of 
protein used in the biotinylation experiments did not vary between samples. 
E. Discussion 
The results from this experiment suggest that the methylphenidate induced-
increase in DAT function was not independent of trafficking, since a significant 
decrease in intracellular DAT was observed. However, this phenomenon where 
methylphenidate did not alter total DAT expression has been observed previously 
with other compounds. For example, one report found that nicotine increased 
Vmax for [3H]DA uptake, however no increase in cell surface DAT expression was 
seen (Middleton et al., 2007). Furthermore, another study reported that insulin 
increased NET function without a change in transport cellular localization 
(Apparsundaram et al., 2001). Methylphenidate may have caused the 
phosphorylation of DAT, thus making DAT unrecognizable to the DAT antibodies 
used in the western blot analysis. Ubiquitination, another enzymatic process that 
involves the ε-amino moiety of lysine residues in target cellular proteins, has the 
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ability to affect DAT cell surface expression and membrane trafficking of 
transporters (Schmitt and Reith, 2010).  
Another possible explanation could be the involvement of PKA and PKC. 
Activation or inhibition of PKC, PI3K, and members of the MAPK family can 
cause transport membrane redistribution, although specific kinases responsible 
for direct phosphorylation are still unknown. One report found that 
methylphenidate had no effect on PKC activator-induced down-regulation of DAT 
function (Gorentla & Vaughan, 2005), however results from a previous study 
showed that methylphenidate decreased PKA levels when given repeatedly for 
five days (Crawford et al., 1998). These results demonstrate that the mechanism 
behind the regulation of DAT by methylphenidate is still under debate and further 
investigation is needed to gain a clearer picture of how methylphenidate 
regulates DAT. In addition, Wagner et al observed a significant increase in Vmax 
in rats with a controlled cortical impact (CCI) that received a daily injection of 
methylphenidate (5 mg/kg) for 14 days, but there was no change in total tissue or 
membrane bound DAT expression compared to the CCI rats that received saline 
(Wagner et al., 2009). These findings demonstrate that methylphenidate has the 
ability to increase the Vmax without altering total of surface DAT expression, which 
is consistent with the results of this current study.     
To our knowledge, no work has been conducted on how methylphenidate 
alters DAT expression. However, Fleckenstein’s group examined the effect of 
methylphenidate on VMAT2 immunoreactivity (Sandoval et al., 2003). They 
found that a single injection of methylphenidate (40 mg/kg, sc) redistributes 
VMAT2 immunoreactivity. Specifically, methylphenidate increased VMAT2 
expression in the vesicular subcellular fraction, but a decrease was found in the 
plasmelemmal membrane fraction, with no change in the whole synaptosomal 
fraction, which included the vesicular subcellular fraction and the plasmelemmal 
membrane fraction. Our current findings demonstrating that methylphenidate did 
not alter total surface DAT coincides with this report where methylphenidate had 
no effect on the whole synaptosomal fraction, but altered the vesicular 
subcellular fraction and the plasmalemmal membrane fraction. Even though this 
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study was done with VMAT2, it provides support that methylphenidate can 
redistribute transporter expression. In summary, there is evidence that 
collectively suggests that multiple pathways exist to regulate neurotransmitter 
transport function (Jayanthi et al., 2005) and our results indicate that 
methylphenidate may regulate transporter function by altering transporter 
expression. 
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Figure 13. Acute MPD did not alter intracellular DAT expression. Rats were 
injected acutely with MPD (20 mg/kg; open bar) and fractions of striatal 
synaptosomes were obtained 60 min after MPD (Clarke & Kumar, 1983).  Control 
(Sal; black bar) represents saline-treated control group. A) Representative 
immunoblots of total synaptosomal fraction (Total), intracellular fraction (non-
biotinylated, Non-biot), and cell surface fraction (biotinylated, Biot) for DA, β-actin 
and PP2A. β –actin was used as a control for protein loading and PP2A was 
used to assess efficiency of biotinylation.  B) DAT immunoreactivity is presented 
as percentage of the saline-treated control. DAT immunoactivity for saline 
controls for total, non-biot, and biot were 3.5 ± 1.04, 6.3 ± 2.79, and 73.0 ± 61.53, 
respectively. Data expressed as mean ±S.E.M of densitometry values of DAT 
immunoreactivity plotted as arbitrary units for n = 5 rats/group. Acute MPD 20 
mg/kg did not alter DAT expression.  
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Figure 14. Repeated 7-day MPD decreased intracellular DAT expression. 
Rats were injected once daily with MPD (20 mg/kg; open bar) for 7 days and 
fractions of striatal synaptosomes were obtained 60 min after MPD (20 mg/kg) 
injection (s.c.). Control (Sal; black bar) represents saline-treated control group. 
A) Representative immunoblots of total synaptosomal fraction (Total), 
intracellular fraction (non-biotinylated, Non-biot), and cell surface fraction 
(biotinylated, Biot) for DAT and β-actin. β –actin was used as a control for protein 
loading and PP2A was used to assess efficiency of biotinylation. B) DAT 
immunoreactivity is presented as percentage of the saline-treated control. DAT 
immunoactivity for saline controls for total, non-biot, and biot were 3.2 ± 0.91, 
16.0 ± 1.79, and 24.2 ± 5.87, respectively. Data expressed as mean ±S.E.M of 
densitometry values of DAT immunoreactivity plotted as arbitrary units for n = 5 
rats/group.  Repeated MPD 20 mg/kg for 7 days decreased intracellular fraction 
(non-biotinylated). * indicates difference from saline-treated control group, 
p<0.001. 
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IV. Chapter Four 
 
Effect of Acute and Repeated In Vivo Administration of Lobeline, 
Methylphenidate, and Amphetamine on Vesicular Monoamine Transporter 
Function 
 
A. Introduction 
Even though the etiology of ADHD is unknown, DAT has become the major 
target of interest for pharmacotherapies to treat ADHD (Easton et al., 2007). The 
striatum, which contains high dopamine concentrations, is suggested to be 
involved in executive function and motor response associated with ADHD (Dinn 
et al, 2001; Volkow et al., 2001; Wilens et al., 2008). Stimulants used to treat 
ADHD (i.e., methylphenidate and amphetamine) interact with DAT (Volkow et al., 
2002).  But they also interact with VMAT2, which is also an important transporter 
protein that is responsible for transporting cytoplasmic DA into vesicles for 
storage and release into the synaptic cleft (Schuldiner, 1994). VMAT2 plays a 
vital role in protecting the cells against damage from toxins, such as hydrogen 
peroxide, by maintaining the low cytoplasmic concentrations of neurotransmitters 
via initiating their reuptake into storage vesicles (Liu & Edwards, 1997). Recent 
studies have shown that VMAT2 function is altered by psychostimulants (Brown 
et al., 2001a; Fleckenstein & Hanson, 2003). 
Methylphenidate inhibits the reuptake of dopamine (DA) into the synaptic 
terminal, thus increasing the amount of DA in the synaptic cleft (Greydanus et al., 
2007).  Recent studies have found that methylphenidate alters VMAT2 transport 
and rapidly and reversibly increases VMAT2 binding and vesicular uptake of 
dopamine (Sandoval et al., 2003; Sandoval et al., 2001). Amphetamine elicits its 
pharmacological effect in three ways: 1) by binding to and reversing the transport 
of neurotransmitters such as dopamine, norepinephrine, and serotonin, 2) by 
facilitating release of neurotransmitters of these same neurotransmitters, and 3) 
by inhibiting MAO (Jones et al., 1998b; Seiden et al., 1993). One study found that 
10 µM amphetamine induced a 15-fold increase in cystosolic dopamine with 10-
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15 min of application, strongly suggesting redistribution of vesicular 
catecholamine (Mosharov et al., 2003). An experiment by Gonzalez and others, 
revealed that amphetamine displaced the VMAT2 ligand tetrabenazine with a 
relatively low (µM) affinity for VMAT2, which suggest amphetamine may be a 
substrate of VMAT2 as well (Gonzalez et al., 1994).  Another study suggests that 
the response to amphetamine is indirect and the apparent inhibition of VMAT2 
involves D2 autoreceptor activation following dopamine release (Brown et al., 
2002). Due to the potential for abuse (Bymaster et al., 2002; Cormier, 2008; 
Greydanus et al., 2007; Holman, 1994; Olfson, 2004) and other additional side 
effects including cardiovascular effects, abnormal growth, and suppressed 
appetite (Gibson et al., 2006) associated with these stimulants, there are 
concerns about the use of these agents.  There is an obvious need for additional 
treatment options that possess a less unfavorable side effect profile. 
However, lobeline, evaluated in behavioral studies, was not self-
administered by rats, nor did it substitute for d-methamphetamine, which suggest 
that it has no abuse liability, (Harrod et al., 2003).  Lobeline is the major 
alkaloidal component of the Indian tobacco plant, Lobelia inflata and is similar to 
nicotine in some ways. For example, both have a high affinity for the nicotinic 
receptor despite their structural differences (Dwoskin & Crooks, 2002). Lobeline 
does not stimulate locomotor activity (Miller et al., 2000) and acts as a nicotinic 
antagonist (Miller et al., 2001).  Lobeline, in addition to, methylphenidate and 
amphetamine also interacts with DAT. Lobeline also binds to and inhibits (IC50 
value ≈ 40-100 µM) DAT, inhibiting DA uptake (Miller et al., 2004; Teng et al., 
1997). In vitro studies, have found that lobeline inhibits [3H]DA uptake into 
vesicles with an IC50 value of 0.88 µM and inhibits the binding of 
[3H]dihydrotetrabenazine, a VMAT2 ligand, to the vesicular membrane with an 
IC50 value of 0.90 µM (Teng et al., 1998; Teng et al., 1997). 
The concern of the use of stimulant medications clearly indicates that 
more treatment options are necessary for ADHD. Based on in vitro experiments, 
lobeline may be an option (Teng et al., 1998; Teng et al., 1997). However, the 
effect of in vivo administration of lobeline on VMAT2 function needs to be 
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examined. In order to determine if the mechanism of lobeline on VMAT2 function 
is similar to methylphenidate and amphetamine, the effects of methylphenidate 
and amphetamine on VMAT2 function were also investigated. Previous research 
in our lab found that after in vivo administration of lobeline, methylphenidate, and 
amphetamine, only methylphenidate altered DAT function. This led us to believe 
that VMAT2 may possibly be the primary target involved in the mechanism of 
action of these agents. Therefore, the goal of the present study was to elucidate 
the effect of acute and repeated in vivo administration of lobeline on VMAT2 
function and compare its effect to the effects of methylphenidate and 
amphetamine. Such experiments are helpful in providing more insight into the 
mechanism of action of all these agents. 
 B.  Methods 
Materials.  
[3H]DA (3,4-ethyl-2[N-[3H]dihydroxyphenylethylamine; Specific Activity 28 
Ci/mmol) was purchased from PerkinElmer Life Sciences Inc. (Boston, MA). L-
Ascorbic acid, bovine serum albumin (BSA), catechol, α-D-glucose, N-(2-
hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) (HEPES), nomifensine 
maleate, pargyline hydrochloride, sucrose, methylphenidate hydrochloride, 
amphetamine hydrochloride, and 3-hydroxytyramine hydrochloride DA were 
obtained from Sigma Chemical Co. (St. Louis, MO). Lobeline was purchased 
from ICN Biomedicals (Costa Mesa, CA). All other chemicals used in the in vitro 
assay buffers were purchased from Fisher Scientific (Pittsburgh, PA).   
Subjects. 
 Adult male Sprague-Dawley rats (200-220g body weight upon arrival) 
were obtained from Harlan Inc. (Indianapolis, IN).  Animals were housed two per 
cage with free access to food and water in the Division of Lab Animal Resources, 
University of Kentucky. Experimental protocols were in concordance with the NIH 
1996 Guide for the Care and Use of Laboratory Animals and were approved by 
the Institutional Animal Care and Use Committee at the University of Kentucky.   
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Drug Administration. 
In the current study, rats were randomly assigned to 3 treatment groups 
(lobeline, methylphenidate, and amphetamine) for acute and repeated 
administration. Lobeline, methylphenidate, and amphetamine were administered 
by subcutaneous (sc) injection in a volume of 1 ml/kg body weight and expressed 
as the salt weights. The rats in the lobeline treatment group were injected acutely 
with lobeline (1, 3, and 10 mg/kg) and repeatedly for 7 days with lobeline (3 
mg/kg). The rats in the methylphenidate treatment group were injected acutely (n 
= 4-18) with methylphenidate (2.5, 10, and 20 mg/kg) and repeatedly for 7 days 
with methylphenidate (2.5 and 10 mg/kg). The rats in the amphetamine treatment 
group were injected acutely with amphetamine (0.25, 1.0, and 5.0 mg/kg) and 
repeatedly for 7 days with amphetamine (0.25 and 5 mg/kg). Control groups for 
the lobeline treatment group were administered saline contemporaneously for all 
doses and the methylphenidate and amphetamine treatment groups had 
independent saline groups for the individual doses.  
Lobeline dose range and time point after injection were chosen based on 
previous behavioral studies in which lobeline (1, 3, and 10 mg/kg) were used and  
lobeline (3 mg/kg) significantly inhibited methamphetamine self-administration 20 
min after injection (Harrod et al., 2001).  Methylphenidate dose range and time 
point were chosen based on experiments assessing [3H]DA uptake, 60 min after 
administration and behavioral studies which concluded that doses of 2.5 and 5.0 
of methylphenidate were more clinically relevant (Kuczenski & Segal, 2001; 
Wooters et al., 2006). Amphetamine doses range and time point were based on 
behavioral studies showing that the low doses of amphetamine (0.25-0.75 mg/kg) 
improved stimulus detection performance in rats 30 minutes after injection. 
(Grilly, 2000). The doses for the repeated experiments were chosen based on 
the effect observed during the acute experiments. If no effect was observed 
during the acute experiments, doses were chosen based on previous behavioral 
and in vitro studies. 
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Vesicle Preparation and [3H]DA Uptake Assay.   
The uptake of [3H]DA into striatal synaptic vesicles were determined by 
using a previously published method (Erickson et al., 1990). Striata from the rats 
were homogenized over a 2-min period in 14ml of 0.32 M sucrose (pH 7.5) with 
10 up and down strokes of a Teflon pestle (clearance ~0.009 inches). The 
homogenate was centrifuged at 2000 g for 10 min at 4°C, and the resulting 
supernatant will be centrifuged at 10,000 g for 30 min at 4°C. Synaptosomes 
(buffy coat) were separated from the underlying mitochondria and cellular debris 
(reddish pellet) by gentle swirling in 2 ml of 0.32 M sucrose. The enriched 
synaptosome fraction (2.0 ml) was subjected to osmotic shock by the addition of 
7 ml distilled H2O and homogenized with 5 up and down strokes of the Teflon 
pestle. The osmolarity was restored by the addition of 900 µl of 0.25 M HEPES 
and 900 µl of 1.0 M neutral potassium-tartrate buffer (pH 7.5) followed by a 20-
min centrifugation (20,000 g at 4°C). The supernatant was centrifuged for 60 min 
(55,000 g at 4°C). Then 1 ml of solution containing 10 mM MgSO4, 0.25 M 
HEPES and 1.0 M potassium-tartrate buffer was added to the supernatant and 
the suspension was centrifuged (100,000 g for 45 min at 4°C). Immediately 
before use, the final pellet was resuspended in the assay buffer (in mM: 25 
HEPES, 100 potassium tartrate, 0.05 EGTA, 0.10 EDTA, 2 ATP-Mg++ and 1.7 
ascorbic acid, pH 7.4). Aliquots (160 µl containing 8-10 µg protein) of the 
resuspension were incubated with 20 µl of drug (final concentrations: nicotine, 
0.001-100 µM; lobeline, 0.001-100 µM; tetrabenazine, 0.001-100 µM) and 20 µl 
of [3H]DA (final concentration 0.3 µM) for 8 min at 37°C in a total volume of 200 
µl. The reaction was terminated by the addition of 2.5 ml of ice-cold assay buffer 
containing 2 mM MgSO4. Samples were rapidly filtered through Whatman GF/F 
filters using the Brandel cell harvester (Model MP-43RS; Biochemical Research 
and Development Laboratories Inc., Gaithersburg, MD). The filters were washed 
three times with 4 ml of ice-cold assay buffer containing 2 mM MgSO4. Filters 
were previously soaked in 0.5% polyethylenimine (Speiser et al., 1983) solution 
for 2 hr at 4 °C. Nonspecific uptake was determined by incubation of duplicate 
samples in the presence of R0412-84 (10 µM), a VMAT2 inhibitor. Filters were 
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placed into scintillation vials, 10 ml scintillation cocktail were added, and 
radioactivity was determined by scintillation spectrometry (Model B1600TR, 
Perkin-Elmer Life Sciences, Downers Grove, IL).     
C. Data Analysis. 
Kinetic parameters (Vmax and Km) for [3H]DA uptake were determined using 
GraphPad Prism software (GraphPad Prism,  version 5.02; GraphPad Software, 
San Diego, CA). Data are represented as mean values ± S.E.M. To analyze the 
kinetic parameters, Vmax and Km for [3H]DA uptake in drug-treated for each drug 
at each dose and saline-control groups, separate unpaired Student t-tests were 
performed. Log transformed Km values were used for statistical analyses using 
the Statistical Packages for the Social Sciences (SPSS; standard version 17, 
SPSS Inc., Chicago, IL). Differences were considered significant at p< 0.05. An 
individual one-way ANOVA  with each dose of methylphenidate, amphetamine 
and lobeline serving as an independent group revealed that [3H]DA uptake was 
not different among the saline groups across the dose range for each drug 
(Tables 9-11). Therefore, the data for the saline-control groups were pooled for 
statistical analysis and graphical presentation, which also explains the wide 
range of n.Specific [3H]DA uptake for the saline-control groups for acute 
methylphenidate 2.5, 10, and 20 mg/kg doses were 19.1 ± 3.6, 23.0 ± 2.7, and 
28.0 ± 4.1 pmol/mg/min, respectively, with a pooled mean of 23.8 ± 2.0 
pmol/mg/min. Specific [3H]DA uptake for the saline-control groups for  acute 
amphetamine  0.25, 1.0, and 5.0 mg/kg doses were 35.3 ± 3.0, 43.1 ± 5.8, and 
31.0 ± 3.2 pmol/mg/min, respectively with a pooled mean of 36.0 ± 3.3 
pmol/mg/min. 
 D.  Results 
Effects of Acute and Repeated In Vivo Methylphenidate Administration on 
Vesicular Monoamine Transporter Function 
Kinetic analysis of [3H]DA uptake was performed on synaptosomes after 
acute in vivo administration of methylphenidate. Methylphenidate (10, and 20 
mg/kg) increased Vmax (53.4 ± 5.0 and 43.4 ± 4.7 pmol/mg/min) for [3H]DA uptake 
compared to pooled saline-control (23.8 ± 2.0 pmol/mg/min), respectively. The 
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current results show an increase (84-124%) of VMAT2 function, with acute 
methylphenidate (10 and 20 mg/kg) having a significantly higher Vmax compared 
to control (Fig. 15). Repeated methylphenidate in vivo administration for 7 days 
at 2.5 and 10 mg/kg doses had a Vmax of 33.0 ± 1.1 and 52.7 ± 4.0 pmol/mg/min, 
respectively, which increased (53% and 145%) VMAT2 function compared to 
pooled saline-control with a Vmax of 21.5 ± 1.4 pmol/mg/min (Fig.16).  Neither 
acute nor repeated methylphenidate in vivo administration had an effect on Km 
values (Table 15).   
Effects of Acute and Repeated In Vivo Amphetamine Administration on 
Vesicular Monoamine Transporter Function 
 Acute, as well as 7 day-repeated in vivo administration of amphetamine 
had no effect on VMAT2 function, (Figs. 17, 18). Specific [3H]DA uptake for 
amphetamine 0.25, 1.0, and 5.0 mg/kg doses were 35.3 ± 3.0, 43.1 ± 5.8, and 
31.0 ± 3.2 pmol/mg/min, respectively, compared to the pooled saline-control 
group with a Vmax of 36.0 ± 3.3 pmol/mg/min.  Amphetamine had no effect on Km 
values following acute in vivo administration (Table 15); however, repeated in 
vivo administration significantly decreased the Km after 7 days (Fig. 19;Table 15). 
Effects of Acute and Repeated In Vivo Lobeline Administration on Vesicular 
Monoamine Transporter Function 
 Kinetic analysis of vesicular [3H]DA uptake after acute (Fig. 20) and 
repeated (Fig. 20) in vivo administration of lobeline for 7 days showed no effect 
on Vmax or  Km values (Tables 11 and 15). Specific [3H]DA uptake at VMAT2 for 
acute lobeline 1.0, 3.0, and 10.0 mg/kg doses were 29.7 ± 4.5, 33.9 ± 6.9, and 
33.7 ± 7.4 pmol/mg/min, respectively, compared to 29.7 ± 5.0 pmol/mg/min for 
the pooled saline-control group.  
E. Discussion 
 In the present study, the effects of acute and repeated in vivo 
administration of lobeline on VMAT2 function were determined and compared to 
the effects of methylphenidate and amphetamine using kinetic analysis of [3H]DA 
uptake into striatal vesicles. This work investigating in vivo drug administration, 
extends previous work in our laboratory demonstrating that in vitro, lobeline 
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inhibits VMAT2 function (Teng et al., 1997). However, the results from these 
studies show that lobeline (1, 3, and 10 mg/kg) has no effect on VMAT2 function 
20 min after in vivo administration. Previous research using striatal vesicles has 
provided evidence that the ability of a compound to alter monoamine uptake in 
vitro does not necessarily predict its ability to modulate monoamine transporters 
after in vivo administration (Fleckenstein et al., 1999).  This may be the case with 
in vesicles as well. Thus, it is necessary to conduct in vivo experiments as well 
as in vitro experiments.   
Another plausible explanation for the lack of effect with lobeline could be 
that the time of the effect was not in the timeframe that was used in this study. 
The time point was based on behavioral effects observed after in vivo 
administration. The pharmacological effect may not coincide with the behavioral 
effect, thus no pharmacological effect was seen at the time point in question.   
Acute in vivo administration of methylphenidate showed an increase in 
VMAT2 function at 10 and 20 mg/kg, but showed no effect with the 2.5 mg/kg 
dose. These results suggest that there is a specific range of doses of 
methylphenidate that elicit an effect on VMAT2 function. If the dose is too high or 
too low, the effect could be lost. This result is consistent with previous results 
showing that a single high dose (40 mg/kg s.c.) of methylphenidate increased 
vesicular DA uptake accessed 60 minutes after in vivo administration 
(Fleckenstein et al., 1999; Sandoval et al., 2002).  After 7 days of repeated in 
vivo methylphenidate administration, the 2.5 and 20 mg/kg doses showed a 
significant increase in Vmax. No tolerance developed with repeated administration 
of methylphenidate after 7 days. Methylphenidate administration did not alter the 
Km, which suggests that methylphenidate competes with dopamine at VMAT2 in 
a noncompetitive manner. Very little is known about VMAT2 regulation and only 
the Fleckstein lab to our knowledge has conducted research on how 
methylphenidate interacts with VMAT2. However, the interest in VMAT2 as a 
target for drugs of abuse is growing based on a current review by Eden and 
Weihe (Eiden, 2011).  
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 Acute and repeated in vivo administration of amphetamine did not alter 
VMAT2 function in these studies. The time points chosen in this current study 
were based on behavioral observations of amphetamine and the time course of 
the neurochemical effects may not correspond with the behavioral effects of 
amphetamine on VMAT2 function. A complete time course would allow more 
insight as to what the optimal time point should be in order to observe the 
maximal pharmacological effect of amphetamine. However, Fon and colleagues 
found that VMAT2 was not required for amphetamine to cause DA release in an 
in vitro measure of amphetamine in VMAT2 knock-out mice with an absence of 
vesicular monoamine stores (Fon et al., 1997). This finding may be difficult to 
relate to methylphenidate, since methylphenidate does not release DA. Based on 
this evidence and what is already known about amphetamine, the current results 
of this study showing amphetamine did not alter VMAT2 function are intriguing to 
say the least.   
The current results suggest that methylphenidate acts differently than 
lobeline and amphetamine, in reference to the effects observed on VMAT2 
function. The observation that amphetamine and methylphenidate influence 
VMAT2 differently at the time point and doses used in this study may be rather 
surprising since both drugs have been shown to target VMAT2 (Greydanus et al., 
2007; Thanos et al., 2007). However, the data in these studies could be a result 
of the difference in their mechanisms of action.   
Overall, the results of the present study, have demonstrated that 
methylphenidate affects VMAT2 function differently than amphetamine and 
lobeline after in vivo administration. These changes in VMAT2 function are 
interesting considering that little is known as to how methylphenidate interacts 
with VMAT2. These findings suggest that methylphenidate increases VMAT2 
function, which decreases the amount of DA in the cytosol. These results also 
imply the VMAT2 is a target of methylphenidate and that VMAT2 could be 
involved in the etiology of ADHD.     
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 Although lobeline did not alter VMAT2 function in the present study, 
additional evidence suggests that lobeline could still be evaluated as a potential 
treatment option for ADHD. Lobeline has been found to improve retention 
performance 24 hours after injection in spatial discrimination water maze (Decker 
et al., 1993). Furthermore, Levin et al. showed lobeline enhanced learning on the 
post-acquisition working memory performance in the radial-arm maze (Levin et 
al., 2003). Previous work has also demonstrated that lobeline may be an 
effective smoking cessation agent by showing that lobeline acts as a nicotinic 
antagonist by inhibiting nicotine-evoked DA release and nicotine-evoked 86 Rb+ 
efflux (Miller et al., 2000). Lobeline has been used as an over-the-counter 
smoking cessation agent in the past in the US (Nunn-Thompson & Simon, 1989; 
Prignot, 1989) and numerous human studies have been conducted to determine 
efficacy of lobeline as a smoking cessation agent, although its use is still 
debatable (Dwoskin & Crooks, 2002). This characteristic gives lobeline an added 
benefit to the currently used ADHD treatments because it has been shown that 
there is a higher rate of smoking in people who have ADHD compared to those 
who do not (Milberger et al., 1997).  Furthermore, lobeline does not have typical 
stimulant side-effects such as abuse liability. 
In conclusion, there is evidence to warrant more investigation into the 
mechanism of action of these agents because it is still unclear as to how they 
elicit their pharmacological effects. Therefore, additional experiments need to be 
conducted to elucidate the pharmacological effects of lobeline, methylphenidate, 
and amphetamine. Ultimately, studies of this nature may help in the discovery of 
new treatment options for ADHD that improve behavioral symptoms while 
reducing detrimental drug side-effects. 
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TABLE 9. Acute saline-treated control groups did not differ between MPD 
doses for VMAT2 experiments. Acute independent saline-treated controls did 
not vary between MPD doses during VMAT2 experiments based on results of a 
one-way ANOVA (F2,15 = 1.428, p>0.05), with the Vmax as the dependent 
variable. This demonstrates that the saline-treated control groups did not differ 
over time or between treatment groups. aData are presented as mean ± S.E.M 
for n = 4-8 rats/group. 
 
 
 
ACUTE 
MPD (mg/kg) 
 
 
Vmax 
pmol/min/mg 
 
MPD 2.5 (n= 4) 19 ± 3.6 
MPD 10 (n= 8) 23 ± 2.7 
MPD 20 (n= 6) 28 ± 4.1 
POOLED MEAN 24 ± 1.8a 
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TABLE 10. Acute saline-treated control groups did not differ between 
AMPH doses for VMAT2 experiments. Acute independent saline-treated 
controls did not vary between AMPH doses during VMAT2 experiments based on 
results of a one-way ANOVA (F2,13 = 3.076, p>0.05), with the Vmax as the 
dependent variable. This demonstrates that the saline-treated control groups did 
not differ over time or between treatment groups. aData are presented as mean ± 
S.E.M for n = 5-6 rats/group. 
 
 
 
ACUTE 
AMPH (mg/kg) 
 
 
Vmax 
pmol/min/mg 
 
AMPH 0.25 (n= 5) 35 ± 3.0 
AMPH 1.0 (n= 5) 43 ± 5.8 
AMPH 5.0 (n= 6) 29 ± 3.3 
POOLED MEAN 36 ± 3.3a 
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TABLE 11. Acute saline-treated control groups did not differ between LOB 
doses for VMAT2 experiments. Acute independent saline-treated controls did 
not vary between LOB doses (1, 3, and 10 mg/kg) during VMAT2 experiments 
based on results of a one-way ANOVA (F3,27 = 0.1494, p>0.05), with the Vmax as 
the dependent variable. This demonstrates that the saline-treated control groups 
did not differ over time or between treatment groups. aData are presented as 
mean ± S.E.M for n = 7 rats/group. 
 
 
 
ACUTE 
LOB (mg/kg) 
 
 
Vmax 
pmol/min/mg 
 
POOLED MEAN 30 ± 5.0a 
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TABLE 12. Repeated 7-day saline-treated control groups did not differ 
between MPD doses for VMAT2 experiments. The 7-day independent saline-
treated controls were used for both MPD doses during VMAT2 experiments. 
Therefore, no ANOVA was performed. aData are presented as mean ± S.E.M for 
n = 8 rats/group. 
 
 
 
7-day 
MPD (mg/kg) 
 
 
Vmax 
pmol/min/mg 
 
POOLED MEAN 22 ± 1.4a 
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TABLE 13. Repeated 7-day saline-treated control groups did not differ 
between AMPH doses for VMAT2 experiments. The 7-day independent saline-
treated controls were used for both AMPH doses during VMAT2 experiments. 
Therefore, no ANOVA was performed. aData are presented as mean ± S.E.M for 
n = 5 rats/group. 
 
 
 
7-day 
AMPH (mg/kg) 
 
 
Vmax 
pmol/min/mg 
 
POOLED MEAN 30 ± 5.3a 
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TABLE 14. Repeated 7-day saline-treated control groups did not differ 
between LOB doses for VMAT2 experiments. The 7-day independent saline-
treated controls were used for both LOB doses during VMAT2 experiments. 
Therefore, no ANOVA was performed. aData are presented as mean ± S.E.M for 
n = 5 rats/group. 
 
 
7-day 
LOB (mg/kg) 
 
 
Vmax 
pmol/min/mg 
 
POOLED MEAN 24 ± 2.5a 
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Figure 15. Acute MPD increased VMAT2 function. Rats were injected acutely 
once daily with MPD (0, 2.5, 10.0, and 20 mg/kg; open bars). Control (0; black 
bar) represents saline-treated control group. An independent control group was 
administered saline contemporaneously with each MPD dose (open bars) for the 
acute treatment group. Vmax is represented in pmol/min/mg. Data are presented 
as mean ± S.E.M for n = 4 -18 rats/group (Data were pooled for control groups).  
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Figure 16. Repeated 7-day MPD increased VMAT2 function. Rats were 
injected repeatedly once daily with MPD (0; black bar; 2.5, and 10.0   mg/kg; 
open bars). Repeated MPD (2.5and 10 mg/kg for 7 days) increased [3H]DA 
uptake (***p<0.001 for 2.5 and 10.0 mg/kg group compared to control). Vmax is 
represented in pmol/min/mg. Data are presented as mean ± S.E.M for n = 6-8 
rats/group. 
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Figure 17. Acute AMPH did not alter VMAT2 function. Rats were injected 
acutely once daily with AMPH (0, 0.25, 1.0, and 5.0 mg/kg). Control (0; black bar) 
represents saline-treated control group. An independent control group was 
administered saline contemporaneously with each AMPH dose (open bars) for 
the acute treatment group. Vmax is represented in pmol/min/mg. Acute AMPH 
had no effect on striatal [3H]DA uptake 30 min after administration. Data are 
presented as mean ± S.E.M for n=4-12 rats/group (Data were pooled for control 
groups).  
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Figure 18. Repeated 7-day AMPH did not alter VMAT2 function. Rats were 
injected repeatedly once daily for 7 days AMPH (0, 0.25, and 5.0 mg/kg; open 
bar). Control (0; black bar) represents saline-treated control group. Vmax is 
represented in pmol/min/mg. Repeated AMPH (7 days) did not alter striatal 
[3H]DA uptake. Data are presented as mean ± S.E.M for n = 5 rats/group. 
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Figure 19. Repeated 7-day AMPH decreased Km for VMAT2. Rats were 
injected repeatedly once daily with AMPH (0, 0.25, and 5.0 mg/kg; open bars) for 
7 days.  Control (0; black bar) represents saline-treated control group. Repeated 
AMPH (5 mg/kg) decreased Km (0.12 ± 0.01) compared to control (0.24 ± 0.05). 
Data are presented as mean ± S.E.M of the log transform of Km for n = 5 
rats/group.  
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Figure 20. Acute LOB did not alter VMAT2 function. Rats were injected 
acutely once daily with LOB (0, 1.0, 3.0, and 10.0 mg/kg) Control (0; black bar) 
represents saline-treated control group. A control group was administered saline 
contemporaneously for all LOB doses (open bars) for the acute treatment group. 
Vmax is represented in pmol/min/mg. Acute LOB did not alter striatal [3H]DA 
uptake 20 min after injection. Data are presented as mean ± S.E.M for n = 7-8 
rats/group.).  
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Figure 21. Repeated LOB did not alter VMAT2 function. Rats were injected 
repeatedly once daily for 7 days LOB (0 and 3.0 mg/kg). Vesicles were prepared 
20 min post-injection. Control (0; black bar) represents saline-treated control 
group. A control group was administered saline contemporaneously for LOB 3 
mg/kg dose (open bar) for the7-day treatment group. Vmax is represented in 
pmol/min/mg. Repeated LOB for 7 days did not alter [3H]DA uptake. Data are 
presented as mean ± S.E.M for n=5-7 rats/group.).  
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Table 15. Km values for [3H]DA uptake at VMAT2 were only 
altered by  the AMPH (7-day treatment) regimen. 
 
 
ACUTE 7-DAY  
MPD 
(mg/kg) 
Km 
(Mick et 
al) 
MPD 
(mg/kg) 
Km ((Mick 
et al) 
0 11 ± 1.0 0 13 ± 1.0 
2.5 12 ± 3.0 2.5 10 ± 1.0 
10 12 ± 3.0 10 12 ± 1.0 
20 9.0 ± 0.4    
ACUTE 
AMPH  
7-DAY 
AMPH  
(mg/kg) 
Km 
(Mick et 
al) (mg/kg) 
Km (Mick et 
al) 
0 11 ± 3.0 0 24 ± 5.0 
0.25 9.0 ± 2.0 0.25 18 ± 4.0 
1 10 ± 1.0 5 12 ± 1.0 
5 10 ± 2.0    
ACUTE 
Lobeline  
7-DAY 
Lobeline 
(mg/kg) 
Km 
(Mick et 
al)  (mg/kg)
Km (Mick et 
al) 
0 20 ± 4.0 0 15 ± 3.0 
1 21 ± 4.0 3 11 ± 2.0 
3 13 ± 1.0    
10 13 ± 3.0     
 
aData are presented as mean ± S.E.M for n = 4-18 rats/treatment group. ANOVA 
(F(6,48) = 3.21, p> 0.05 revealed that Km values were not different among 
independent control groups across the given treatments, and thus, these data for 
the saline-treated groups for each treatment group were pooled for statistical 
analysis. 
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V. Chapter Five 
 
Discussion and Conclusions 
A. Summary 
 ADHD is a psychiatric disorder that has a worldwide impact. ADHD has 
become more of a focus in research due to the increasing number of children 
and adults being diagnosed with ADHD and there is still much to be learned 
about the safety issues of ADHD medications (Meijer et al., 2009). This increase 
in ADHD research, has also led to a need to develop novel agents without the 
harmful side effects associated with the current therapies used to treat ADHD. 
The first line therapy for ADHD consists of stimulants, namely methylphenidate 
and amphetamine. Amphetamine is a DAT substrate, which competes with DA 
for DAT and also reverses the transport of dopamine causing release of 
dopamine, where as methylphenidate binds to DAT and inhibits DAT function, 
without releasing DA (Bannon et al., 2000; Seiden et al., 1993; Solanto, 2002; 
Sonders et al., 1997).  These agents also interact with VMAT2, which is the 
transporter responsible for moving  cytoplasmic dopamine into the synaptic 
vesicles for storage and future release (Yelin & Schuldiner, 2002).  
Methylphenidate has been shown to rapidly and reversibly increase VMAT2 
binding and vesicular uptake of dopamine (Sandoval et al., 2001). Amphetamine 
has been found to  displace the VMAT2 ligand tetrabenazine with a relatively low 
(µM) affinity for VMAT2, which suggest amphetamine may be a substrate of 
VMAT2  (Gonzalez et al., 1994).  
Lobeline, a major alkaloidal component of the Indian tobacco plant, has 
been shown in previous in vitro studies performed in our laboratory, to interact 
with DAT and VMAT2.  For instance, lobeline binds to and inhibits (IC50 value ≈ 
40-100 µM) DAT, inhibiting DA uptake (Miller et al., 2004; Teng et al., 1997). 
Lobeline  also inhibits [3H]DA uptake into vesicles with an IC50 value of 0.88 µM 
and inhibits the binding of [3H]dihydrotetrabenazine, a VMAT2 ligand, to the 
vesicular membrane with an IC50 value of 0.90 µM (Teng et al., 1998; Teng et al., 
1997). However, lobeline may not have any abuse liability based on results from 
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behavioral studies, that showed lobeline was not self-administered by rats, nor 
did it substitute for d-methamphetamine (Harrod et al., 2003). 
The purpose of this dissertation research was to examine the effects of 
acute and repeated in vivo administration of a compound called lobeline on 
dopamine and vesicular monoamine transporter functions and compare those 
effects with the effects of methylphenidate and amphetamine to warrant further 
investigation of lobeline as a potential treatment option for ADHD. The 
experiments for this dissertation research were conducted in the striatum, a 
region of the brain rich in dopamine and is also suggested to be involved in 
executive function and motor response associated with ADHD (Dinn et al., 2001; 
Volkow et al., 2001; Wilens, 2008).  
The first aim of this dissertation research was to determine the effect of 
lobeline on DAT function after acute and repeated in vivo administration using 
[3H]DA uptake assay and compare its effects with the effects of methylphenidate 
and amphetamine. The novel findings from these experiments showed an 
increase of DAT function (~60%), with acute methylphenidate (5 and 20 mg/kg) 
having a significantly higher Vmax compared to control. Repeated 
methylphenidate administration for 7 days at 2.5 and 20 mg/kg doses also 
increased DAT function (36% and 48%) compared to pooled saline-control. 
Neither acute nor repeated methylphenidate in vivo administration had an effect 
on Km values. Acute, as well as repeated (7 or 14 days) in vivo administration of 
amphetamine and lobeline had no effect on DAT function. Amphetamine and 
lobeline had no effect on Km values following acute or repeated in vivo 
administration. The results of these experiments do not support the hypothesis 
that lobeline would decrease DAT function in vivo as observed in the in vitro 
experiments. To our knowledge, this is the first report of the effects of DAT and 
VMAT2 function after acute and repeated in vivo administration of 
methylphenidate, amphetamine, and lobeline.  
 The second aim was to determine the effect of lobeline on VMAT2 
function after acute and repeated in vivo administration and compared its effects 
to methylphenidate and amphetamine. Acute in vivo administration of 
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methylphenidate showed an increase in VMAT2 function at 10 and 20 mg/kg.  
After 7 days of repeated in vivo methylphenidate administration, the 2.5 and 20 
mg/kg doses showed a significant increase in Vmax. Methylphenidate 
administration did not alter the Km.  Acute and repeated in vivo administration of 
amphetamine did not alter VMAT2 function in these studies. Amphetamine had 
no effect on Km values following acute in vivo administration; however, repeated 
in vivo administration significantly decreased the Km after 7 days. Acute and 
repeated in vivo administration of lobeline did not alter VMAT2 function or Km in 
these studies.  In summary, all three compounds act differently at this site. The 
results of these experiments did not support the hypothesis that lobeline would 
decrease VMAT2 function as seen in the previous in vitro studies. 
The third aim was to determine if the underlying mechanism of the 
methylphenidate-induced increase of DAT function was due to DAT trafficking 
using biotinylation and western blot analysis. The biotinylation and western blot 
assay revealed that methylphenidate given acutely, slightly but not significantly 
decreased intracellular DAT expression with no change in total or surface DAT 
expression. However, in vivo administration of methylphenidate after 7 days 
significantly decreased intracellular DAT expression, where only ~ 20 %   of 
intracellular DAT was found compared to control, without a change  in the total or 
surface DAT expression. These results agree with the hypothesis that DAT 
trafficking was responsible for the methylphenidate-induced increase in DAT 
function, but in a different manner since there was no increase in surface DAT 
expression. Nevertheless, the significant decrease in intracellular DAT caused by 
methylphenidate administration for 7 days does suggest that methylphenidate 
redistributes DAT, which means that some type of trafficking is involved and that 
this effect is time-dependent. 
B. Potential Mechanism for the Methylphenidate-Induced Increase in 
DAT  Function 
  Methylphenidate is a potent DAT inhibitor, which results in an increase in 
extracellular dopamine (Easton et al., 2007; Ferris et al., 1972; Richelson & 
Pfenning, 1984). Other studies have investigated the effect methylphenidate has 
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on DAT density and occupancy (Muneoka et al., 2006; Spencer et al., 2006; 
Volkow et al., 1998; Volkow et al., 2007; Wilcox et al., 2008). The results from the 
current work revealed that methylphenidate increased DAT function rather than 
inhibited DAT function. Specifically, acute methylphenidate (5.0 and 20 mg/kg) 
increased DAT function by ~60% and repeated methylphenidate (2.5 and 20 
mg/kg) increased DAT function by 36% and 48% respectively. However, 
repeated in vivo administration of methylphenidate (2.5, 5.0, or 20 mg/kg) after 
14 days did not alter DAT function. These findings suggest that the effect of 
methylphenidate is lost between 7 and 14 days and is time-dependent. This 
observation may be due to the compensatory effect of the potent inhibition of 
methylphenidate on DAT function. As methylphenidate inhibits DAT function, the 
system may respond by upregulating the existing DAT in order to compensate for 
the lack of DAT function. Overtime the compensatory effect could become less, 
thus causing methylphenidate to have no effect on DAT function, which was 
observed in the 14-day experiments. 
  Another potential explanation could be the involvement dopamine 
transporter phosphorylation and protein-protein interactions. A study investigating 
the effect of methylphenidate on dopamine-and cAMP-regulated phosphoprotein, 
Mr 32kDa (DARPP-32) phosphorylation using neostriatal slices found that 
methylphenidate increased (DARPP-32) phosphorylation in adult (6-8-week old) 
slices but not young (14-15-and 21-22-day old) slices (Fukui, 2003).  The 
phosphorylation state of DARPP-32 is involved in the mechanism for integrating 
information coming from dopamine neurons, multiple brain regions, utilizing 
various neurotransmitters, neuromodulators, neuropides and steroid hormones 
(Svenningsson et al., 2004). This finding suggests that age is an important factor 
to consider when determining the effect of methylphenidate on phosphorylation.  
Vaughan’s group conducted a more recent study to determine if certain DAT 
blockers, including methylphenidate, had an effect on basal and phorbol 12 
myristate 13 acetate (PMA) (Li et al)-stimulated DAT phosphorylation (Gorentla & 
Vaughan, 2005). PMA is a PKC activator and PKC regulates DAT activity and 
phosphorylation. The authors exposed rDAT LLC-PK1 cells to methylphenidate 
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(10 µM) for 30 minutes and found that methylphenidate had no effect on basal or 
PMA-stimulated phosphorylation.  This evidence suggests that methylphenidate 
does not cause DAT phosphorylation, thus no decrease in DAT function with 
methylphenidate was observed. Taken together, these data imply that DAT 
function can be regulated by various mechanisms and more work is required to 
elucidate the intricacies of these mechanisms. 
1. Methylphenidate increase in DAT Function is trafficking 
dependent  
 Several lines of evidence suggest that psychostimulants are involved in 
the regulation of DAT at the level of surface expression (Zhu & Reith, 2008).  In 
the current study, methylphenidate decreased intracellular DAT without altering 
total or surface DAT.  DAT function is regulated by numerous cellular signaling 
pathways, including PKC, tyrosine kinases, phosphatases, calcium and 
calmodulin-dependent kinases, and protein kinase A (PKA), which strongly 
modulate DAT expression on the plasma membrane (Melikian, 2004; Robinson, 
2002; Vaughan, 2004; Zahniser & Doolen, 2001).  G protein-coupled receptors 
(GPCRs), enzymatic modification such as phosphorylation or ubiquitination, and 
protein-protein interactions between DAT and other scaffolding proteins have 
also been found to be involved in the regulation of DAT (Schmitt et al., 2010). 
Methylphenidate may have caused the phosphorylation of DAT, thus making 
DAT unrecognizable to the DAT antibodies used in the western blot analysis. 
Ubiquitination is the covalent attachment of the small soluble protein ubiquitin to 
the ε-amino moiety of lysine residues in target cellular proteins. This process 
affects DAT cell surface expression and membrane trafficking of transporter 
(Schmitt et al., 2010). A possible mechanism mediating the methylphenidate-
induced decrease in intracellular DAT could be D3 receptor activation. Zapata et 
al conducted an experiment using hEK and neuro2A  cells, found a significant 
increase in cell surface DAT parallel to a significant increase in DAT function 
after brief D3 receptor stimulation (Zapata et al., 2007). This result suggests D3 
activation increases DAT redistribution from the intracellular compartment to the 
cell surface. This finding is consistent with our results where methylphenidate 
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caused the same DAT redistribution from the intracellular compartment based on 
the significant decrease in intracellular DAT that was observed. However, 
prolonged D3 receptor activation had the opposite effect, causing a decrease in 
cell surface DAT. In addition, this study also found that the D3 activation requires 
mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) 
activation. This suggests that there are multiple mechanisms and pathways that 
may be involved in the methylphenidate-induced decrease of intracellular DAT.  
Another possible explanation could be the involvement of PKA and PKC.  
Activation or inhibition of PKC, PI3K, and members of the MAPK family can 
cause transport membrane redistribution, although specific kinases responsible 
for direct phosphorylation are still unknown. One report found that 
methylphenidate had no effect on PKC activator-induced down-regulation of DAT 
function (Gorentla & Vaughan, 2005), however results from a previous study 
showed that methylphenidate decreased PKA levels when given repeatedly for 
five days (Crawford et al., 1998). These results demonstrate that the mechanism 
behind the regulation of DAT by methylphenidate is still under debate and further 
investigation is needed to gain a clearer picture of how methylphenidate 
regulates DAT. In addition, Wagner et al., observed a significant increase in Vmax 
in rats with a controlled cortical impact (CCI) that received a daily injection of 
methylphenidate (5 mg/kg) for 14 days, but there was no change in total tissue or 
membrane bound DAT expression compared to the CCI rats that received saline 
(Wagner et al., 2009). These findings demonstrate that methylphenidate has the 
ability to increase the Vmax without altering total of surface DAT expression, which 
is consistent with the results of this current study. A more recent study examined 
the long-term effects on striatal DAT density of a 2-week methylphenidate 
treatment given to SHR rats and WKY rats (Roessner et al., 2010). 
Methylphenidate was given through drinking water and was adjusted to about 2 
mg/kg/day based on daily monitoring of amounts consumed by the two rats per 
cage and their body weight. Methylphenidate significantly decreased [3H]GBR 
binding in SHR and WKY models at post-natal day 90 when compared to 
controls. This study demonstrates that long-term administration of 
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methylphenidate reduced the striatal DAT density in both rat strains. However, 
this finding reveals that methylphenidate caused a decrease in the amount of 
DAT, but the effect on DAT function after in vivo administration of 
methylphenidate was not assessed. Due to a time constraint, the 14-day 
experiment on DAT trafficking could not be performed, however based on the 
results from the 7-day experiment, it is speculated that methylphenidate may 
cause  a decrease in surface DAT in regards to DAT trafficking because the 
effect of methylphenidate on DAT function was no longer observed after 14 days. 
One study found that prolonged D3 receptor stimulation can cause a decrease in 
DAT function and a decrease in DAT cell surface expression (Zapata et al., 
2007). In addition, a study has shown that methylphenidate interacts with the D3 
receptors (Andersen et al., 2008), adding credence to the theorized results for 
the 14-day experiment. 
This current work, to our knowledge, is the first to report the effect of acute 
and repeated in vivo administration of methylphenidate on DAT function.  In 
summary, with DAT being a part of such a dynamic system, there is evidence 
that collectively suggests that multiple pathways exist to regulate 
neurotransmitter transport function (Samuel et al., 2005). 
There have also been other examples where there was an increase in DAT 
function, but no change in DAT expression. For instance, one report found that 
nicotine increased Vmax for [3H]DA uptake, however no increase in cell surface 
DAT expression was seen (Middleton et al., 2007). In addition, subfractionation 
experiments revealed no difference in dopamine transporter levels in total and 
plasma membrane fractions. Furthermore, another study reported that insulin 
increased NET function without a change in transport cellular localization 
(Apparsundaram et al., 2001).  Taken together, these results suggest that it is 
possible to have an increase in DAT function with no change in total DAT 
expression, which is what the present study found. 
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C. Potential Mechanism for the Methylphenidate-Induced 
Increase in VMAT2 Function 
The results of the VMAT2 experiments with methylphenidate are 
consistent with previous results showing that a single 40 mg/kg s.c. injection of 
methylphenidate increased vesicular DA uptake (Fleckenstein et al., 1999; 
Sandoval et al., 2002). The latter study also revealed that D1 and D2 receptor 
activity may also by involved in the increase in VMAT2 function by 
methylphenidate, since pretreatment with SCH23390, a D1 receptor antagonist 
and eticlopride, a D2 receptor antagonist both, completely inhibited 
methylphenidate-induced increases in VMAT2 function. Furthermore, 
methylphenidate may indirectly act as a DA agonist (Wilens, 2008).  This may 
also explain the increase of VMAT2 function because if methylphenidate acts as 
a DA agonist, it could activate both pre and post synaptic D2 DA receptors, thus 
indirectly causing an increase in VMAT2 function in order to remove the DA in 
the cytosol, which would increase the activation of the D2 DA receptors.  
Previous reports have shown that methylphenidate (40 mg/kg) can 
increase VMAT2 function accessed 60 minutes after in vivo administration 
(Sandoval et al., 2002). Based on the present results, it is very likely that 
methylphenidate may be interacting with vesicles in the same way as its 
interactions with synaptosomes, since methylphenidate increased both VMAT2 
and DAT function. Methylphenidate administration did not alter the Km, which 
suggests that methylphenidate competes with dopamine at VMAT2 in a 
noncompetitive manner. The current results suggest that methylphenidate acts 
differently than lobeline and amphetamine, in reference to the effects observed 
on VMAT2 function. The observation that amphetamine and methylphenidate 
influence VMAT2 differently at the time point and doses used in this study maybe 
rather surprising since both drugs have been shown to target VMAT2  
(Greydanus et al., 2007; Thanos et al., 2007).  However, the data in these 
studies could be a result of the difference in their mechanisms of action. This 
could possibly explain our observations of an increase in DAT and VMAT2 
function by methylphenidate and no effect by amphetamine. The data produced 
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from this dissertation research are the first to show that in vivo administration of 
methylphenidate increased DAT and VMAT2 function. A recent review on 
VMAT2 regulation suggest that the altered sensitivity to the locomotor activity 
effects of cocaine, amphetamine, and alcohol in VMAT2-knockout mice is tied 
closely to the expression of VMAT2 (Takahashi et al., 1997). This review also 
states that by gaining a better understanding of VMAT2 dynamics may open the 
door to improved pharmacotherapies used to treat psychiatric disorders and 
addiction. In addition, methylphenidate was shown to decrease the intracellular 
DAT expression, implying that methylphenidate does redistribute DAT. Initially, 
methylphenidate was thought to have a more direct and less complicated 
mechanism of action based on previous studies. However, the novel results from 
this research demonstrate that the mechanism of action of methylphenidate may 
be more complicated than previously thought.   
D. Implications 
 The results of this dissertation work imply that methylphenidate interacts 
with DAT in a different manner than amphetamine and lobeline. Based on the 
current results showing that lobeline had no effect on DAT and VMAT2 function, 
lobeline does not appear to be a plausible treatment option for ADHD. The lack 
of effect on DAT and VMAT2 function observed with lobeline could be that the 
behavioral effect, which was the decreased self-administration of 
methamphetamine observed in the behavioral study, may involve an interaction 
with the α4β2 nAChR and not due to DAT or VMAT2 involvement. However, 
lobeline, an analogue of lobeline, causes this same behavioral effect and has 
little or no affinity for α4β2* or α7* nAChRs (Miller et al., 2004; Zheng et al., 
2005). Therefore, the cause of the behavioral effect of lobeline requires 
additional research to determine what receptors and transporter proteins are 
involved in eliciting the behavioral effect of lobeline. 
However, amphetamine, an effective treatment for ADHD, had no effect 
either. Therefore, additional information is needed to determine if lobeline is 
actually a potential treatment option for ADHD. Furthermore, Levin et al. showed 
lobeline enhanced learning on the post-acquisition working memory performance 
139 
in the radial-arm maze (Levin et al., 2003). In addition, lobeline has been found to 
improve retention performance 24 hours after injection in spatial discrimination 
water maze (Decker et al., 1993). Previous work has also demonstrated that 
lobeline may be an effective smoking cessation agent by showing that lobeline 
acts as a nicotinic antagonist by inhibiting nicotine-evoked DA release and 
nicotine-evoked 86 Rb+ efflux (Miller et al., 2000). Lobeline has been used as an 
over-the-counter smoking cessation agent in the past in the US (Nunn-Thompson 
& Simon, 1989; Prignot, 1989) and numerous human studies have been 
conducted to determine efficacy of lobeline as a smoking cessation agent, 
although its use is still debatable (Dwoskin & Crooks, 2002). This characteristic 
gives lobeline an additional advantage to the currently used ADHD treatments 
because it has been shown that there is a higher rate of smoking in people who 
have ADHD compared to those who do not (Milberger et al., 1997).  Another 
benefit of lobeline is that it does not have typical stimulant side-effects such as 
abuse liability (Harrod et al., 2003). 
  In addition, this study unexpectedly found that amphetamine had no effect 
on DAT function. However, there have been behavioral reports that have 
demonstrated a difference in effect between methylphenidate and amphetamine. 
For example, a previous study discovered that 5 mg/kg of amphetamine 
produced more sniffing over a 2-hour observation period than rats receiving 
either saline or 30 mg/kg of methylphenidate (Roffman & Raskin, 1997).  In 
addition, methylphenidate-treated rats exhibited significantly higher total gnawing 
than saline or amphetamine-treated rats. Moreover, another study found that 
amphetamine and methylphenidate had differential effects on enriched 
environmental condition (EC) and impoverished condition (IC) rats. Amphetamine 
increased impulsivity choice in EC rats, however methylphenidate had no 
significant effect in EC rats (Perry et al., 2008).  The authors hypothesized that 
the differences in DAT function in mPFC may be associated with these results 
because EC rats show a decreased DAT function in mPFC, but not in striatum or 
nucleus accumbens, implying that EC rats could have higher levels of 
extracellular DA in the mPFC than IC rats (Zhu et al., 2004; Zhu et al., 2005).     
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  Biochemical studies have also obtained similar results. For instance, one 
study found that methylphenidate may interact with a domain on DAT that is 
distinct from that of amphetamine due to their different affinities observed with 
mutant DAT (Dar et al., 2005).  In addition, Schiffer et al., found that 
amphetamine increased extracellular DA more than methylphenidate using 
microdialysis, suggesting that the differences between these agents in 
modulating extracellular DA may be based on their differences in their molecular 
mechanisms, i.e., amphetamine also causes release of DA and methylphenidate 
does not (Schiffer et al., 2006).  The differential effects of amphetamine and 
methylphenidate have been recorded in the clinical setting as well. Borcherding 
conducted a study with 45 hyperactive boys and found that subjects taking 
amphetamine had increased cleaning and checking behaviors similar to 
childhood-onset Obsessive-Compulsive Disorder (OCD). On the other hand, the 
subjects that were given methylphenidate displayed perfectionistic and detail-
oriented behavior, as well as abnormal movements and compulsive behavior 
(Borcherding et al., 1990). Taken together, the results of the preclinical 
behavioral and biochemical studies, as well as the clinical findings, suggest that 
methylphenidate and amphetamine may interact at DAT in different manners to 
cause these differential effects.  
This research has also led to clinical implications. Based on the preclinical 
data of lobeline, a clinical trial was conducted using lobeline. The clinical trial was 
a single small-N pilot study to determine the ability of lobeline to decrease ADHD 
symptoms in adults. The study was a double-blind, double-dummy, placebo-
controlled, within-subject design. Inclusion criteria for the study included being 
healthy individuals between 21 and 45 yrs old, with childhood histories and 
current symptoms of ADHD (meet diagnostic criteria on the clinical interview and 
CAARS) and able to stop current medications for 7 days prior to the clinical trial. 
Females were either nonchildbearing (tubal ligation or total hysterectomy) or of 
childbearing potential using one or more of the following barrier methods of 
contraception: male or female condoms (with spermicide), diaphragm (with 
spermicide) and/or intrauterine device (with/without spermicide). No other 
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contraceptives were acceptable. Subjects must have a body mass index (BMI) 
between 18 and 30 and be willing and able to give written consent. Subjects must 
have no medical contraindications determined by the following: an adequate 
medical history, a physical examination including vital signs, 12-lead ECG, CBC 
with differential and liver functions and urinalysis and a negative drug test 
(barbiturates, benzodiazepines, amphetamines, opiates, cocaine, cannabinoids, 
ethanol) at screening and at the time of each admission to the GCRC and CO ≤ 8. 
Salivary cotinine was collected and assessed at baseline to determine whether or 
not the subject was using smokeless tobacco included being a non-smoker 
between the ages of 21-45, in good general health, no current drug use, and 
having a history of childhood ADHD symptoms and current ADHD symptoms. 
Medical and psychiatric evaluations were conducted. The medical evaluation 
consisted of a physical examination (conducted by the PI) and an EKG reviewed 
by an Internist/pediatrician (Dr. C. Feddock) with particular attention to 
arrhythmias, prolonged QT or heart block. Subjects provided a urine sample for 
drug screening, standard urinalysis and βHCG pregnancy tests (for female 
subjects).  A blood sample was drawn for a complete blood count with differential 
and liver function tests. Subjects will undergo breath sample analysis on-site with 
an Alco-Sensor Intoximeter and an Innovative Medical CO Monitor. To qualify for 
the study, subjects must be non-smokers and CO must be ≤ 8 ppm.  
The psychiatric assessment included a structured clinical interview based on 
the DSM-IV (SCID) supplemented with ADHD symptoms from the KSADS-E 
(Wilens et al, 2003). In addition, the Conners Adult Rating Scale (CAARS) will be 
completed. These measures assessed the presence of ADHD and degree of 
symptomatology. The Shipley Institute of Living Test was obtained to determine 
an estimate of intellectual functioning.   
 Exclusion criteria included regular use of drugs of abuse, current use of 
psychiatric medications other than short acting medications for ADHD, having an 
abnormal EKG or hypertension (blood pressure over 150/90 on two consecutive 
measures over 15 min when the subject is at rest), being pregnancy, having 
current medical difficulties or legal problems, regular use of prescription medicine 
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that cannot be discontinued and current use of nicotine and active suicidal 
behaviors. 
 The acute effects of LOB on indices of attention, impulsivity and working 
memory were the primary outcomes measures to be assessed; outcomes will be 
compared to results obtained with placebo and with the positive control 
comparator, methylphenidate, a medication with efficacy for this disorder. 
Secondary outcome measures will include physiological and subjective drug effect 
reports to provide additional information on safety, abuse liability and tolerability 
(e.g., appetite, sleep, side effects).  
 The first subject was consented on July 30, 2008 and the final subject 
consented on October 8, 2009. A total of 42 subjects were enrolled in the study 
and screened at intake (18 females and 24 males). Out of the 42 subjects, only 13 
were randomized into the protocol because 29 did not meet the inclusion criteria. 
Some of the screening failures included elevated BMI, elevated scores on the 
Beck Depression Inventory, a CAARS score of >65, 2 positive drug screens, 
failure to meet the demands of the protocol (i.e., scheduling conflicts), and family 
history of early cardiac death. Out of the 13 subjects that were randomized 4 
withdrew, leaving a total of 9 subjects that completed the study. In regards to 
demographics of the 13 subjects, 1 was an African American female, 5 were 
White females, and 7 were White males. The subjects that withdrew were the 
African American female, 1 White female, and 2 White males. 
 The results of the study showed that lobeline did not have a significant 
effect on reducing ADHD symptoms using the outcomes assessed in this trial. 
However, it was also difficult to observe a significant effect with methylphenidate, 
suggesting that the testing parameters may not have been most appropriate to 
use. In addition, various subjects complained of a bitter taste and a burning 
sensation with the administration of lobeline sublingual tablet. This adverse effect 
could have played a role in the lack of effect observed with lobeline, causing the 
subjects to become distracted by the bitter taste or burning sensation. Therefore, 
if the subjects were distracted, they might have performed worse on the tests 
used to assess for improved attention after administration of lobeline. To 
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determine if the adverse effects affected the results of the study, another study 
should be conducted with a different dosage form of lobeline, such as a 
transdermal patch to alleviate the adverse effect of the bitter taste and burning 
sensation. This additional study would confirm if lobeline is able to reduce ADHD 
symptoms and provide an overall perspective of the clinical implications of 
lobeline as a treatment option for ADHD. 
E. Limitations 
One limitation was the choice of using adult rats for the study rather than 
adolescent rats, since ADHD is known to be a childhood disorder. However, adult 
rats were used to obtain preliminary results as to how lobeline interacts with DAT 
and VMAT2 in normal adult rats. Just as clinical studies use healthy subjects to 
investigate the characteristics of an investigational drug, such as 
pharmacokinetics and side effects, we used normal adult rats to gain knowledge 
as to how lobeline interacts with DAT and VMAT2. In fact, using adults rats may 
not be an actual limitation since ADHD has been shown to persist into adulthood 
and more cases of adult ADHD are being diagnosed (American Psychiatric 
Association, 2000; de Graaf et al., 2008). 
Another limitation was only examining one region of the brain. The 
striatum was initially chosen based on the support that DAT is highly expressed 
in the striatum (Ciliax et al., 1999). However, recent research focused on the 
PFC and reports that it is an essential region of the brain that governs and 
maintains attention (Arnsten et al., 2009). For example, improved PFC cognitive 
function, i.e., spatial working memory, in monkeys was observed with the optimal 
dose of methylphenidate and amphetamine (Gamo et al., 2010). This same study 
also stated that PFC function is vastly controlled by DA and NE. In addition, the 
authors found that the regulation of the PFC is altered in many ADHD patients.  
Based on this increasing amount of evidence,   it is necessary to conduct studies 
in the PFC to gain a better understanding of the mechanisms of actions of 
lobeline, methylphenidate, and amphetamine in this brain region. 
The use of individual doses for the chronic studies could be a limitation as 
well. The chronic doses were to be based on the effective acute doses. However, 
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amphetamine and lobeline did not have an effect in the actue experiments. 
Therefore, the doses chosen for the chronic studies for these compounds were 
based on behavioral studies. Since a complete dose-response was used for 
acute studies, it would be more beneficial to also conduct a complete dose-
response with the chronic studies as well. This would ensure a more complete 
picture as to how the compounds interact with the various targets. Determining 
the dose-response relationship is imperative when studying different compounds 
and their effects on certain targets because it provides vital information as to how 
the dose affects the primary outcome measure. Therefore, to address this 
limitation it would be prudent to include a dose-response for the chronic studies 
as well.   
F. Future Directions 
The experiments completed in this dissertation examined the effects of 
acute and repeated in vivo administration of lobeline, methylphenidate, and 
amphetamine on DAT function in the striatum. Further studies are needed to 
investigate the effects of acute and repeated in vivo administration of lobeline, 
methylphenidate, and amphetamine on DAT function in the PFC since the PFC is 
also widely studied because of its involvement in the regulation of behavior, 
attention, affect, motor and cognitive control (Arnsten, 2006; Kieling et al., 2008). 
Numerous studies have considered the PFC as a region of interest in examining 
the pathophysiology of ADHD (Barkley et al., 1992; Goldman-Rakic, 1996; 
Robbins, 1996).   
  Due to the recent addition of atomoxetine, a selective NET inhibitor, as a 
treatment option for ADHD, it is important to determine the effects lobeline has 
on this transporter function as well. Impaired regulation of NE neurotransmission 
is suggested to contribute to ADHD (Beane & Marrocco, 2004).  Studies have 
shown, using microdialysis that methylphenidate and amphetamine substantially 
increased NE and DA efflux within the PFC to enhance cognitive function 
(Berridge et al., 2006; Berridge & Stalnaker, 2002). Methylphenidate also has an 
affinity for NET (Andersen, 1989; Easton et al., 2007; Kuczenski & Segal, 1997; 
Richelson & Pfenning, 1984). One report even suggests that methylphenidate 
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has a higher affinity for NET than DAT (Eshleman et al., 1999). Moreover, a 
preclinical study found that methylphenidate-treated rats (0.5 mg/kg, ip) produced 
a maximal increase in NE levels significantly larger than the increase of DA in the 
PFC (Berridge et al., 2006). Furthermore, the first in vivo study in humans 
showed that clinically relevant doses of methylphenidate occupy significant levels 
of NET. The results from this study imply that the therapeutic effect of 
methylphenidate in ADHD may be modulated via NET inhibition as well as DAT 
(Hannestad et al., 2010). A recent review also stated that the majority of drugs 
shown to be effective in treating ADHD have important effects on NE 
transmission (Del Campo et al., 2011). Thus, there is overwhelming evidence 
that NET is an important target that needs to be investigated to determine the 
effect lobeline may have on it.   
Another suggested future study involves investigating the effects of acute 
and repeated in vivo administration of lobeline, methylphenidate, and 
amphetamine on DAT and VMAT2 function in adolescent rats as well. Studies 
have indicated that age plays a major role in response to ADHD medications due 
to the fact that the adolescent brain is still undergoing development, which makes 
it more sensitive to the effects of these medications (Canese et al., 2009; Yang et 
al., 2003; Yang et al., 2006).   
Furthermore, in order to validate the use of lobeline for the treatment of 
ADHD, it would be useful to determine if lobeline is effective in reducing the 
symptoms of ADHD found in an ADHD rat model. Based on the review of the 
literature, convergent evidence suggests that the SHR is one of the best animal 
ADHD models (Heal et al., 2008; McCarty et al., 1980; Sagvolden, 2000). Thus, it 
would be worthwhile to investigate the effect lobeline has on SHR rats and to 
compare its effect to the effects of methylphenidate and amphetamine.   
In conclusion, this dissertation research has provided new insights into the 
mechanism of action of lobeline and how it interacts with DAT and VMAT2. This 
work also extended previous findings as to how methylphenidate interacts with 
DAT and VMAT2. Further studies are needed to gain a better understanding of 
the exact mechanism responsible for the increase in DAT function caused by 
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methylphenidate. Based on the current results showing that lobeline had no 
effect on DAT and VMAT2 function, lobeline does not appear to be a plausible 
treatment option for ADHD. However, amphetamine, an effective treatment for 
ADHD, had no effect either. Therefore, more experiments are warranted in order 
to elucidate the mechanism of lobeline and the other compounds. Ultimately, 
these additional studies may offer leads for developing related novel and more 
effective neuropharmacologic therapeutic agents for ADHD and other psychiatric 
disorders. Furthermore, we did find exciting new data that showed that acute and 
repeated methylphenidate increased DAT and VMAT2 function after in vivo 
administration. These data provide evidence that VMAT2 is also an important 
target worthy of further research for additional novel therapeutic compounds. 
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